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 In order for our society to avoid entering a post-antibiotic era, we need 
new antibiotics that function through pathways and mechanisms previously 
untargeted by our current regimen of antibiotics.  One such pathway is that of 
menaquinone biosynthesis.  Menaquinone is responsible for electron transport 
in bacterial respiration and is required for the growth and proliferation of many 
virulent bacteria such as Mycobacterium tuberculosis.   Herein, we report 
efforts in developing a new class of antibiotics, which aim to inhibit 
menaquinone biosynthesis through targeting of a key enzyme in the 
biosynthetic pathway, MenE.  MenE is an acyl-CoA ligase, which converts o-
succinyl benzoate (OSB) to OSB-CoA via an OSB-AMP intermediate. Using 
5’-O-(N-acylsulfamoyl) adenosine (acyl-AMS) analogues of the cognate acyl-
AMP intermediate, we can effectively inhibit MenE in biochemical assays, but 
these inhibitors show poor cellular activity as well as unfavorable 
physicochemical and pharmacological properties, impeding the progression of 
this inhibitor platform.  Utilizing crystal and docking structures, exploration of 
the structure-activity relationships of the scaffold, and the unique keto-
acid/lactol equilibrium of OSB-AMS, we are developing a series of second and 
third generation OSB-AMS analogues designed to increase cellular activity 
and progress this inhibitor class.  
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CHAPTER 1 
INHIBITION OF MENAQUINONE BIOSYNTHESIS AS A NOVEL ANTIMICROBIAL TARGET 
 
1.1 The Problem of Antimicrobial Resistance 
The proliferation of drug resistant bacteria presents a global health 
threat that cannot be ignored.  The current Centers for Disease Control and 
Prevention (CDC) report on instances of drug-resistant bacteria in the US 
show an average rate of 80,000 new reported cases of severe methicillin-
resistant Staphylococcus aureus (MRSA) infections each year, resulting in 
11,000 deaths annually.1  While the human cost of infection and associated 
morbidity should not be ignored, the cost to our society and healthcare 
systems these infections represent is also of great concern.  The average 
treatment cost for a single case of MRSA is $34,657,2 and when considered 
with the aforementioned CDC data suggests an annual cost of $2.8 billion to 
the US healthcare system.  It is important to note that this cost addresses only 
MRSA cases.  The CDC estimates at least 2 million people become infected 
with a variety of bacteria that are resistant antibiotics each year.1   
A microbe less common in the US but posing a global health threat is 
drug-resistant M. tuberculosis (TB).  In the most recent World Health 
Organization (WHO) global tuberculosis report, they estimate in 2015 there 
were approximately 10.4 million new cases of TB, 480,000 new cases of multi-
drug resistant TB (MDR-TB), and 100,000 new cases of rifampicin-resistant 
TB (RR-TB), which resulted in an estimated 1.4 million deaths.3   Therefore, 
the proliferation of drug-resistant bacteria poses a national and global threat to 
human lives as well as our economies as a whole.   
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Figure 1.1. Structures of recent approved novel antibiotics.   
Unfortunately, the increase in drug-resistant microbes has 
accompanied a sharp decline in the number of companies investigating new 
antibiotics and consequently, the number of new antibiotics to be introduced to 
the market.4-5  From the period of ~1970 to 2005, there were no novel 
antibiotics introduced to the market.  While new antibiotics were reported and 
approved for use during this time period, they all relied on previously 
discovered scaffolds and mechanisms of action.6   Since then, there have 
been four novel classes of antibiotics to be approved (Figure 1.1):7 
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diarylquinolines (bedaquiline),8 oxazolidinones (linezolid),9 lipopeptides 
(daptomycin),10 and tiacumicins (fidaxomicin).11  Another novel antimicrobial 
agent class released during this time is the pleuromutilins (retapamulin),12 
however these compounds are approved only for topical treatment of skin 
infections.    
Although the recent influx of novel antibiotics is promising and shows a 
slight reversal of the trends observed in the previous 35 years, these new 
antibiotics are typically narrow spectrum and carry with them severe toxicity 
profiles, making them drugs of last resort in most cases.13-17  Taken together, 
the increase in the spread of drug-resistant bacteria, the cost in human lives 
and to our healthcare systems, and relative decline in new antibiotics over the 
past 60 years, makes it clear that we need new antibiotics that inhibit 
pathways previously untargeted by our current arsenal.   
 
1.2 Menaquinone Biosynthesis 
Menaquinone (vitamin K2), ubiquinone, and phylloquinone belong to a 
class of lipid-soluble electron carriers (lipoquinones), and are essential for 
cellular function for all living organisms (Figure 1.2A).18-21  Menaquinone acts 
as a redox-active cofactor for many proteins, including the electron transport 
chain of many species of bacteria during cellular respiration.22  Importantly, it 
is the sole electron carrier for all Gram-positive bacteria, mycobacteria, and all 
bacteria growing anaerobically.23-25  
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Figure 1.2. Menaquinone biosynthesis A) Canonical menaquinone biosynthetic pathway. B) 
Alternative biosynthetic pathway (futalosine).  Menaquinone n = 4-13, Ubiquinone n = 6-13, 
Phylloquinone n = 3.  SEPHCHC = 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-
carboxylic acid, SHCHC = 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate, DHNA = 
1,4-di-hydroxy-2-naphthoic acid, DMK = demethylmenaquinone. 
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Menaquinone is commonly produced in bacteria from chorismate, 
through at least nine distinct enzymes (Figure 1.2A).20,26-27  Through genetic 
work by several groups, the main biosynthetic pathway has been shown to be 
essential for survival and proliferation of bacteria for which it is the sole 
electron transporter.23-25  Although some Gram-negative bacteria such as 
Helicobacter pylori, use an alternative biosynthetic pathway to produce 
menaquinone (futalosine, Figure 1.2B), the two pathways are mutually 
exclusive with the majority of pathogenic bacteria using the canonical 
menaquinone biosynthetic pathway.25,28-29 
Menaquinone is also used in mammals as a cofactor for vitamin K 
dependent proteins, which are known to play a role in vascular cell migration, 
angiogenesis, and blood-clotting cascades.30-31  However, humans lack the 
necessary de novo pathway to produce menaquinone and must acquire it from 
diet (phylloquinone from plants) and gut flora,30,32 making menaquinone 
biosynthesis an attractive target for the development of novel of antibiotics.   
Many groups have recognized menaquinoneʼs unique niche in relevant 
biological systems and have developed inhibitors of the biosynthetic pathway 
as potential antimicrobial agents.  To date, inhibitors of the biosynthetic 
pathway have been reported for MenD,33-34 MenC,35 MenE,36-40  MenB,41-43 
MenA,44-47 and MenG.48 Importantly, these compounds have all shown 
antimicrobial activity in a variety of bacteria, including M. tuberculosis. These 
findings also provide pharmacological validation of the earlier genetic studies 
showing menaquinone biosynthesis to be essential and a potential target for 
future antibiotics.   
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1.2 MenE: An Acyl-CoA Synthetase 
MenE is an acyl-CoA synthetase (ligase) in the menaquinone 
biosynthetic pathway and has been shown through genetic knockout studies to 
be essential for the survival and fecundity of Mycobateria spp., Bacillus spp., 
and other bacterial species, both pathogenic and nonpathogenic.49-51  MenE 
catalyzes the thioesterification of ortho-succinylbenzoate (OSB) with CoA 
through an ordered bi uni uni bi ping-pong mechanism in the presence of Mg2+ 
and ATP (Figure 1.3).37,40  In the first half-reaction, MenE catalyzes the 
adenylation of OSB with ATP, expelling inorganic pyrophosphate, to form a 
tightly bound OSB-AMP intermediate.  MenE then catalyzes the second half-
reaction, binding CoA, which attacks the activated carboxylate of OSB, to form 
OSB-CoA and release AMP.41,52-53   
	  
Figure 1.3. MenE mechanism of action.  AMP = adenosine monophophate, ATP = 
adenosine triphosphate, PPi = inorganic pyrophosphate.  
MenE, as an acyl-CoA synthetase, belongs to the ANL (acyl-CoA 
synthetase, nonribosomal peptide synthetase adenylation domain, luciferase) 
protein family.54  Proteins in this family share a similar structure containing a 
C-terminal “lid” domain connected via a flexible hinge to a much larger            
N-terminal “hammer and anvil” domain.  This general architecture is observed 
for all members of the ANL family of adenylation enzymes (Figure 1.4).55-56  
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Figure 1.4. ANL family members. C-terminal domain = cyan, N-terminal domain = green.   
A) MenE, OSB-CoA synthetase, (PDB ID: 3IPL).57  B) Firefly Luciferase (PDB ID: 1LCI).55     
C) CBL, 4-Chlorobenzoate-CoA synthetase, (PDB ID: 3CW8).58  D) Gramicidin Synthetase, 
Phenylalanine-CoA synthetase  (PDB ID: 1AMU).59 
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The ANL family is itself a member of the much larger adenylate-forming 
enzyme superfamily which also includes aminoacyl-tRNA synthetases, E1 
activating enzymes, A-ATPases, biotin protein ligase, and NRPS-independent 
siderophore (NIS) synthetases.54  The members of this superfamily have large 
variability in structure, but all catalyze the activation of carboxylic acid 
substrates through adenylation to form an acyl-AMS intermediate, followed by 
coupling with nitrogen, oxygen, and sulfur nucleophiles by carbonyl addition–
elimination.56  
 
1.3 Inhibition of MenE and related cellular activity 
Due to the reactivity of the acyl-AMP intermediate, adenylate forming 
enzymes such as MenE, bind their cognate acyl-AMP intermediate several 
orders of magnitude more strongly than the corresponding carboxylate and 
AMP starting materials.60-62  This tight-binding sequestration by the enzyme of 
its cognate acyl-AMP intermediate has been exploited successfully by groups 
using rationally designed inhibitors that mimic the cognate ligand.63-64  The 
most successful and widespread inhibitors use the non-hydrolyzable acyl-AMP 
bioisostere, acyl-5´-O-sulfamoyladenosine (acyl-AMS) or acyl-5´-N-
sulfamoylazadeoxyadenosine (acyl-AMSN).65  
Acyl-AMS based inhibitors draw inspiration from the natural products 
ascamycin66-68 and nucleocidin,69-70 which themselves have potent 
antimicrobial activity (Figure 1.5).  Synthetic acyl-AMS inhibitors were first 
pioneered by Ishida and coworkers, where he explored the use L-alanyl-AMS 
as an inhibitor of alanyl-tRNA synthetases.71  This inhibition strategy has since 
been applied to a wide swath of the adenylate-forming enzyme superfamily, 
including those of the ANL family,72-74 E1-activating enzymes,75-77 asparagine 
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synthetases,78 and pantothenate synthetases.79  
	  
Figure 1.5. Examples of reported acyl-AMS inhibitors for adenylation-forming enzmes.   
Work in our laboratory36-37 and others40 have used this well established 
acyl-AMS strategy to target MenE.  Mesecar and coworkers reported in 2008, 
the synthesis of acyl-AMS based OSB-AMP analogue 1 (Figure 1.6), which 
substituted a trifluoromethyl group in place of the ortho-carboxylate of OSB. 
The reported trifluoromethyl analogue 1 showed modest activity in biochemical 
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assays (Ki = 108 μM), but no antimicrobial activity was reported.   
	  
Figure 1.6. Reported OSB-AMP based inhibitors of MenE.	  
Concurrent to this work, our own laboratory reported the synthesis and 
inhibitory activity of rationally designed acyl-AMS based analogues of OSB-
AMP.36  These analogues interrogated the structure–activity relationships 
(SAR) around three key areas of the OSB-AMP scaffold with MenE from 
M. tuberculosis (mtMenE), S. aureus (saMenE), and E. coli (ecMenE).36-37  
The first area of focus was the SAR around the free carboxylate of OSB by 
making both the free-acid (OSB analogues: 2, 5, 7, 10, 12, Figure 1.5) and the 
masking carboxylate as the methyl ester (MeOSB analogues: 3, 4, 6, 8, 9, 11, 
13, 14).  The second area of focus was the SAR around the ketone of the 
succinyl chain by replacement with an exo-methylene (analogues: 4, 9, 14) or 
elimination completely (desketo analogues: 7, 8, 12, 13).  The final area of 
focus was the SAR around the acyl-phosphate group (linker region) where 
O
HO OH
N
NN
NH2
O NSN
O O O
X
OR
O
O
HO OH
N
NN
NH2
O NSN
O O O
O
CF3
1 2: OSB-AMS (R = H, X = O)
3: MeOSB-AMS (R = Me, X = O)
4: (R = Me, X = CH2)
O
HO OH
N
NN
NH2
N
H
NSN
O O O
X
OR
O
5: OSB-AMSN (R = H, X = O)
6: MeOSB-AMSN (R = Me, X = O)
7: OCPB-AMSN (R = H, X = H,H)
8: MeOCPB-AMSN (R = Me, X = H,H)
9: (R = Me, X = CH2)
O
HO OH
N
NN
NH2
N
H
NS
O O
X
OR
O
10: OSB-AVSN, (R = H, X = O)
11: MeOSB-AMSN (R = Me, X = O)
12: OCPB-AVSN (R = H, X = O)
13: MeOCPB-AVSN (R = Me, X = O)
14: (R = Me, X = CH2)
	   11	  
acyl-sulfamoyl analogues (AMS analogues: 2-4), acyl-sulfamide analogues 
(AMSN: 5-9), and vinyl-sulfonamide analogues (AVSN: 10–14) were 
synthesized and screened for related biochemical and antimicrobial activity.  
Table 1.1.   Biochemical activity of reported MenE inhibitors.36-37,40   
 IC50 [μM] of MenE from 
Inhibitor M. tuberculosis S. aureus E. coli 
 2, OSB-AMS      0.049 ± 0.007      0.060 ± 0.005        0.21 ± 0.16 
 3, MeOSB-AMS    14.2 ± 3.3    24.6 ± 3.5      38.0 ± 3.0 
 4, emMeOSB-AMS n.d n.d > 200 
    
 5, OSB-AMSN        0.20 ± 0.02        0.24 ± 0.01        0.63 ± 0.14 
 6, MeOSB-AMSN      23.5 ± 1.0 > 200      34.1 ± 2.8 
 7, OCPB-AMSN    101 ± 14      85 ± 17 n.d 
 8, MeOCPB-AMSN > 200 > 200  > 200 
 9, emMeOSB-AMSN n.d n.d  > 200 
    
10, OSB-AVSN        0.16 ± 0.05        0.33 ± 0.05        0.57 ± 0.06 
11, MeOSB-AVSN    117 ± 12      45.7 ± 2.8        5.7 ± 0.7 
12, OCPB-AVSN    106 ± 10      54.4 ± 2.3      31.6 ± 5.5 
13, MeOCPB-AVSN > 200 > 200 > 200 
14, emMeOSB-AVSN n.d n.d > 200 
Assays were performed with mtMenE (50 nm), saMenE (100 nm), or ecMenE (100 nm).  n.d = 
not determined 
OSB-AMS (2, Table 1) was found to be a tight-binding, low nM inhibitor 
of MenE with a Kiapp = 5.4 nM.37 The most drastic SAR observed centered 
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around the succinyl ketone, where removal of the ketone or substitution to an 
exo-methylene resulted in almost complete loss of inhibition.  The SAR at the 
carboxylate was less dramatic but still showed a 2–3 log decrease in inhibitory 
activity when the free carboxylate was masked as the methyl ester (OSB vs 
MeOSB).   
SAR in the linker region appears to be far more nuanced and contingent 
on other factors.36-37  Substitution of the acyl-AMS group to the acyl-AMSN 
resulted in little to no change in IC50 for MeOSB analogues (MeOSB-AMS 3, 
MeOSB-AMSN 6) against ecMenE.  However, there was a 3-fold decrease in 
inhibitory activity for the free-carboxylate analogues (OSB-AMS 2, OSB-
AMSN 5) with the same enzyme.  Likewise, there was 2-fold decrease in 
inhibitory activity for MeOSB analogues upon substitution of the AMS group 
(MeOSB-AMS 3, MeOSB-AMSN 6) against mtMenE, but a 4-fold decrease in 
inhibitory activity of OSB analogues (OSB-AMS 2, and OSB-AMSN 5) with the 
same enzyme.  These results suggest a certain amount of enzyme and 
scaffold dependence on toleration of substitution at the linker region of OSB-
AMS.  Whether this is due to an actual conformational shift in the binding 
between MeOSB and OSB analogues that places the acyl-sulfamoyl group in 
a more or less tolerant position in the MenE binding pocket or some other 
mechanism is unknown.  
Although OSB-AMS showed low nanomolar inhibition of MenE in 
biochemical assays, OSB-AMS was shown to have comparatively poor 
antimicrobial activity.  Canonically there are three main factors that determine 
cellular activity: compound accumulation (influx vs efflux), specificity (on-target 
binding vs off-target binding [specific and non-specific]), and degradation or 
metabolism (Figure 1.7B). OSB-AMS has two acidic moieties (Figure 1.7A): 
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the OSB carboxylate (pKa = 4.3) and the acyl-sulfonamide (pKa = 1.5), which 
at physiological pH will make OSB-AMS a highly polar, di-anionic species.    
This high polarity is believed to have a significant negative impact on the 
permeability of OSB-AMS into the bacterial cytosol (influx), and thereby reduce 
the antimicrobial activity of the compound.  
	  
Figure 1.7.  Cellular activity modeling of OSB-AMS.  A) OSB-AMS at physiological pH, 
carboxylate (red) pKa = 4.3, acyl-sulfamate (blue) pKa = 1.5.  B) Simplified model of factors 
determining cellular activity. 
The extent of this exclusion from the bacterial cytosol has been 
measured in work conducted by Dr. Tony Davis in our laboratory though use of 
LC-MS/MS based compound accumulation studies.80  In Gram–positive cells 
(B. subtilis) OSB-AMS has roughly 24% cellular accumulation at 100 μM and 
7% cellular accumulation at 100 μM in mycobacteria (M. smegmatis), showing 
cellular permeability is a factor in the poor antimicrobial activity of OSB-AMS.   
However, it was noted during the course of the study that in the 1–1000 μM 
extracellular concentration range, the intracellular concentrations of AMS 
compounds appear to increase in a linear fashion.  Therefore, with B. subtilis, 
we have reported a MIC with OSB-AMS of 113 μM (62.5 μg/mL) which would 
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indicate an intracellular OSB-AMS concentration of ~27 μM.39 Likewise, with 
mycobacteria we have reported a MIC (M. tuberculosis) of 227 μM (125 
μg/mL), which would indicate an intracellular concentration of ~16 μM.  While 
the nearness of the intracellular concentrations at MIC across species is 
promising, the ~4-log disparity between intracellular concentrations at MIC and 
the Kiapp and IC50 of OSB-AMS for MenE indicates a likelihood of additional 
factors being involved.   One possible factor that also arises from the di-
anionic nature of OSB-AMS at physiological pH, is specificity.  In our 
laboratory, a similar acyl-AMS compound (salicyl-AMS) has shown high levels 
of non-specific plasma protein binding, which is hypothesized to arise primarily 
from the negatively charged acyl-sulfamoyl group.  This correlation between 
an increase in the negative charge of a compound and an increase in 
nonspecific protein binding has been noted in the literature.81-82  Given the 
highly anionic nature of OSB-AMS at physiological pH, it is possible there are 
appreciable levels of non-specific binding to proteins which could result in a 
relative decrease of free-drug able to interact with and inhibit MenE.  Thus, to 
progress this project forward, it is clear a solution to the di-anionic nature of 
OSB-AMS would need to be addressed.    
 
1.4 Keto-acid/lactol equilibrium 
During the synthesis of the OSB-AMS analogues, Dr. Indrajeet Sharma 
in our laboratory found that OSB-AMS exists in a keto-acid/lactol equilibrium 
(Figure 1.8).37  The equilibrium is shifted from the keto-acid to the lactol based 
on the protonation state of the OSB carboxylate.  When the carboxylate is in 
its deprotonated state, the open-chain keto-acid form predominates.  However,  
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Figure 1.8. The keto-acid/lactol equilibrium. A) Keto-acid/lactol equilibrium of OSB-AMS. B) 
Keto-acid form of OSB-AMSN docked to saMenE. C) Lactol form of OSB-AMSN docked to 
saMenE. Key interactions with R222 and S302 shown. 
 
 A) 
 B) 
 C) 
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when the carboxylate is protonated to form the carboxylic acid, it cyclizes on 
the ketone of the succinyl chain, resulting in the cyclic or closed-chain lactol 
form of OSB.  Although at physiological pH the keto-acid form would 
predominate, there was no direct evidence to determine which form is the 
active pharmacophore of MenE.  
In an attempt to determine which form of OSB-AMS is the active 
pharmacophore of MenE, docking studies using the unliganded crystal 
structure of S. aureus MenE (saMenE) were performed in collaboration with 
Dr. Subramanyam Swaminathan (Brookhaven National Laboratories).  The 
study found two key residues (Arg222, Ser302) in the putative binding pocket 
of OSB, believed to interact with the OSB side-chain.  In the docking structure, 
the free carboxylate of keto-acid form OSB is within 5 Å of Arg222 and the 
ketone of the succinyl chain within 3 Å of Ser302.  The lactol form of OSB 
docked similarly with the lactol hydroxyl within 3 Å of Ser302.  Although, the 
proximity of the free carboxylate of OSB to Arg222 does suggest the keto-acid 
form of OSB to be the active pharmacophore, the possibility of the lactol form 
cannot be eliminated due to the proximity of Ser302, which might favor the 
lactol form.  Likewise, the docking scores from the study gave inconclusive 
results.  Where the keto-acid form of OSB-AMS docked with a score of  –7.7 
kcal/mol, the lactol form of OSB-AMS docked with a score of –11.43 kcal/mol, 
suggesting the lactol form to be the active pharmacophore.  However, the 
keto-acid form of OSB-AMSN docked with a score of –11.82 kcal/mol and the 
lactol form of OSB-AMSN docked with a score of –10.22 kcal/mol, which 
suggests the keto-acid form to be the active pharmacophore.   Thus, the 
known SAR and docking experiments were not able to provide strong 
evidence as to the identity of the OSB-AMS pharmacophore of MenE.  
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1.6 SAR of acyl-AMS based linker analogues 
Although the acyl-sulfamoyl group is a well-established bioisostere of 
the acyl-phosphate, it presents significant stability issues with OSB-AMS 
based inhibitors as well as presumed negative effects on ADME (absorption, 
distribution, metabolism, and excretion) of similar acyl-AMS based inhibitors in 
our laboratory.  While we have reported two modifications to the OSB-AMS 
scaffold in the linker region (AMSN, AVSN), this problem has not yet been fully 
addressed with inhibitors of MenE.  However, groups targeting other 
adenylate-forming enzymes have investigated alternative bioisosteres of the 
native acyl-phosphate group.   
MbtA is a member of the ANL family and a key enzyme in the non-
ribosomal peptide synthesis of the siderophore mycobactin. Courtney Aldrich 
and coworkers have reported analogues probing the SAR of the salicyl-AMS 
(Figure 1.8) scaffold originally reported by our laboratory.64,74,83-89  To address 
problems of the acyl-sulfamoyl group and investigate the binding pocket at that 
region, the Aldrich group proposed and made a series of analogues that 
probed the linker region of MbtA (Figure 1.9).72,90-91    
Although the changes made in most of the reported analogues were 
relatively minor, the loss of antimicrobial activity (MIC) was drastic.  The only 
reported analogue to show antimicrobial activity (15), had a ~2-log reduction in 
activity compared to the lead AMS/AMSN compounds, while all other 
analogues were inactive up to 100 μM (>3-log reduction in activity).  These 
results show the area of the acyl-phosphate group is engaged in multiple 
interactions with the binding pocket and so is highly intolerant of relatively 
minor changes to the scaffold.  Therefore, although it may be necessary to 
alter the acyl-sulfamoyl group to improve ADME for acyl-AMS compounds, 
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substitution at the linker region while retaining activity will be extremely 
challenging.    
	  
Figure 1.9. Reported linker analogues of Sal-AMS and corresponding activity in 
antimicrobial assays against M. tuberculosis. 64,74,83-89   
 1.5 Goals of this work 
 The previous work by our laboratory had identified OSB-AMS, a tight-
binding inhibitor of MenE with low nM inhibition of its biochemical activity.  
Despite the excellent biochemical activity, OSB-AMS was also shown to have 
poor antimicrobial activity, which is believed to be due to its di-anionic form at 
physiological pH.    Previous work had provided the necessary validation for 
MenE as an antibacterial target, but the poor antimicrobial activity of our lead 
O
HO OH
N
NN
NH2
O NSN
H
OOOOH
O
HO OH
N
NN
NH2
N
H
NSN
H
OOOOH
O
HO OH
N
NN
NH2
N
H
NS
OOOOH
O
HO OH
N
NN
NH2
N
H
NS
OOOOH
FF
O
HO OH
N
NN
NH2
O NSN
H
OOOH
O
HO OH
N
NN
NH2
N
H
NP
OOOH O
O
HO OH
N
NN
NH2
N N
OOH
N N
Sal-AMS
MIC99 = 0.29 µM
Sal-AMSN
MIC99 = 0.19 µM
15
MIC99 = 25 µM
16
MIC99 > 100 µM
17
MIC99 > 100 µM
18
MIC99 > 100 µM
19
MIC99 > 100 µM
O
HO OH
N
NN
NH2
N
H
NS
OOO
20
MIC99 > 100 µM
O
O
HO OH
N
NN
NH2
N
H
NS
OOO
21
MIC99 > 100 µM
O N
	   19	  
compound necessitated additional investigation of the scaffold to move the 
project forward.   
The overarching goal of this work is to design and synthesize selective 
inhibitors of MenE with improved antimicrobial activity while retaining or 
decreasing cytotoxic activity.  To achieve this goal, the project focused on two 
primary areas of interest that are believed to have a significant negative 
impact on antimicrobial activity, the OSB carboxylate and the acyl-sulfamoyl 
group.   Secondary objectives to be addressed while working towards our 
primary objective include: improving our understanding of the MenE binding 
pocket and the accompanying SAR of our scaffold, and remedying a problem 
inherent with this scaffold, namely compound stability.  
In Chapter 2, we investigate the keto-acid/lactol equilibrium of OSB-
AMS and how we might leverage the knowledge from this equilibrium to 
increase antimicrobial activity.  The design, synthesis, biochemical activity, 
and cellular activity of a series of OSB-AMS analogues using keto-acid and 
lactol bioisosteres will be addressed.  Additionally, we will discuss the first 
liganded co-crystal structure of MenE (OSB-AMS•MenE) achieved by our 
collaborators in the laboratory of Prof. Peter Tonge at Stony Brook University.  
In so doing, we provide interesting and important SAR about the OSB region 
of OSB-AMS, answer the question of the active pharmacophore of MenE, and 
discover a difluoroindanediol analogue that shows unusual but improved 
antimicrobial activity. 
In Chapter 3, we investigate the unusual activity of the 
difluoroindanediol analogue.  To do so, we begin with addressing a previously 
non-stereoselective synthetic route by designing and executing a 
stereoselective route to the four difluoroindanediol diastereomers.  We also will 
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discuss the computational docking of the four difluoroindanediol diastereomers 
to the newly acquired OSB-AMS•MenE co-crystal structure.  Finally, we will 
discuss the biochemical and antimicrobial activity of each of the four 
diastereomers, how it compares to our docking model, and what it means for 
the future of the difluoroindanediol scaffold.   
The Chapter 4, we return to address the final problematic area of the 
OSB-AMS scaffold, the acyl-sulfamoyl linker.  We will discuss the design, 
synthesis, and activity of a number of rationally designed OSB-AMS 
analogues designed to mimic key interactions in the MenE binding pocket 
while improving overall stability of these compounds.  We will also discuss the 
implications this work has toward improvements of the ADME of existing and 
future acyl-AMP analogues to inhibit adenylation-forming enzymes.   
The work herein describes the design and synthesis of novel inhibitors 
of menaquinone biosynthesis through the inhibition of MenE, an improved 
docking model for future use of pre-screening proposed inhibitors of MenE, 
and how this work can guide the future of this and similar projects.   
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CHAPTER 2 
TARGETING OF MENE USING THE KETO-ACID/LACTOL EQUILIBRIUM* 
 
2.1 The keto-acid/lactol equilibrium of OSB-AMS 
 Work in our laboratory to target MenE has focused on the use of acyl-
sulfamoyladenosine bioisosteres of the cognate ligand of MenE, OSB-AMP.1-2  
Through this work, OSB-AMS (1, Figure 2.1B) was found to be a low 
nanomolar, tight-binding inhibitor of MenE across various species.   
	  
Figure 2.1. OSB-AMS targeting of MenE.  A) Catalytic cycle of MenE with cognate bound 
ligand (OSB-AMP). B) The keto-acid/lactol equilibrium of OSB-AMS 
However, although OSB-AMS showed potent biochemical activity 
against MenE (IC50), in antimicrobial assays OSB-AMS exhibited only mid-
micromolar activity (MIC) against a variety of bacteria.   We rationalized this 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  Adapted from: Matarlo, J. S.; Evans, C. E.; Sharma, I.; Lavaud, L. J.; Ngo, S. C.; Shek, R.; 
Rajashankar, K. R.; French, J. B.; Tan, D. S.; Tonge, P. J., "Mechanism of MenE Inhibition by 
Acyl-Adenylate Analogues and Discovery of Novel Antibacterial Agents." Biochemistry 2015, 
54, 6514–6524.  
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lack of antimicrobial activity to be largely a consequence of the di-anionic 
nature of OSB-AMS at physiological pH, which would inhibit its ability to diffuse 
into bacteria efficiently and has negative implications for its pharmacokinetics 
in vivo.   
We chose to focus first on addressing to the negatively charged 
carboxylate region of OSB-AMS.  There are a number of known approaches 
such as prodrugs and other masking strategies that could be used to 
effectively hide the carboxylate until it enters the cell, which are then removed 
in the cytoplasm to reveal the more active carboxylate form.  However, a more 
elegant possible solution became available upon the discovery by Dr. Indrajeet 
Sharma in our laboratory that OSB-AMS exists in a keto-acid/lactol equilibrium 
(Figure 2.1B).2  As was discussed in Chapter 1, after examining the structure–
activity relationships (SAR) of our existing analogues and subsequent docking 
experiments, we were unable to determine which form is the active 
pharmacophore for MenE.   We hypothesized that if the lactol form of OSB-
AMS is the active pharmacophore, a stable bioisostere of the lactol form would 
be less polar than OSB-AMS and would therefore more easily pass from the 
extracellular medium into the bacterial cytosol, leading to increased 
antimicrobial activity. We further hypothesized that if the keto-acid form of 
OSB-AMS was the active pharmacophore, stable bioisosteres of the 
carboxylate that are uncharged at physiological pH, less acidic, or better able 
to distribute the negative charge would exhibit increased diffusion into the cell 
and thereby increased antimicrobial activity compared to OSB-AMS.   
 In this light, we proposed a series of keto-acid and lactol analogues of 
OSB-AMS (Figure 2.2).  Ostensibly this work was to determine which form of 
OSB-AMS is the active pharmacophore of MenE and explore the SAR in the 
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OSB binding pocket.  However, the overarching goal was that of finding an 
analogue of OSB-AMS with increased antimicrobial activity.  
	  
Figure 2.2. Proposed keto-acid and lactol analogues of OSB-AMS.   
2.2 Synthesis of proposed analogues 
The synthetic strategy we anticipated being able to use for the 
proposed compounds relied on the general approach used by our laboratory 
for the synthesis of OSB-AMS based inhibitors.1-2  The final compounds 11 
(Figure 2.3) would be derived from various protected forms of the acyl-AMS 
derivatives 12.  These in turn could be obtained through EDCI (1-ethyl-3-(3-
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dimethylaminopropyl)carbodiimide) coupling of the corresponding protected 
sulfamoyladenosine scaffold 14 and carboxylic acid 13.  This general 
approach requires the acyl chain to be in its final form, or a protected version 
of that form before coupling onto the AMS scaffold.  As such, this strategy 
avoids subjecting the less stable acyl-sulfamate to more steps and potentially 
damaging conditions than necessary.   
	  
Figure 2.3. Retrosynthetic approach to the synthesis of proposed analogues. PG = 
protecting group, R = keto-acid and lactol form OSB analogues.  
2.2.1 Synthetic routes to proposed analogues using the general 
approach 
  The synthesis of the tetrazole analogue 2 proceeded rapidly by first 
engaging commercially available 2-cyano-bromobenzene (15, Figure 2.4) in a 
cycloaddition reaction with sodium azide to achieve the tetrazole intermediate 
16 in high yield.  The intermediate 16 was treated with n-BuLi, which allowed 
for lithium–halogen exchange to form the corresponding lithiated species, 
before being quenched with succinic anhydride to provide the desired acyl 
side chain 17.  Attempts to optimize this step by first deprotonating the 
tetrazole with strong bases such as NaH, followed by addition of n-BuLi to 
execute the lithium–halogen exchange failed to appreciably increase the yield.  
The acyl side chain 17 was then coupled to the protected AMS scaffold 18 and 
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deprotected to yield the desired tetrazole analogue 2.  
	  
Figure 2.4. Synthesis of tetrazole analogue 2. HMPA = hexamethylphosphoramide, TFA = 
2,2,2-trifluoroacetic acid, THF = tetrahydrofuran. 
 Synthesis of the trifluoroethanol analogue 3 began by converting the 
commercially available 1,2-dibromobenzene (20, Figure 2.5) into the 
corresponding Grignard with isopropylmagnesium chloride.  The Grignard was 
then quenched with trifluoroacetic anhydride and the newly formed ketone 
reduced with sodium borohydride to form the desired (2-bromophenyl)- 
trifluoroethanol intermediate 21.   Protection of the alcohol as the                  
tert-butyldimethylsilyl (TBS) ether gave intermediate 22, to which was added 
isopropylmagnesium chloride to convert to the corresponding Grignard before 
being quenched with succinic anhydride.  However, the expected succinyl 
ketone intermediate 23 was not observed in this case.  The major product of  
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Figure 2.5. Synthesis of trifluoroethanol analogue. A) Original route to trifloroethanol 
analogue B) Retro-brook rearrangement of intermediate 20.  C) Final synthetic route to the 
trifluoroethanol analogue 3.  BOM = benzyl chloromethyl, TBS = tert-butyldimethylsilyl, THF = 
tetrahydrofuran. 
this reaction was the succinyl ester 26, presumably arising from a retro-Brook 
rearrangement of the Grignard to form intermediate 25.3  Alteration of the 
solvent, temperature, and other reaction conditions did not result in 
observation of the desired product.  Use of n-BuLi in place ofresulted in a 
significantly increased yield of the undesired retro-Brook rearrangement 
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product 26.  Therefore, an alternative protecting group that was stable to 
strongly basic conditions and could be removed under relatively mild 
conditions was needed. 
After screening a number of protecting groups, the benzyloxymethyl 
acetal (BOM) protecting group was found to be the most able to withstand the 
subsequent steps and to be removed without destroying the relatively fragile 
acyl-sulfamate bond of the final product.  Using the BOM protected 
intermediate 27, we converted to the corresponding Grignard before forming 
the succinyl ketone intermediate 28 as originally proposed.  Although the BOM 
group was the best suited to our overall needs, we still observed decreased 
yields due to self-immolation at this step.  The carboxylate 28 was protected 
as the methyl ester 29 before the succinyl ketone was reduced (30) and 
immediately protected to form the bis-BOM ether intermediate 31.  The 
protection of the carboxylate and immediate carrying forward of the crude 
reduced product into the protection step, was found to be necessary due to 
rapid lactonization of the newly formed alcohol onto the free acid or ester of 
the succinyl chain.   The methyl ester was then saponified to give the needed 
carboxylic acid 32, which could be carried forward to give the desired 
trifluoroethanol analogue 3. 
Synthesis of the oxazole analogue 4 proceeded by converting 1,2-
dibromobenzene (20, Figure 2.6) to the corresponding Grignard, followed by 
quenching with succinic anhydride and protection of the carboxylate as the 
methyl ester to provide intermediate 33.  Wilson and coworkers reported the 
efficient palladium–catalyzed arylation of oxazole with various aryl bromides, 
chlorides, and triflates with good yields and selectivity.4  After optimization of 
the reaction with our scaffold, we were able to achieve the desired protected 
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oxazole side chain 34 in modest yield.  This material was then saponified to 
give the carboxylic acid 35, which was carried forward to give the desired 
oxazole analogue 4.  
	  
Figure 2.6. Synthesis of oxazole analogue 4.  THF = tetrahydrofuran. 
Using a similar strategy towards the boronic acid analogue 5, we 
converted the aryl bromide intermediate 33 (Figure 2.7) to the corresponding 
pinacolatoboron intermediate 36 with a Miyaura borylation reaction using 
bis(pinacolato)diboron (B2pin2) before saponification to yield the carboxylic 
acid 37.  The material was then carried forward as previously described to 
yield what was expected to be the open-chain boronic acid analogue 5a.  
However, we observed the succinyl ketone preferentially coordinates with the 
boronic acid to form the cyclic boronate complex (5b, Figure 2.7). Given work 
by Jeremy May and others that use the intermolecular coordination of ketones 
to boronic acids to perform various reactions and observe the coordination 
step to occur very rapidly,5 this intramolecular coordination to form a highly 
favorable five-membered ring is not surprising in retrospect.   As such, our 
originally proposed keto-acid bioisostere is instead an atypical lactol 
bioisostere.  
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Figure 2.7. Synthesis of boronate analogue 5. Pin = pinacolato. 
 Synthesis of the nitro analogue 6 (Figure 2.8) began with a Hosomi–
Sakurai allylation of commercially available o-nitrobenzaldehyde (38) to 
provide the desired olefin intermediate 39.  Hydroboration–oxidation followed 
by two-step oxidation provided the desired carboxylic acid 41.  The completed 
acyl-acid 41 was then carried forward to achieve the desired nitro analogue 6. 
	  
Figure 2.8. Synthesis of nitro analogue 6. THF = tetrahydrofuran, TMS = trimethylsilane. 
Two-step oxidation of intermediate 40 was found to be necessary due 
to the unfavorable kinetics of a one step oxidation, which first oxidizes the 
primary alcohol to the carboxylic acid. The secondary alcohol then quickly 
lactonizes on the activated carboxylic acid, blocking further oxidation.  While 
the secondary alcohol almost certainly cyclizes onto the aldehyde during the 
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Dess–Martin oxidation step to form the hemiacetal, this cyclization is 
sufficiently reversible to allow for oxidation of the secondary alcohol to the 
desired ketone. 
	  
Figure 2.9. Synthesis of squarate analogue 7. TFAA = 2,2,2-trifluoroacetic anhydride, THF 
= tetrahydrofuran. 
 The synthesis of squarate analogue 7 began with alkyne intermediate 
42 (Figure 2.9) which was obtained by Sonogashira coupling of 
homopropargyl alcohol to 1,2-dibromobenzene (20).6  Subsequent gold-
catalyzed tandem cycloisomerization−hydroalkoxylation of intermediate 42 
gave the tetrahydrofuranyl ether product 43.7  Lithium–halogen exchange with 
n-BuLi provided the corresponding ortho-lithiated species which was 
quenched with dimethylsquarate to give intermediate 44.  Treatment of the 
squarate with trifluoroacetic anhydride with concomitant acid catalyzed 
opening of the tetrahydrofuranyl ether provided the reduced succinyl 
intermediate 45. Jones oxidation supplied the desired carboxylic acid 46, 
which was then carried forward to provide the desired squarate analogue 7.  
 To achieve the lactol analogue 8, ortho-lithiation of benzamide 47 
followed by quenching with γ-butyrolactone yielded the reduced succinate 
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intermediate 48.  Reduction of the ketone with sodium borohydride followed by 
acid catalyzed lactonization on the ortho-benzamide formed the reduced 
lactone side chain 50, which was oxidized to the corresponding carboxylic acid 
51.  The acid 51 was then carried forward to provide the desired lactol 
analogue 8.  
	  
Figure 2.10. Synthesis of lactol analogue 8. THF = tetrahydrofuran 
 
2.2.2 Synthetic route to the lactam analogue 9 
 One analogue that was not amenable to our general synthetic approach 
was the lactam analogue 9.  Initial attempts used an OSB diester intermediate 
52, which was treated with ammonia in an effort to form the corresponding 
benzamide 53.  However, this benzamide was never observed, as it 
immediately cyclized on the succinyl-ketone to provide the desired lactam 
scaffold 54.  Upon deprotection of the primary ester to provide the necessary 
carboxylic acid, we observed immediate formation of the lactam/lactone 
spirocycle 55 and other decomposition products.   
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Figure 2.11. Synthesis of the lactam analogue 9. A) Original synthetic route of lactam side-
chain.  B) Successful route to desired lactam analogue.  TBAF = tetrabutylammonium fluoride, 
THF = tetrahydrofuran.   
 To avoid spirocyclization, we executed a late-stage modification where 
the protected MeOSB-AMS scaffold 56 was treated with anhydrous ammonia 
to produce the desired lactam scaffold intermediate 57.  This intermediate was 
then deprotected to yield the desired lactam analogue 9.  
 
2.2.3 Exploration of the hydroxyindanone scaffold and the 
difluoroindanediol 74 
 The final lactol analogue proposed was the hydroxyindanone 10, which 
substituted a methylene in place of the oxygen of the five-membered lactol 
ring.  Initial success en route to this analogue proceeded via a coupled Heck–
aldol annulation cascade with a protected aryl-bromide intermediate 58 (Figure 
2.12) to give the desired protected hydroxyindanone scaffold 59.8   
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Figure 2.12. Synthetic approaches to the proposed hydroxyinanone analogue. dppp = 
1,3-bis(diphenylphosphino)propane, PG = protecting group 
However, as was observed with the lactam analogue, once the free 
carboxylic acid was formed we observed immediate formation of the undesired 
spirocycle 60.   Attempts to open the spirocycle with various nucleophiles in 
hopes to form the desired connection through an orthogonal route (62) gave 
only decomposition products.  Likewise, attempts to protect the tertiary alcohol 
(61) proved unsuccessful, giving only decomposition products.  During this 
work it became apparent that the intrinsically unstable tertiary-benzylic alcohol 
is further destabilized by the presence of the acidic α-keto protons of the 
indanone ring, which can deprotonate before rapidly undergoing undesired 
reaction pathways such as β-elimination.    
 To circumvent the issue of spirocycle formation, we attempted a late 
stage Heck–aldol with various protected forms of the aryl-bromide-AMS 
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scaffold 63 (Figure 2.12B).  While the majority of the material decomposed 
along the acyl-sulfamate bond in the reaction conditions, enough desired 
product was formed to shed light on an important aspect of the scaffold.  Upon 
attempting to isolate the desired product and variations of it, we discovered 
that the hydroxyindanone motif is intrinsically unstable as a part of the acyl-
AMS scaffold.  As was mentioned in Chapter 1, the acyl-sulfamate has a pKa = 
1.3, which is sufficiently acidic to induce decomposition of the 
hydroxyindanone moiety upon concentration.  Therefore, to move this 
analogue forward we needed to address two main issues.  The first issue of 
spirocyclization would require modifications to the proposed acyl chain 
allowing for formation of the acyl-sulfamate bond.  The second issue of self-
immolation would require modifications to the proposed hydroxyindanone 
analogue to increase the stability of the final compound.  
 As protecting the tertiary alcohol was not favorable to circumvent 
spirocyclization, we envisioned modifying the route to use an alkyne between 
the hydroxyindanone and the carboxylic acid (66, Figure 2.13).  While this 
would prevent spirocyclization, installation of an alkyne at that position posed 
additional problems.  The protected alkynyl-bromobenzene 65 was unable to 
undergo the coupled Heck–aldol annulation cascade due to the highly 
activated alkyne.   Likewise, known literature methods of installing an alkyne 
moiety at the desired position ketone position of the indanone scaffold were 
not amenable to the reactive α-keto protons of either 1,3-indandione (68) or 3-
hydroxyindanone (67).  Additionally, we had already established the tertiary 
alcohol to be highly unstable. The conjugation of an alkynyl group seemed 
likely to exacerbate the intrinsic instability of this scaffold. 
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Figure 2.13. Proposed alkynyl intermediate and attempted routes.  dppp =1,3-
bis(diphenylphosphino)propane 
To solve this problem we returned to the second issue of overall 
compound stability and altering our proposed inhibitor.  Historically, when 
similar hydroxyindanone scaffolds are prepared and used, they contain alkyl 
substituents at the α-keto position.9-12  This functionally blocks the primary 
decomposition pathway and allows for a wider breath of chemistries to be 
performed.  Rather than use alkyl substituents, we opted to use fluorine, which 
would block the α-keto position from engaging in unwanted side reactions and 
inductively increase the stability the tertiary alcohol.   
The synthesis of the newly proposed difluorohydroxyindanol analogue 
began with the fluorination of commercially available 1,3-indanone (68, Figure 
2.14) to supply the difluoronated intermediate 69. Treatment with lithiated tert-
butyl propiolate provided the desired difluorohydroxyindanone scaffold 70, 
which was deprotected to give the free carboxylic acid intermediate 71.  This 
was coupled onto the protected AMS scaffold 18 and the alkyne reduced to 
give the desired reduced form of the aliphatic chain 73.  
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Figure 2.14: Synthesis of difluoroindanediol analogue 74.  
Interestingly, all successful attempts to reduce the alkyne resulted in 
concurrent reduction of the benzylic ketone.  A number of different reducing 
conditions were screened with identical results, and known selective 
conditions to reduce alkynes such as diimide reduction resulted in 
decomposition of the acyl-sulfamate group.  Attempts to reoxidize the alcohol 
to the desired ketone also resulted only in decomposition of the starting 
material.  However, upon analysis of the difluoroketone in aqueous media, we 
observed that it exists as the hydrate, which is consistent with literature reports 
of α-fluorinated ketones.13-14  We rationalized therefore that moving forward 
with the fully reduced analogue would not be unreasonable and in aqueous 
media could arguably be a better ketone analogue than the larger and bulkier 
hydrate, so intermediate 73 was deprotected to give the difluoroindanediol 
O
O
F
F
O
O
1% SDS H2O, 93%
SelectFluor LDA,
THF, 64%
O
F
F
HO
O
O
O
F
F
HO
O
OH
O
O O
N
NN
NHBoc
O NSN
H
O OO
O
OH
Pd/C, H2
CH2Cl2, 68%
O
HO OH
N
NN
NH2
O NSN
H
O OO
OH
TFA, H2O,
TFA
HO
F
F
F
F
68
O
O
+ O
O O
N
NN
NHBoc
O NSH2N
O O EDCI, DMAP
CH2Cl2, 57%
CH2Cl2, 50%MeOH
O
O O
N
NN
NHBoc
O NSN
H
O OO
OH
HO F F
69 70
71 18 72
73 74
	   47	  
analogue 74.  
  
2.3 Biochemical activity of keto-acid and lactol analogues 
 The newly synthesized keto-acid and lactol analogues were tested for 
inhibitory activity in biochemical assays against E. coli MenE (ecMenE) by our 
collaborators in the laboratory of Professor Peter Tonge at Stony Brook 
University.  Briefly, assays were performed using a MenE-MenB coupled 
assay with percent inhibition determined by the relative decrease in the rate of 
DHNA (1,4-dihydroxy-2-naphthoic acid) production observed by fluorescence 
spectroscopy (see experimental section 2.5 for details).2  
 The oxazole (4), trifluoroethanol (3), and nitro (6) analogues of the keto-
acid form of OSB-AMS as well as the boronate (5), lactol (8), and lactam (9) 
analogues of the lactol form of OSB-AMS showed no inhibitory activity up to 
100 µM (Table 2.1).  The squarate analogue (7) was the most potent of the 
keto-acid and lactol analogues, with an IC50 of 0.17 ± 0.05 µM, while the 
tetrazole analogue (2) showed modest activity with an IC50 of 2.2 ± 0.4 µM.  
Interestingly, the difluoroindanediol analogue (74) also showed modest 
inhibitory activity with an observed IC50 of 1.5 ± 0.1 µM.  While the majority of 
the SAR indicates that the keto-acid form of OSB-AMS is the active 
pharmacophore, we could not yet rationalize the activity of the 
difluoroindanediol analogue.    
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Table 2.1.  Biochemical activity of keto-acid and lactol analogues of OSB-AMS.   
Inhibitor IC50 (µM) pKa 
(1) OSB-AMS 	   0.025 ± 0.005 4.5 
(2) tetrazole 	   2.2 ± 0.4 3.4 
(3) trifluoroethanol 	   > 100 11.8 
(4) oxazole 	   > 100 > 14 
(5) boronate 	   > 100 > 14 
(6) nitro 	   > 100 > 14 
(7) squarate 	   0.17 ± 0.05 1.3 
(8) lactol 	   > 100 > 14 
(9) lactam 	   > 100 > 14 
(74) difluoroindandiol 	   1.5 ± 0.1 11.5 
IC50 values for inhibition of E. coli MenE (ecMenE). All IC50 measurements were performed in 
triplicate. 
 
O
O
O
O
O
O
N
N
NN
OCF3
OH
OH
O
N
O
O
O
OB
HO
HO
N
O
O
O
O
O
OO
OO
O
OO
O
NHO
OH
O
OH
HO F F
	   49	  
After observing that the most active keto-acid analogues carried 
negative charges at physiological pH [tetrazole (3) pKa = 3.4, squaric acid (7) 
pKa = 1.3], we measured the pKa of the difluoroindanediol analogue 74 and 
determined a pKa of 11.5.   Although this is not sufficiently acidic to be in a 
deprotonated state at physiological pH, it is within range of deprotonation by 
the arginine we postulated could interact with the free carboxylate of OSB 
(arginine pKa = 12.4).  However, upon analyzing the pKa of the trifluoroethanol 
analogue (3), we found that it has a nearly identical pKa of 11.8, and so could 
presumably engage in the same interaction profile.  However, it has an IC50 
> 100-fold worse than that of the difluoroindanediol analogue.  Additionally, 
upon investigating the Kd of the active compounds using isothermal titration 
calorimetry (ITC), we observed that, unlike the other active compounds 
(including OSB-AMS), the difluoroindanediol analogue bound with no 
detectable change in enthalpy and so required fluorescence binding assays to 
determine the Kd.  Given the carboxylate of OSB will exist in a charged state at 
physiological pH prior to binding MenE, while the difluoroindanediol would 
exist in an uncharged state prior to binding MenE, if MenE was indeed 
deprotonating the difluoroindanediol in the binding pocket to form the 
postulated ionic interaction or is being deprotonated prior to binding, we would 
expect to see the opposite trend in the enthalpic binding profiles of the two 
inhibitors.15-19  Taken together, the asymmetric activity of the trifluoroethanol 
analogue relative to the difluoroindanediol analogue, the notable decline in 
binding enthalpy compared to OSB-AMS, and crystallographic evidence 
(discussed in the next section) suggests the difluoroindanediol analogue has a 
distinct binding mode from that of OSB-AMS and our keto-acid analogues.  
Therefore, although the difluoroindanediol shows modest inhibition of 
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MenE in biochemical assays, it appears to do so outside the paradigm of the 
keto-acid and lactol pharmacophore hypothesis.  This leaves us with only 
keto-acid analogues showing activity against MenE, suggesting the keto-acid 
form of OSB-AMS is the active pharmacophore of MenE.  This was confirmed 
a short time later by work that will be discussed in the next section.   
 
2.3 Studies with the R195K mutant MenE enzyme.  
 As was discussed in Chapter 1, previous docking studies with the 
unliganded structure of S. aureus MenE found the highly conserved residue 
Arg222 (E. coli = R195, M. tuberculosis = R90) could engage in ionic 
interactions with the free carboxylate of OSB.  To investigate the importance 
and role of this residue while potentially shedding light on the active 
pharmacophore of MenE, Dr. Joe Matarlo in the laboratory of Professor Peter 
Tonge replaced the Arg195 residue of ecMenE with either a lysine (R195K) or 
glutamine (R195Q) by site-directed mutagenesis.   
 
Table 2.2. Catalytic and ITC data for the interaction between OSB and OSB-AMS with 
wild-type and mutant MenE. 
 
ecMenE 
KMOSB 
(µM)a 
kcat 
(min-1)a 
kcat/KM 
(µM-1 min-1)a 
KdOSB-AMS 
(nM)b 
ΔG 
(kcal/mol)b 
wt   1 ± 0.02 46 ± 0.12  46 ± 0.023   44 ± 11 –10.0  
R195K 16 ± 1.4 47 ± 0.33     3 ± 0.2 394 ± 36 –8.8 
R195Q not active 4500 ± 112 –7.3 
aKinetic parameters were obtained using the MenE−MenB coupled assay.  Measurements 
were performed in 20 mM NaHPO4 buffer (pH 7.4) containing 150 mM NaCl and 1 mM MgCl2 
at 25 °C. All measurements were performed in triplicate. bBinding of OSB-AMS to ecMenE 
determined by ITC. A 1 mM solution of inhibitor [dissolved in 20 mM NaHPO4 buffer (pH 7.4) 
containing 150 mM NaCl and 1 mM MgCl2 at 25 °C] was titrated in 4 μL increments into the 
1.8 mL cell containing a 25 μM solution of ecMenE in the same buffer. The data were fit to a 
single-binding site model. Measurements were taken in triplicate. 
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 While both ecMenE mutants showed no significant alteration to the 
secondary structure by circular dichroism spectroscopy, testing and analysis of 
the catalytic activity of the two mutants showed significant changes when 
compared to the wild-type MenE in MenE-MenB coupled assays.  The R195K 
mutant MenE possessed a catalytic efficiency (kcat/KM) approximately 15-fold 
worse than the wild-type MenE and the R195Q mutant showed no catalytic 
activity with up to 240 µM OSB.   Although the turnover rate was nearly 
identical between the wild-type and the R195K mutant, the binding efficiency 
of the R195K mutant was ~8-fold worse than that of the wild-type and the 
R195Q mutant showed a ~100-fold decrease in binding efficiency.  Suggesting 
that the arginine is critically responsible for interactions with OSB in the 
binding pocket and likely engages the carboxylate in two distinct interactions.  
The lack of activity with the glutamine mutant also indicates that a negatively 
charged residue is necessary for optimal substrate recognition, which adds 
further evidence that the keto-acid is the active pharmacophore of MenE.   
 In order to fully validate the keto-acid as the active pharmacophore, 
Dr. Joe Matarlo began work towards a MenE•OSB-AMS cocrystal structure. 
These efforts met success with the R195K mutant of MenE, resulting in a 
2.4 Å resolution OSB-AMS liganded crystal structure of MenE (PDB entry 
5C5H).  The electron density of the bound OSB-AMS is well defined and 
models clearly with the keto-acid form of OSB (Figure 2.15).  The lactol forms 
of OSB-AMS are unable to adopt conformations that allow fitting to the 
electron density of the cocrystalized ligand in either the (R)-lactol or (S)-lactol 
forms.  Taken together, our combined SAR, enzyme kinetics, and cocrystal 
structure support the conclusion that the keto-acid form of OSB-AMS is the 
active pharmacophore.  
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Figure 2.15: Modeling of the lactol isomer of OSB-AMS in the electron density of the 
ligand in E. coli MenE (R195K) active site.  The electon density observed in the E. coli 
Mene (R195) mutant, shown contoured at 2.6 σ.  A) Keto-acid form of OSB-AMS (B = rotated 
100º on y-axis). C) (S)-lactol form of OSB-AMS (D = C rotated 100º on y-axis).  E) (R)-lactol 
form of OSB-AMS (F = E rotated 100º on y-axis). 
Using the crystal structure, we identified a number of highly conserved 
residues (Ser188, Lys195, Ser222, Thr277) in the OSB binding pocket that 
would confer binding specificity.  While Lys195 (Arg195), Ser188, and Ser222 
interact with the free-carboxylate of OSB via two bridging water molecules 
(Figure 2.16), Thr277 appears to interact directly with the free carboxylate.  It 
is not known whether Arg195 in the wild-type MenE interacts with the free-
carboxylate of OSB through these bridging water molecules or if they are 
eliminated upon binding and the arginine interacts directly with the free-
carboxylate.    In either case, the crystal structure clearly shows the keto-acid 
form of OSB-AMS binding to ecMenE in much the same conformation 
predicted in our previously published docking structure of OSB-AMSN to 
saMenE.2  
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Figure 2.16: X-ray crystal structure of OSB-AMS•MenE (R195K) active site.  A) OSB-AMS 
bound MenE with conserved residues (green).  B) MenE binding pocket with interactions and 
distances between Thr277 (green) and Lys195 (yellow, via bridging waters) with carboxylate 
of OSB shown.  
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2.4 Cellular activity of OSB-AMS and the active keto-acid and lactol 
analogues.  
 In addition to biochemical assays against MenE, our collaborators in the 
laboratory of Prof. Peter Tonge tested the keto-acid and lactol analogues in 
antimicrobial assays against M. tuberculosis, methicillin-resistant 
Staphylococcus aureus (MRSA), and B. subtilis.    OSB-AMS (1, Table 3) has 
an observed MIC of 62.5 µg/mL against B. subtilis, 31.25 µg/mL against 
MRSA, and 25 µg/mL against M. tuberculosis.  Interestingly, the keto-acid 
analogues (tetrazole 2 and squarate 7) showed no antimicrobial activity up to 
250 µg/mL, while the difluoroindanediol analogue (74) had an MIC of 31.25 
µg/mL against B. subtilis, 15.6 µg/mL against MRSA, and 15.6 µg/mL against 
M. tuberculosis.  Importantly, this increase in toxicity was not observed in 
mammalian cell lines (Vero).  
 
Table 2.3. Antimicrobial and cytotoxicity of MenE inhibitors.   
 
MIC  
(µg/mL)a 
MIC + MK4  
(µg/mL)b 
Cytotoxicity 
(µg/mL)c 
Inhibitor B. subtilis MRSA M. tuberculosis MRSA M. tuberculosis Vero 
1 62.5      31.25 125 > 250 > 250 125 
2 > 250 > 500 ND > 500 ND ND 
7 > 250 > 500 ND > 500 ND ND 
74   31.25   15.6     15.6 > 250 > 250 > 250 
aMIC values were obtained against B. subtilis (ATCC 6057), methicillin-resistant S. aureus 
(ATCC BAA-1762), and M. tuberculosis (H37Rv). Inoculum levels for each MIC measurement 
ranged from 1 Å ~ 106 to 2 Å ~ 106 cells/mL. All MICs were determined in technical and 
experimental triplicate. bMICs determined with exogenous 10 µg/mL MK4 added to the 
synthetic growth medium. cCytotoxicity values were obtained against Vero (monkey kidney 
epithelial) cells. Measurements were performed in technical and experimental triplicate.  ND = 
not determined. 
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To validate the observed antimicrobial activity is due to inhibition of 
menaquinone production, assays against MRSA and M. tuberculosis were 
repeated in the presence of menaquinone-4 (MK4, 10 µg/mL).  When cells 
treated with OSB-AMS based inhibitors were coadministered exogenous MK4, 
we observed rescue of normal cell growth, suggesting that antimicrobial 
activity arises through inhibition of MenE.  To provide additional validation of 
on-target activity, the laboratory of Professor Peter Tonge used LC-MS/MS 
analysis of OSB-AMS treated MRSA to quantify levels of endogenous 
menaquinone.  In MRSA treated with sub-lethal doses of OSB-AMS we 
observed a 3-5-fold decrease in endogenous menaquinone levels over non-
treated cells, suggesting further that the observed antimicrobial activity is due 
to on-target inhibition of menaquinone biosynthesis.   
 
2.4 Discussion and Conclusions 
 While the initial goal of this work was to determine which form of     
OSB-AMS is the active pharmacophore of MenE and gain a better 
understanding of the MenE binding pocket, the overarching goal of the work 
was to potentially discover an analogue able to exhibit increased antimicrobial 
activity over our lead compound OSB-AMS.  To this end, keto-acid and lactol 
analogues of OSB-AMS were synthesized and tested in biochemical assays to 
determine their ability to inhibit MenE.  We found the tetrazole (2), squarate 
(7), and difluoroindanediol (74) analogues of OSB-AMS inhibited MenE in 
good (squarate: ecMenE IC50 = 0.17 µM) to modest (tetrazole: ecMenE IC50 = 
2.2 µM, difluoroindanediol: ecMenE IC50 = 1.5 µM) concentrations.  We 
determined that the difluoroindanediol is likely inhibiting MenE through a 
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distinct binding mode from OSB-AMS and the other keto-acid analogues, 
which resulted in only keto-acid form analogues showing appreciable activity 
in biochemical assays.  These results suggested that the keto-acid form of 
OSB-AMS is the active pharmacophore.   
Through the use of MenE mutants (R195K, R195Q), we showed the 
importance of the previously discovered Arg195 to proper recognition of the 
OSB substrate.  Additionally, the R195K mutant of MenE was cocrystalized 
with OSB-AMS to show the keto-acid form of OSB-AMS interacting with the 
R195K side-chain via two bridging water molecules.  Taken together, our 
evidence strongly suggests the keto-acid form of OSB-AMS is the active 
pharmacophore.   
In antimicrobial assays we discovered the keto-acid analogues 
(tetrazole 2 and squarate 7) showed no activity (MIC) up to 250 µg/mL, while 
the difluoroindanediol analogue 74 exhibited antimicrobial activity (MIC)        
2–10-fold better than that of OSB-AMS against a variety of bacterial species.  
Importantly, the difluoroindanediol analogue showed improved antimicrobial 
activity but exhibited no increase in cytotoxicity against mammalian cells.  We 
observed a rescue of normal cell growth through addition of exogenous 
menaquinone-4 in bacteria treated with difluoroindanediol and OSB-AMS, and 
showed menaquinone production in MRSA is inhibited through treatment with 
OSB-AMS.  These results suggest that the active analogues are in fact 
inhibiting menaquinone production, ostensibly through inhibition of the desired 
target MenE.   
While these results are promising and seem to achieve the goals set 
out at the beginning of the chapter, the reason for the increased antimicrobial 
activity of the difluoroindanediol is uncertain.   One possible explanation of the 
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increase activity is the loss of one of the negative charges in the 
difluoroindanediol analogue relative to OSB-AMS at physiological pH, thereby 
allowing for higher intracellular concentrations of drug.  However, as was 
noted in Chapter 1, antimicrobial activity of OSB-AMS is only observed with 
intracellular concentrations ~4-log higher than the IC50 of the inhibitor to MenE.  
If this trend were generally true for all OSB-AMS based inhibitors of MenE, it 
would imply the difluoroindanediol analogue must have an intracellular 
concentration of ~15 mM, or roughly 1000-fold higher than the extracellular 
concentration of drug at the observed MIC.  While cells rely on establishment 
of concentration gradients between the cytosol and the extracellular medium 
for maintaining membrane potential and uptake of key nutrients from the 
environment; examples of drugs known to use active-transport in the literature 
never reach such disparity in concentrations across the membrane.20-21  Such 
a disparity would also stand in stark contrast to observed trends observed by 
our laboratory with acyl-AMS based compounds in published LC-MS/MS 
based compound accumulation assays.22  Another possible explanation for the 
antimicrobial activity is the difluoroindanediol analogue exhibits a level of 
selectivity for MenE far higher than that of OSB-AMS.   However, if we assume 
the difluoroindanediol is unique from every other polar acyl-AMS based 
compound and perfectly able to cross the cellular membrane to achieve 100% 
accumulation in the cells, it would require a specificity ~3-log better for MenE 
than that of OSB-AMS.   While technically possible, given the IC50 of the 
difluoroindanediol is roughly ~3-log less potent than that of OSB-AMS, the 
likelihood of increased specificity being the cause of the increased activity is 
remote.  The third possibility is the antimicrobial activity of the 
difluoroindanediol analogue is due to an unknown off-target binding event or 
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mechanism of action.    While we do see rescue of normal cell growth in 
difluoroindanediol analogue treated MRSA with supplementation of exogenous 
MK-4, this is not proof that we are in fact inhibiting MenE.  Certainly the 
difluoroindanediol analogue shows promise and warrants further investigation 
as to the mechanism behind the surprising improvement in antimicrobial 
activity. 
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2.5 Experimental Section 
A. Materials and Methods 
 Reagents were obtained from Aldrich Chemical (www.sigma-
aldrich.com) or Acros Organics (www.fishersci.com) and used without further 
purification. Optima or HPLC grade solvents were obtained from Fisher 
Scientific (www.fishersci.com), degassed with Ar, and purified on a solvent 
drying system. Reactions were performed in flame-dried glassware under 
positive Ar pressure with magnetic stirring.  
 
TLC was performed on 0.25 mm E. Merck silica gel 60 F254 plates and 
visualized under UV light (254 nm) or by staining with potassium 
permanganate (KMnO4), cerium ammonium molybdenate (CAM), or iodine (I2). 
Silica flash chromatography was performed on E. Merck 230–400 mesh silica 
gel 60. Preparative scale HPLC purification was carried out on a Waters 2545 
HPLC with 2996 diode array detector using a Sunfire Prep C18 reverse phase 
column (10 Å~ 150 mm, 5 μm) with UV detection at 254 nm. Samples were 
lyophilized using a Labconco Freezone 2.5 instrument. 
 
IR spectra were recorded on a Bruker Optics Tensor 27 FTIR 
spectrometer with Pike technologies MIRacle ATR (attenuated total 
reflectance, ZnSe crystal) accessory and peaks reported in cm–1. NMR spectra 
were recorded on a Bruker Avance III 500 instrument or Bruker Avance III 600 
instrument at 24 °C in CDCl3 unless otherwise indicated. Spectra were 
processed using Bruker TopSpin or nucleomatica iNMR (www.inmr.net) 
software, and chemical shifts are expressed in ppm relative to TMS (1H, 0 
ppm) or residual solvent signals: CDCl3 (1H, 7.24 ppm; 13C, 77.23 ppm), 
CD3OD (1H, 3.31 ppm; 13C, 49.15 ppm), D2O (1H, 4.80 ppm); coupling 
constants are expressed in Hz. Mass spectra were obtained at the MSKCC 
Analytical Core Facility on a Waters Acuity SQD LC-MS by electrospray (ESI) 
ionization or atmospheric pressure chemical ionization (AP-CI). 
 
Atom numbers shown in chemical structures herein correspond to 
standard nucleoside numbering system and not to IUPAC nomenclature, 
which was used solely for each compound. Compounds not cited above are 
numbered henceforth from S1. 
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B. Tetrazole Analogue (2). 
 
 
 
5-(2-Bromophenyl)-2H-tetrazole (16).  2-Bromobenzonitrile (15) (1 g, 5.494 
mmol, 1 equiv), triethylamine hydrochloride (2.269 g, 16.482 mmol, 3.0 equiv), 
and sodium azide (1.072 g, 16.482 mmol, 3.0 equiv) were suspended in 20 mL 
toluene and stirred at 100 ºC for 6 h.  The reaction was then cooled to rt, 
filtered through a celite pad, and concentrated under vacuum.  The residue 
was reconstituted in 20 mL water, acidified with 1 M KHSO4, and extracted 
with EtOAc (5 x 20 mL).  The combined organic extracts were dried (Na2SO4), 
filtered, and concentrated by rotary evaporation.  Purification by silica flash 
chromatography (0% → 25% EtOAc in hexanes with 1% AcOH) yielded the 
title product 16 (1.175 g, 95% yield) as a white solid.  
 
IR (ATR): 2465, 1604, 1574, 1475, 1447, 1435, 1396, 1276, 1247, 1165, 1093, 
1056, 1027, 1011, 995, 924, 879, 773, 7485, 712, 643.  1H-NMR (600 MHz; 
CD3OD): δ 7.83 (dd, J = 8.0, 0.9 Hz, 1H), 7.69 (dd, J = 7.6, 1.5 Hz, 1H), 7.56 
(td, J = 7.6, 1.2 Hz, 1H), 7.51 (td, J = 7.8, 1.7 Hz, 1H).  13C-NMR (150 MHz; 
CD3OD): δ 156.211, 134.966, 133.866, 133.025, 129.233, 127.560, 123.224.  
HRMS (ESI) m/z calcd for C7H6BrN4 ([M+H]+) 224.9776; found 224.9781. 
 
 
 
 
4-(2-(2H-Tetrazol-5-yl)phenyl)-4-oxobutanoic acid (17). Aryl bromide 16 
(107 mg, 0.475 mmol, 1 equiv) and HMPA (191.5 mg, 1.069 mmol, 2.25 equiv) 
were dissolved in 0.5 mL THF before being cooled to –78 ºC.  n-BuLi (0.668 
mL, 1.069 mmol, 2.25 equiv, 1.6 M in THF)  was added drop wise and the 
reaction stirred for 1 h at –78 ºC.  The reaction was added via cannula to a 
suspension of succinic anhydride (190 mg, 1.901 mmol, 4.0 equiv) in 2 mL 
THF at –78 ºC, then stirred for 6 h.  The reaction was warmed to rt and 
quenched with 10 mL 1M HCl before being extracted with EtOAc (5 x 10 mL). 
The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  Purification by silica flash 
N
N
NHN
Br
O
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chromatography (25% → 75% EtOAc in hexanes, 1% AcOH) yielded the 
product (17) as a white crystalline solid (65 mg, 56%).  
 
IR (ATR): 2964, 2926, 1712, 1402, 1368, 1176, 1102, 991, 778, 756.  1H-NMR 
(600 MHz; CD3OD): δ 7.96–7.95 (m, 1H), 7.72 (dq, J = 6.0, 3.0 Hz, 3H), 3.19 
(t, J = 6.4 Hz, 2H), 2.67 (t, J = 6.4 Hz, 2H).  13C-NMR (150 MHz; CD3OD): δ 
203.563, 176.568, 140.785, 132.760, 132.282, 131.786, 129.928, 124.609, 
37.299, 29.125.  HRMS (ESI) m/z calcd for C11H9N4O3 ([M+H]+) 269.0651; 
found 269.0668. 
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(N-[4-(2-(2H-tetrazol-5-
yl)phenyl)-4-oxobutanoyl]sulfamoyl)adenosine (19). Keto acid 17 (100 mg, 
0.406 mmol, 1 equiv), protected 5´-O-sulfamoyladenosine 18 (296 mg, 0.609 
mmol, 1.5 equiv), prepared as previously described,2,23 and DMAP (50 mg, 
0.406 mmol, 1 equiv) were suspended in 25 mL CH2Cl2 and EDCI (311 mg, 
1.624 mmol, 4 equiv) added.  The reaction was stirred for 3 h at rt before 
being quenched with 25 mL water and extracted with dichloromethane (5 x 25 
mL).  The combined organic extracts were dried (Na2SO4), filtered through a 
pad of celite, and concentrated by rotary evaporation to afford the crude 
protected tetrazole analogue 19 (473 mg, 163% crude yield), which was used 
without further purification. 
 
 
 
 
5´-O-(N-[4-(2-(2H-Tetrazol-5-yl)phenyl)-4-oxobutanoyl]sulfamoyl) 
adenosine (2). Crude protected tetrazole AMS analogue 19 was dissolved in 
15 mL DCM and 1 mL H2O, cooled to 0 ºC.  TFA (15 mL) was added and the 
reaction stirred for 3 h while returning to rt. Concentration by rotary 
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evaporation, purification by preparative HPLC (5% → 95% MeCN in H2O with 
0.01% TFA), and lyophilization yielded tetrazole analogue 2 as a fluffy white 
solid (78 mg, 33% over two steps).  
 
IR (ATR): 3321, 3115, 2908, 2824, 1693, 1615, 1479, 1424, 1363, 1201, 1121, 
975, 872, 730.  1H-NMR (600 MHz; CD3OD): δ 8.45 (s, 1H), 8.33 (s, 1H), 
7.95–7.93 (m, 1H), 7.71–7.68 (m, 3H), 6.09 (d, J = 5.1 Hz, 1H), 4.62 (t, J = 5.1 
Hz, 1H), 4.55–4.48 (m, 2H), 4.36 (t, J = 4.7 Hz, 1H), 4.32 (q, J = 3.8 Hz, 1H), 
3.25 (td, J = 6.1, 2.4 Hz, 2H), 2.67 (t, J = 6.1 Hz, 2H).  13C-NMR (151 MHz; 
CD3OD): δ 203.1, 172.8, 153.1, 150.3, 147.4, 143.2, 140.2, 133.0, 132.5, 
131.8, 130.1, 124.2, 120.5, 90.2, 83.7, 75.8, 72.3, 71.7, 36.6, 30.9.  HRMS 
(ESI) m/z calcd for C21H23N10O8S ([M+H]+) 575.1421; found 575.1436. 
 
 
 
C. Trifluoroethanol analogue (3). 
 
 
 
1-(2-Bromophenyl)-2,2,2-trifluoroethanol (21).  Isopropylmagnesium 
bromide (40.75 mL, 52.98 mmol, 1.25 equiv, 1.3 M in THF) was cooled to 
0 ºC, 1,2-dibromobenzene (10 g, 42.39 mmol, 1 equiv) was added drop wise 
and allowed to stir for 1.5 h.  The solution was added drop wise via cannula 
over 30 min to a stirring solution of trifluoroacetic anhydride (32.63 g, 211.9 
mmol, 5.0 equiv) in THF (100 mL) at 0 ºC.  The reaction was stirred for 30 min, 
quenched with saturated ammonium chloride (100 mL), diluted with water (200 
mL) and extracted with Et2O (3 x 200 mL).  The combined organic extracts 
were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  The 
crude product was dissolved in MeOH (75 mL) and cooled to 0 ºC.  NaBH4 
(1.9 g, 50.38 mmol, 1.25 equiv) was added in three portions over 15 min.  The 
reaction was stirred for 15 min before being quenched with 1M HCl (250 mL) 
and extracted with CH2Cl2 (4 x 200 mL).  The combined organic extracts were 
dried (Na2SO4), filtered, and concentrated by rotary evaporation.  Purification 
by silica flash chromatography (0% → 15% EtOAc in hexanes) yielded the 
product (21) as a clear, colorless oil (8.6 g, 84% over two steps). 
 
IR (ATR): 3377, 1441, 1265, 1173, 1125, 1077, 1026, 874, 830, 757, 730, 701, 
674, 624.  1H-NMR (500 MHz; CDCl3): δ 7.68 (d, J = 7.8 Hz, 1H), 7.60 (dd, J = 
8.0, 0.9 Hz, 1H), 7.40 (td, J = 7.6, 0.6 Hz, 1H), 7.28–7.25 (m, 1H), 5.65–5.61 
CF3
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(m, 1H), 2.66 (d, J = 4.1 Hz, 1H).  13C-NMR (126 MHz; CDCl3): δ 133.7, 133.0, 
131.0, 129.3, 127.9, 124.3, 123.9, 77.3, 77.0, 76.8, 71.3.  19F-NMR (471 MHz; 
CDCl3): δ -77.6.  HRMS (ESI) m/z calcd for C8H5BrF3O ([M-H]-) 252.9481; 
found 252.9476. 
 
 
 
 
1-(1-((Benzyloxy)methoxy)-2,2,2-trifluoroethyl)-2-bromobenzene (27).  
NaH (70 mg, 2.940 mmol, 1.5 equiv) was suspended in THF (3 mL), cooled to 
0 ºC, and trifluoroethanol analogue 21 (500 mg, 1.960 mmol, 1 equiv) in THF 
(2 mL) was added drop wise.  The reaction was stirred for 15 min, then BOMCl 
(613 mg, 3.920 mmol, 2.0 equiv) in THF (2 mL) was added drop wise.  The 
reaction was stirred for 4 h, then quenched with saturated ammonium chloride 
(50 mL), and extracted with CH2Cl2 (4 x 50 mL).   The combined organic 
extracts were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (0% → 15% EtOAc in hexanes) 
yielded the product (27) as a clear, colorless oil (680 mg, 92%).  
 
IR (ATR): 2956, 2898, 1497, 1472, 1441, 1372, 1272, 1167, 1133, 1041, 980, 
906, 846, 734, 699, 677, 626.  1H-NMR (500 MHz; CDCl3): δ 7.65 (d, J = 7.8 
Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.30 (td, J = 11.7, 
5.8 Hz, 3H), 7.26–7.23 (m, 3H), 5.69 (q, J = 6.5 Hz, 1H), 4.87 (d, J = 6.9 Hz, 
1H), 4.67 (dd, J = 16.2, 9.3 Hz, 2H), 4.48 (d, J = 11.6 Hz, 1H).  13C-NMR (126 
MHz; CDCl3): δ 136.9, 133.0, 132.7, 131.0, 130.0, 128.5, 128.08, 127.97, 
127.82, 124.8, 124.1, 93.1, 73.9, 70.1.  19F-NMR (471 MHz; CDCl3): δ -
75.909.  HRMS (ESI) m/z calcd for C16H14BrF3O2Na ([M+Na]+) 397.0027; 
found 397.0020. 
 
 
 
 
4-Oxo-4-(2-(1-((benzyloxy)methoxy)-2,2,2-trifluoroethyl)phenyl)butanoic 
acid (28). Isopropylmagnesium chloride (4.1 mL, 5.33 mmol, 2.0 equiv, 1.3 M 
in THF) was cooled to 0 ºC and arylbromide 27 (1 g, 2.665 mmol, 1 equiv) in 
THF (2.5 mL) was added drop wise.  The reaction was stirred at 0 ºC for 1 h, 
then added drop wise via cannula to a stirring suspension of succinic 
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anhydride (800 mg, 7.995 mmol, 3.0 equiv) in THF (10 mL) at 0 ºC.  The 
reaction was stirred for 6 h while returning to rt, then quenched with 1 M HCl 
and extracted with EtOAc (4 x 100 mL).  The combined organic extracts were 
dried (Na2SO4), filtered, and concentrated by rotary evaporation afford the 
crude acid 28 (1.4 g, 141% crude yield), which was used without further 
purification.  
 
 
 
 
Methyl 4-oxo-4-(2-(1-((benzyloxy)methoxy)-2,2,2-trifluoroethyl)phenyl) 
butanoate (29).  Keto acid 28 from previous step and K2CO3 (1.471 g, 10.65 
mmol, 4 equiv.) were suspended in 25 mL MeCN before CH3I (1.511 g, 10.65 
mmol, 4 equiv) added.  The reaction was heated to 50 ºC for 2 hours, then 
cooled to room temperature before being diluted with water (100 mL) and 
extracted with CH2Cl2 (4 x 100 mL).  The combined organic extracts were dried 
(Na2SO4), filtered, and concentrated by rotary evaporation.  Purification by 
silica flash chromatography (10% → 30% EtOAc in hexanes) yielded the 
product (29) as a clear, colorless oil (440 mg, 40%). 
 
IR (ATR): 2956, 2899, 1734, 1689, 1579, 1438, 1359, 1269, 1218, 1164, 1125, 
1040, 978, 845, 735, 987, 628.  1H-NMR (500 MHz; CDCl3): δ 7.85 (d, J = 7.8 
Hz, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.60–7.56 (m, 1H), 7.49 (td, J = 7.6, 1.2 Hz, 
1H), 7.31–7.24 (m, 3H), 7.20 (d, J = 6.8 Hz, 2H), 6.16 (q, J = 6.7 Hz, 1H), 4.80 
(dd, J = 62.2, 6.8 Hz, 2H), 4.54 (dd, J = 86.9, 11.6 Hz, 2H), 3.68 (s, 3H), 3.25 
(ddd, J = 18.4, 7.3, 6.1 Hz, 1H), 3.09 (dt, J = 18.4, 6.3 Hz, 1H), 2.77–2.65 (m, 
2H).  13C-NMR (126 MHz; CDCl3): δ 201.9, 173.1, 138.3, 137.1, 132.6, 131.9, 
129.4, 129.1, 128.51, 128.38, 128.02, 127.83, 124.2, 93.6, 70.6, 69.9, 51.9, 
36.3, 28.1.  19F-NMR (471 MHz; CDCl3): δ -75.685.  HRMS (ESI) m/z calcd for 
C21H21F3O5Na ([M+Na]+) 433.1239; found 433.1238. 
 
 
 
 
Methyl 4-(2-(1-((benzyloxy)methoxy)-2,2,2-trifluoroethyl)phenyl)-4-
hydroxybutanoate (30).   Aryl ketone 29 (158 mg, 0.385 mmol, 1 equiv) was 
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dissolved in MeOH (1 mL) and cooled to 0 ºC and NaBH4 (18 mg, 0.481 mmol, 
1.25 equiv) was added.  The reaction was stirred for 1 h, then acetone (0.5 
mL) was added.  The reaction was stirred for 10 min at 0 ºC, then phosphate 
buffer (10 mL, 0.5 M, pH 7.0) was added.  The reaction was stirred for 10 min 
0 ºC, then extracted with CH2Cl2 (4 x 10 mL).  The combined organic extracts 
were dried (Na2SO4), filtered, and reduced to 5 mL in volume by rotary 
evaporation at 0 ºC.  The crude benzyl alcohol 30 solution was used 
immediately in the next step.  
 
 
 
 
Methyl 4-((benzyloxy)methoxy)-4-(2-(1-((benzyloxy)methoxy)-2,2,2-
trifluoroethyl)phenyl)butanoate (31).  Crude benzyl alcohol 30 from 
previous step in 5 mL CH2Cl2 was cooled to 0 ºC, then NaI (23 mg, 0.1542 
mmol, 0.1 equiv) and BOMCl (241 mg, 1.542 mmol, 4.0 equiv) were added 
quickly, followed by diisopropylethylamine (199 mg, 1.542 mmol, 4.0 equiv) 
added drop wise.  The reaction stirred for 36 h at 0 ºC, then diluted with 
saturated sodium bicarbonate (10 mL) and extracted with CH2Cl2 (4 x 10 mL).   
The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  Purification by silica flash 
chromatography (0% → 10% EtOAc in CH2Cl2) yielded the product (31) as a 
clear, colorless oil (125 mg, 62% over 2 steps).   
 
IR (ATR): 3032, 2952, 1735, 1497, 1454, 1381, 1268, 1237, 1162, 1132, 1109, 
1027, 979, 907, 844, 765, 736, 698, 625.  1H-NMR (600 MHz; CDCl3): δ 7.66 
(t, J = 8.7 Hz, 1H), 7.50 (ddd, J = 16.6, 7.7, 1.3 Hz, 1H), 7.43-7.38 (m, 1H), 
7.37–7.29 (m, 3H), 7.26 (td, J = 4.9, 2.8 Hz, 5H), 7.25–7.20 (m, 2H), 7.13 (dd, 
J = 7.3, 1.9 Hz, 1H), 5.62 (dq, J = 28.0, 6.7 Hz, 1H), 5.03 (ddd, J = 67.3, 9.9, 
3.4 Hz, 1H), 4.83 (dd, J = 64.6, 7.0 Hz, 1H), 4.74–4.59 (m, 4H), 4.57–4.50 (m, 
1H), 4.48–4.42 (m, 2H), 2.56–2.37 (m, 2H), 2.16–2.06 (m, 1H), 2.01–1.80 (m, 
1H).  13C-NMR (151 MHz; CDCl3): δ 173.6, 141.9, 141.5, 137.9, 137.27, 
137.10, 131.2, 130.5, 129.70, 129.66, 128.7, 128.38, 128.36, 128.09, 128.03, 
127.85, 127.82, 127.80, 127.66, 127.63, 127.52, 126.5, 124.44, 124.37, 93.17, 
93.02, 92.81, 92.69, 73.7, 73.3, 71.3, 71.0, 69.87, 69.83, 51.58, 51.53, 32.8, 
32.5, 30.8, 30.1.  19F-NMR (471 MHz; CDCl3): δ -74.964, -75.855.  HRMS 
(ESI) m/z calcd for C29H31F3O6Na ([M+Na]+) 555.1970; found 555.1984.   
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4-((Benzyloxy)methoxy)-4-(2-(1-((benzyloxy)methoxy)-2,2,2-
trifluoroethyl)phenyl)butanoic acid (32).  Methyl ester 31 (175 mg, 0.329 
mmol, 1 equiv) and LiOH (31 mg, 1.314 mmol, 4.0 equiv) were suspended in 
MeOH:H2O (4 mL, 9:1) and stirred at 50 ºC for 1 h.  The reaction was returned 
to rt, diluted with 1 M KHSO4 (15 mL) and extracted with EtOAc (4 x 15 mL).  
The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  Purification by silica flash 
chromatography (25% → 50% EtOAc in hexanes) yielded the product (32) as 
a white solid (164 mg, 96%).   
 
IR (ATR): 3035, 2954, 2892, 1709, 1499, 1456, 1384, 1270, 1165, 1134, 1040, 
982, 910, 846, 767, 738, 670, 651.  1H-NMR (600 MHz; CDCl3): δ 7.65 (dd, J = 
14.5, 7.6 Hz, 1H), 7.52–7.47 (m, 1H), 7.43–7.38 (m, 1H), 7.37–7.33 (m, 1H), 
7.31–7.21 (m, 8H), 7.19 (dd, J = 8.5, 6.7 Hz, 1H), 7.11 (dd, J = 7.3, 1.8 Hz, 
1H), 5.60 (dquintet, J = 15.5, 5.4 Hz, 1H), 5.03 (ddd, J = 67.1, 9.8, 3.3 Hz, 1H), 
4.80 (dd, J = 41.6, 7.0 Hz, 1H), 4.68–4.66 (m, 2H), 4.64–4.60 (m, 1H), 4.59–
4.57 (m, 1H), 4.54–4.52 (m, 1H), 4.50–4.42 (m, 2H), 2.56–2.40 (m, 2H), 2.17–
2.03 (m, 1H), 1.99–1.80 (m, 1H). 13C-NMR (151 MHz; CDCl3): δ 179.5, 141.7, 
141.3, 137.8, 137.2, 137.0, 131.1, 130.4, 129.7, 128.8, 128.4, 128.17, 128.09, 
128.03, 127.90, 127.85, 127.81, 127.69, 127.66, 127.52, 126.6, 124.40, 
124.32, 92.99, 92.91, 92.83, 92.70, 73.7, 73.4, 71.12, 71.02, 69.94, 69.79, 
32.3, 32.1, 30.8, 30.0.  19F-NMR (471 MHz; CDCl3): δ -75.044, -75.900.  
HRMS (ESI) m/z calcd for C28H29F3O6Na ([M+Na]+) 541.1814; found 
541.1837.   
 
 
 
 
2´,3´-O-TBS-5´-O-(N-[4-((benzyloxy)methoxy)-4-(2-(1-((benzyloxy) 
methoxy)-2,2,2-trifluoroethyl)phenyl)butanoyl]sulfamoyl)adenosine (S1).  
Keto acid 32 (164 mg, 0.316 mmol, 1 equiv), protected sulfamoyladenosine 18 
(227 mg, 0.395 mmol, 1.25 equiv), prepared as previously described,2,23 and 
DMAP (38 mg, 0.316 mmol, 1 equiv) were suspended in CH2Cl2 (5 mL) and 
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EDCI (241 mg, 1.264 mmol, 4 equiv.) added.  The reaction was stirred for 6 h, 
then water (20 mL) added, and extracted with ethyl acetate (5 x 20 mL).  The 
combined organic extracts were dried (Na2SO4), filtered, and concentrated by 
rotary evaporation afford the crude acid S1 (428 mg, 126% crude yield), which 
was used without further purification. 
 
 
 
 
5´-O-(N-[4-Hydroxy-4-(2-(2,2,2-trifluoro-1-hydroxyethyl)phenyl)butanoyl] 
sulfamoyl)adenosine (3).  Crude product S1 from the previous step and 10% 
Pd/C (33 mg, 0.032mmol, 0.1 equiv) were dissolved in MeOH (30 mL) and 1 M 
HCl (0.3 mL) added.  The reaction was stirred under H2 (balloon) for 12 h at rt, 
then diluted with CH2Cl2 (70 mL), filtered through a pad of celite, and 
concentrated by rotary evaporation.  The residue was suspended in DMF 
(5 mL) and TASF (260 mg, 0.944 mmol, 3.0 equiv) in DMF (1.5 mL) added.  
The reaction was stirred for 12 h, then concentration by rotary evaporation, 
purification by preparative HPLC (5% → 95% MeCN in H2O with 0.01% TFA), 
and lyophilization yielded the product (3) as a fluffy white solid (42 mg, 22% 
over three steps). 
 
IR (ATR):  3339, 2504, 1677, 1474, 1429, 1381, 1263, 1199, 1131, 1051, 978, 
889, 834, 801, 768, 724, 706, 641, 613.  1H-NMR (500 MHz; CD3OD): δ 8.50 
(d, J = 4.1 Hz, 1H), 8.36 (s, 1H), 7.62–7.60 (m, 1H), 7.56–7.52 (m, 1H), 7.39–
7.35 (m, 1H), 7.32–7.29 (m, 1H), 6.11 (dd, J = 4.6, 2.1 Hz, 1H), 5.60–5.52 (m, 
1H), 5.01 (dd, J = 9.2, 3.4 Hz, 1H), 4.64 (dt, J = 10.2, 5.0 Hz, 1H), 4.60–4.51 
(m, 2H), 4.42 (td, J = 5.0, 1.0 Hz, 1H), 4.32 (q, J = 4.0 Hz, 1H), 2.62–2.54 (m, 
1H), 2.50–2.44 (m, 1H), 2.01–1.96 (m, 1H), 1.83–1.74 (m, 1H). 13C-NMR (151 
MHz; CD3OD): δ 173.57, 162.11, 147.10, 144.96, 143.42, 133.44, 130.19, 
128.97, 128.96, 128.33, 126.71, 126.66, 126.54, 90.46, 83.58, 75.84, 72.32, 
71.60, 69.80, 68.24, 34.57, 33.02.  HRMS (ESI) m/z calcd for C22H26F3N6O9S 
([M+H]+) 607.1434; found 607.1423.   
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D. Oxazole analogue (3). 
 
 
 
Methyl 4-(2-bromophenyl)-4-oxobutanoate (33). Isopropylmagnesium 
chloride (7.89 mL, 10.26 mmol, 1.1 equiv, 1.3 M in THF) was cooled to –23 ºC 
and 1, 2 dibromobenzene (2.2 g, 9.3 mmol, 1 equiv) was added.  The reaction 
was stirred for 45 min, then slowly transferred via cannula to a stirring solution 
of succinic anhydride (2.799 g, 27.977 mmol, 3.0 equiv) in THF (20 mL) at –23 
ºC. The reaction was stirred for 2 h, then quenched with ammonium chloride, 
acidified with 50 mL 1 M KHSO4, and extracted with dichloromethane (3 x 
50 mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  The crude material was dissolved in 
MeOH (50 mL) and conc. sulfuric acid (92 mg, 0.9326 mmol, 0.1 equiv).  The 
reaction was heated to reflux for 4 h and cooled to room temperature.  The 
reaction was reduced to approximately 10 mL by rotary evaporation, diluted 
with 50 mL saturated sodium bicarbonate and extracted with dichloromethane 
(5 x 50 mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  Purification by silica flash 
chromatography (10% EtOAc in hexanes) yielded the product (33) as a clear 
and colorless oil (1.45 g, 58% yield).  
 
IR (ATR): 2952, 1736, 1703, 1587, 1564, 1467, 1436, 1354, 1020, 1281, 1217, 
1167, 1123, 1072, 1048, 1027, 993, 946, 906, 847, 753, 722, 684, 642.  
1H-NMR (600 MHz; CDCl3): δ 7.61 (dd, J = 8.0, 1.0 Hz, 1H), 7.49 (dd, J = 7.6, 
1.7 Hz, 1H), 7.38 (td, J = 7.5, 1.1 Hz, 1H), 7.30 (td, J = 7.7, 1.7 Hz, 1H), 3.71 
(s, 3H), 3.24 (t, J = 6.6 Hz, 2H), 2.78 (t, J = 6.6 Hz, 2H).  13C-NMR (150 MHz; 
CDCl3): δ 202.0, 173.0, 141.2, 133.7, 131.8, 128.8, 127.5, 118.7, 52.0, 37.4, 
28.2.  HRMS (ESI) m/z calcd for C11H12O3Br ([M+H]+) 270.9970; found 
270.9979. 
 
 
 
 
Methyl 4-(2-(5-oxazolyl)phenyl)-4-oxobutanoate (34). Bromobenzene 
compound 33 (130 mg, 0.4795 mmol, 1 equiv), pivalic acid (20 mg, 0.1918 
Br
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mmol, 0.4 equiv), oxazole (66 mg, 0.959 mmol, 2.0 equiv), Pd(OAc)2 (11 mg, 
0.048 mmol, 0.1 equiv), RuPhos (45 mg, 0.0959 mmol, 0.2 equiv), and K2CO3 
(199 mg, 1.4385 mmol, 3.0 equiv) were suspended in toluene (2 mL) and 
stirred at 110 ºC for 14 h.  The reaction was cooled to rt, diluted with 5 mL H2O 
and extracted with dichloromethane (4 x 5 mL).  The combined organic 
extracts were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (15% → 30% EtOAc in hexanes) 
yielded the title product (34) as a clear and colorless oil (60 mg, 49% yield).   
 
IR (ATR): 1737, 1704, 1559, 1516, 1438, 1359, 1319, 1217, 1169, 1076, 1027, 
987, 948, 920, 845, 779, 748, 717.  1H-NMR (600 MHz; CDCl3): δ 7.99–7.97 
(m, 1H), 7.71 (s, 1H), 7.55–7.50 (m, 2H), 7.44–7.43 (m, 1H), 7.22 (s, 1H), 3.11 
(t, J = 6.8 Hz, 2H), 2.82 (t, J = 6.8 Hz, 2H).  13C-NMR (150 MHz; CDCl3): δ 
204.638, 173.360, 160.180, 140.929, 139.064, 130.361, 130.002, 128.695, 
128.136, 126.696, 123.891, 51.863, 38.086, 28.489.  HRMS (ESI) m/z calcd 
for C14H13NO4Na ([M+H]+) 282.0742; found 282.0736.   
 
 
 
 
4-(2-(5-Oxazolyl)phenyl)-4-oxobutanoic acid (35). Methyl ester 34 (50 mg, 
0.1929 mmol, 1 equiv) and LiOH (14 mg, 0.5787 mmol, 3.0 equiv) were 
dissolved in MeOH/H2O (2 mL, 10:1) and stirred at room temperature for 2 h.  
The reaction was concentrated by rotary evaporation and purified by silica 
flash chromatography (25% → 50% EtOAc in hexanes with 1% AcOH) to yield 
the product (35) as an off white solid (40 mg, 85%).   
 
IR (ATR): 1703, 1584, 1560, 1398, 1360, 1220, 1165, 1106, 1075, 991, 916, 
824, 778, 731.  1H-NMR (600 MHz; CDCl3): δ 7.99–7.97 (m, 1H), 7.71 (d, J = 
0.7 Hz, 1H), 7.53 (qdd, J = 7.8, 7.4, 1.6 Hz, 2H), 7.43–7.41 (m, 1H), 7.23 (d, J 
= 0.5 Hz, 1H), 3.11 (t, J = 6.7 Hz, 2H), 2.86 (t, J = 6.7 Hz, 2H).  13C-NMR 
(150 MHz; CDCl3): δ 204.359, 178.129, 160.181, 140.702, 139.153, 130.419, 
130.131, 128.625, 128.248, 126.691, 123.891, 37.820, 28.507.  HRMS (ESI) 
m/z calcd for C13H11NO4Na ([M+Na]+) 268.0586; found 268.0578.   
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2´,3´-O-TBS-5´-O-(N-[4-(2-(5-oxazolyl)phenyl)-4-oxobutanoyl]sulfamoyl) 
adenosine (S2).  Keto acid 35 (52 mg, 0.212 mmol, 1 equiv), protected 5´-O-
sulfamoyladenosine 18 (152 mg, 0.265 mmol, 1.25 equiv), prepared as 
previously described,2,23 and DMAP (26 mg, 0.212 mmol, 1 equiv) were 
dissolved in CH2Cl2 and EDCI (121 mg, 0.636 mmol, 3 equiv.) added.  The 
reaction was stirred at rt for 4 h, quenched with 20 mL water, extracted with 
dichloromethane (5 x 20 mL).  The combined organic extracts were dried 
(Na2SO4), filtered through a pad of celite, and concentrated by rotary 
evaporation to afford the crude protected oxazole analogue S2 (240 mg, 141% 
crude yield), which was used without further purification.   
 
 
 
 
5´-O-(N-[4-(2-(5-Oxazolyl)phenyl)-4-oxobutanoyl]sulfamoyl)adenosine (4). 
Crude protected oxazole analogue S2 from previous step was dissolved in 
THF (2 mL), cooled to 0 ºC and TBAF (0.3 mL, 0.2991 mmol, 3 equiv, 1.0 M in 
THF) was added before stirring for 1 h. Concentration by rotary evaporation, 
purification by preparative HPLC (5% → 95% MeCN in H2O with 0.01% TFA), 
and lyophilization yielded the product (4) as a white fluffy solid (23 mg, 40% 
over 2 steps).   
 
IR (ATR): 3325, 3131, 2922, 2824, 1698, 1471, 1421, 1365, 1199, 1135, 979, 
886, 831, 721.  1H-NMR (600 MHz; CD3OD): δ 8.48 (s, 1H), 8.34 (s, 1H), 7.95 
(d, J = 0.8 Hz, 1H), 7.91 (dd, J = 7.6, 1.0 Hz, 1H), 7.61 (td, J = 7.5, 1.5 Hz, 
1H), 7.57 (td, J = 7.5, 1.3 Hz, 1H), 7.53 (dd, J = 7.6, 1.2 Hz, 1H), 7.26 (d, J = 
0.7 Hz, 1H), 6.10 (d, J = 4.9 Hz, 1H), 4.62 (t, J = 5.0 Hz, 1H), 4.58 (qd, J = 
11.0, 3.3 Hz, 2H), 4.40 (t, J = 4.8 Hz, 1H), 4.33 (q, J = 3.8 Hz, 1H), 3.13 (t, J = 
6.1 Hz, 2H), 2.71 (t, J = 6.3 Hz, 2H).  13C-NMR (125 MHz; CD3OD): δ 205.844, 
172.740, 161.911, 152.480, 150.178, 164.425, 143.537, 141.614, 141.433, 
131.828, 131.740, 129.667, 129.259, 128.355, 125.382, 120.414, 90.289, 
O
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83.674, 75.885, 72.276, 71.692, 38.044, 31.082.  HRMS (ESI) m/z calcd for 
C23H24N7O9S ([M+H]+) 574.1356; found 574.1367. 
 
 
E. Boronate analogue (5). 
 
 
 
Methyl 4-oxo-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) 
butanoate (36). Aryl bromide 33 (290 mg, 1.0697 mmol, 1 equiv), prepared as 
described above, B2(Pin)2 (340 mg, 1.3371 mmol, 1.25 equiv), sodium acetate 
(395 mg, 4.8137 mmol, 4.5 equiv), and Pd(PPh3)2Cl2 (75 mg, 0.107 mmol, 0.1 
equiv) were suspended in degassed dioxane (10 mL) and stirred at 90 ºC for 
14 h.  Concentration by rotary evaporation and purification by silica flash 
chromatography (10% → 20% EtOAc in hexanes) yielded the product (36) as 
a clear semisolid (240 mg, 71%). 
 
IR (ATR): 2977, 1739, 1678, 1598, 1565, 1488, 1438, 1373, 1341, 1300, 1266, 
1217, 1147, 1126, 1083, 1035, 962, 858, 755, 653.  1H-NMR (600 MHz; 
CDCl3): δ 7.85 (d, J = 7.8, 1H), 7.54–7.53 (m, 2H), 7.44 (ddd, J = 7.8, 5.3, 3.4, 
1H), 3.70 (s, 3H), 3.33 (t, J = 7.0, 2H), 2.78 (t, J = 7.0, 2H), 1.42 (s, 12H).  
13C-NMR (150 MHz; CDCl3): δ 199.80, 173.23, 140.43, 132.46, 132.34, 
129.01, 127.56, 83.81, 51.84, 33.024, 28.14, 24.88.  HRMS (ESI) m/z calcd for 
C17H24BO5 ([M+H]+) 319.1717; found 319.1729.   
 
 
 
 
4-Oxo-4-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butanoic 
acid (37).  Methyl ester 36 (80 mg, 0.2514 mmol, 1 equiv.) and LiOH (12 mg, 
0.5028 mmol, 2.0 equiv.) were suspended in MeOH/H2O (2 mL, 10:1) and 
stirred for 2 h at rt.  Concentration by rotary evaporation and purification by 
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silica flash chromatography (10% → 20% EtOAc in hexanes with 1% AcOH) 
yielded the product (37) as a white oily solid (50 mg, 65%).   
 
IR (ATR): 2982, 1714, 1679, 1604, 1570, 1490, 1378, 1345, 1300, 1200, 1151, 
1090, 1040, 965, 683, 758, 674, 654.  1H-NMR (600 MHz; CDCl3): δ 7.83 (d, J 
= 7.8 Hz, 1H), 7.53 (d, J = 4.1 Hz, 2H), 7.44 (dt, J = 8.3, 4.1 Hz, 1H), 3.32 (t, J 
= 6.9 Hz, 2H), 2.82 (t, J = 6.9 Hz, 2H), 1.42 (s, 11H).  13C-NMR (150 MHz; 
CDCl3): δ 199.70, 177.95, 140.37, 132.51, 132.396, 129.05, 128.25, 127.55, 
83.88, 32.80, 24.86.  HRMS (ESI) m/z calcd for C16H21BO5Na ([M+Na]+) 
327.1380; found 327.1359.   
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(N-[4-oxo-4-(2-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)butanoyl]sulfamoyl) 
adenosine (S3).  Keto acid 37 (100 mg, 0.3288 mmol, 1 equiv), protected 5´-
O-sulfamoyladenosine 18 (240 mg, 0.4932 mmol, 1.5 equiv), prepared as 
previously described,2,23 and DMAP (40 mg, 0.3288 mmol, 1 equiv.) were 
dissolved in CH2Cl2 (25 mL) and EDCI (251 mg, 1.315 mmol, 4 equiv) added.  
The reaction was stirred at rt for 4 h then quenched with water (30 mL) and 
extracted with dichloromethane (5 x 25 mL).  The combined organic extracts 
were dried (Na2SO4), filtered through a pad of celite, and concentrated by 
rotary evaporation to afford the crude protected analogue S3 (322 mg, 127% 
crude yield), which was used without further purification.  
 
 
 
5´-O-(N-[4-(2-Boronophenyl)-4-oxobutanoyl]sulfamoyl)adenosine (5). 
Crude protected boronic acid analogue S3 was dissolved in CH2Cl2 (2 mL) and 
water (0.2 mL) at 0 ºC and TFA (2 mL) added.  The reaction was stirred for 1 h 
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at 0 ºC, then warmed to rt and stirred for 3 h.  Concentration by rotary 
evaporation, purification by preparative HPLC (5% → 95% MeCN in H2O with 
0.01% TFA), and lyophilization yielded the product (7) as a fluffy white solid 
(74 mg, 41%).   
 
IR (ATR): 3376, 2510, 1678, 1377, 1203, 1140, 979, 637. 1H-NMR (600 MHz; 
CD3OD/d-TFA): δ 8.49 (s, 1H), 8.35 (s, 1H), 8.06 (d, J = 7.6 Hz, 1H), 7.62 (t, J 
= 7.3 Hz, 1H), 7.51 (td, J = 7.7, 1.1 Hz, 1H), 7.39 (d, J = 7.1 Hz, 1H), 6.10 (d, J 
= 4.9 Hz, 1H), 4.65 (q, J = 5.4 Hz, 1H), 4.63–4.57 (m, 2H), 4.41 (t, J = 4.8 Hz, 
1H), 4.35 (dt, J = 7.3, 3.6 Hz, 1H), 3.42–3.36 (m, 2H), 2.75 (t, J = 6.2 Hz, 2H), 
1.38 (s, 1H), 1.20 (s, 1H). 13C-NMR (150 MHz; CD3OD/d-TFA): δ 203.749, 
181.273, 155.558, 153.028, 149.146, 139.987, 138.573, 133.461, 131.048, 
128.881, 128.838, 118.600, 87.245, 82.715, 75.504, 74.155, 70.484, 68.321, 
32.796, 24.322.  HRMS (ESI) m/z calcd for C20H24BN6O10S ([M+H]+) 551.1368; 
found 551.1387.   
 
 
 
F. Squaric acid analogue (7). 
 
 
 
2-(2-Bromophenyl)-2-methoxytetrahydrofuran (43). Alkyne 42 (5.699 g, 
25.3197 mmol, 1 equiv) and p-toluenesulfonic acid (482 mg, 2.532 mmol, 0.1 
equiv) were dissolved in 250 mL MeOH and cooled to 0 ºC.  PPh3AuCl (125 
mg, 0.2532 mmol, 0.01 equiv) and AgOTf (65 mg, 0.2532 mmol, 0.01 equiv) 
was added and the reaction stirred for 2 h at 0 ºC.  The reaction was diluted 
with 500 mL saturated sodium bicarbonate and extracted with 
dichloromethane (3 x 500 mL).  The combined organic extracts were dried 
(Na2SO4), filtered, and concentrated by rotary evaporation.  Purification by 
silica flash chromatography (0% → 10% EtOAc in hexanes) yielded the 
product (43) as a clear and colorless oil (6.5 g, 99%).   
 
IR (ATR): 3063, 2976, 2946, 2885, 2820, 1589, 1567, 1470, 1418, 1266, 1237, 
1182, 1134, 1098, 1048, 1020, 936, 852, 755.  1H-NMR (600 MHz; CDCl3): δ 
7.78 (dd, J = 7.8, 1.8 Hz, 1H), 7.61 (dd, J = 7.9, 1.2 Hz, 1H), 7.30–7.28 (m, 
1H), 7.15 (td, J = 7.6, 1.8 Hz, 1H), 4.07 (dtd, J = 33.1, 8.0, 6.1 Hz, 2H), 3.00 
(s, 3H), 2.76 (ddd, J = 12.9, 8.5, 4.4 Hz, 1H), 2.21–2.14 (m, 1H), 2.02 (ddd, J = 
12.9, 9.7, 7.4 Hz, 1H), 1.97–1.91 (m, 1H). 13C-NMR (150 MHz; CDCl3): δ 
139.550, 134.449, 129.415, 129.408, 126.856, 121.129, 108.608, 67.158, 
Br
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49.615, 38.026, 24.726.  HRMS (ESI) m/z calcd for C11H14BrO2 ([M+H]+) 
257.0177; found 257.0158.   
 
        
 
 
3-(2-(4-Hydroxybutanoyl)phenyl)-4-methoxycyclobut-3-ene-1,2-dione (45). 
Aryl bromide 43 (145 mg, 0.5639 mmol, 1 equiv) was dissolved in 0.5 mL THF 
and cooled to –78 ºC.  n-BuLi (0.4053 mL, 0.6485 mmol, 1.15 equiv, 1.6 M in 
THF) was added drop wise and the reaction stirred for 1 h.  Dimethyl squarate 
(160 mg, 1.128 mmol, 2.0 equiv) in 1 mL THF was added drop wise at –78 ºC, 
and the reaction stirred for 1.5 h.  Trifluoroacetic anhydride (0.120 mL, 0.8459 
mmol, 1.5 equiv) was added drop wise and the reaction stirred for 20 min.  
The reaction was quenched with 1 M HCl (5 mL) and warmed to 0 ºC before 
extracting with CH2Cl2 (5 x 5 mL). The combined organic extracts were dried 
(Na2SO4), filtered, diluted with 25 mL acetone, and reduced in volume to 
approximately 10mL by rotary evaporation at 0 ºC.  The reaction was diluted 
with 25 mL acetone and reduced in volume to approximately 5 mL by rotary 
evaporation at 0 ºC.  The crude product 45 in acetone was used immediately 
in the next step without further purification.   
 
 
 
 
 
4-(2-(2-Methoxy-3,4-dioxocyclobut-1-enyl)phenyl)-4-oxobutanoic acid 
(46).  Jones reagent was prepared by dissolving CrO3 (280 mg, 2.8075 mmol, 
5.0 equiv) in 1.5 mL H2O and cooling to 0 ºC.  Concentrated sulfuric acid 
(0.4679 mL, 8.4225 mmol, 15 equiv) was added drop wise and the solution 
allowed to stir for 15 min.  The Jones reagent was added drop wise slowly to 
the stirring solution of crude alcohol 45 in 5 mL at 0 ºC until the reaction 
remained a persistent bright red (~30 min).  The reaction was stirred for 
15 min and quenched with isopropyl alcohol before being diluted with 10 mL 
water,  and extracted with EtOAc (3 x 10 mL).  The combined organic extracts 
were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
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Purification by silica flash chromatography (50% EtOAc in hexanes with 1% 
AcOH) yielded the product (46) as a white solid (77 mg, 48% over 2 steps). 
 
IR (ATR): 3073, 2964, 1790, 1756, 1691, 1599, 1489, 1454, 1370, 1219, 1169, 
11034, 923, 813, 763, 614.  1H-NMR (600 MHz; CDCl3): δ 7.82 (dd, J = 7.6, 
0.8 Hz, 1H), 7.73 (dd, J = 7.6, 1.0 Hz, 1H), 7.62 (td, J = 7.6, 1.2 Hz, 1H), 7.58 
(td, J = 7.6, 1.2 Hz, 1H), 4.50 (s, 3H), 3.35 (t, J = 6.4 Hz, 2H), 2.85 (t, J = 6.4 
Hz, 2H).  13C-NMR (150 MHz; CDCl3): δ 201.040, 194.598, 192.453, 191.455, 
176.055, 138.487, 131.764, 131.298, 128.863, 128.137, 124.563, 61.708, 
35.351, 28.091.  HRMS (ESI) m/z calcd for C15H11O6 ([M-H]-) 287.0556; found 
287.0556.   
 
      
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(N-[4-(2-(2-methoxy-
3,4-dioxocyclobut-1-enyl)phenyl)-4-oxobutanoyl]sulfamoyl)adenosine 
(S4). Keto acid 46 (69 mg, 0.2394 mmol, 1 equiv), protected 5´-O-
sulfamoyladenosine 18 (146 mg, 0.2993 mmol, 1.25 equiv), prepared as 
previously described,2,23 and DMAP (29 mg, 0.2394 mmol, 1 equiv) were 
suspended in 1 mL dichloromethane and EDCI (184 mg, 0.9576 mmol, 4.0 
equiv) added.  The reaction was stirred at rt for 4 hours, quenched with 1 mL 
water, diluted with 4 mL saturated sodium chloride, and extracted with 
dichloromethane (5 x 5 mL).  The combined organic extracts were dried 
(Na2SO4), filtered through a pad of celite, and concentrated by rotary 
evaporation to afford the crude protected squarate analogue S4 (353 mg, 
195% crude yield), which was used without further purification.   
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5´-O-(N-[4-(2-(2-Methoxy-3,4-dioxocyclobut-1-enyl)phenyl)-4-
oxobutanoyl]sulfamoyl)adenosine (7). Crude protected squaric acid 
analogue S17 was dissolved in 3 mL DCM and 0.2 mL H2O.  TFA (2mL) was 
added and the reaction heated to 50 ºC for 24 h before being returned to rt.  
Concentration by rotary evaporation, purification by preparative HPLC (5% → 
95% MeCN in H2O with 0.01% TFA), and lyophilization yielded the product (4) 
as a white fluffy solid (55 mg, 46% over 2 steps).   
  
IR (ATR): 3321, 3124, 2972, 2930, 1696, 1454, 1360, 1205, 1124, 978, 882, 
759, 917.  1H-NMR (600 MHz; DMSO-d6/D2O): δ 8.54 (s, 1H), 8.40 (s, 1H), 
7.92–7.89 (m, 1H), 7.51 (td, J = 7.6, 1.3 Hz, 1H), 7.44 (dd, J = 7.7, 1.1 Hz, 
1H), 7.33 (td, J = 7.5, 1.2 Hz, 1H), 5.98 (d, J = 5.1 Hz, 1H), 4.56 (t, J = 4.9 Hz, 
1H), 4.51 (dd, J = 11.0, 3.2 Hz, 1H), 4.44 (dd, J = 11.0, 5.4 Hz, 1H), 4.21 (td, J 
= 7.0, 3.7 Hz, 2H), 3.09 (t, J = 6.5 Hz, 2H), 2.70 (t, J = 6.6 Hz, 2H).  13C-NMR 
(150 MHz; DMSO-d6/D2O): δ 215.520, 202.677, 195.756, 195.592, 175.892, 
170.894, 148.415, 141.365, 137.499, 130.121, 127.738, 127.505, 127.429, 
126.619, 125.220, 118.756, 87.782, 81.503, 73.371, 71.326, 69.900, 39.932, 
35.952, 29.967.  HRMS (ESI) m/z calcd for C24H23N6O11S ([M+H]+) 603.1146; 
found 603.1146.   
 
 
     
G. Lactone analogue (8). 
 
 
 
 
2-(4-Hydroxybutanoyl)-N,N-diisopropylbenzamide (48). N,N- 
Diisopropylbenzamide (47) (2 g, 9.742 mmol, 1 equiv.) was dissolved in dry 
THF (75 mL), cooled to -78 °C, and t-BuLi (6.35 mL, 10.81 mmol, 1.11 equiv, 
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1.7 M in THF) was added.  The reaction was stirred for 45 min, then γ-
butyrolactone (1.023 g, 11.89 mmol, 1.22 equiv) was added drop wise.  The 
reaction was stirred for 1 h while returning to rt, then quenched with saturated 
ammonium chloride (75 mL) and extracted with ethyl acetate (5 x 75 mL).  The 
combined organic extracts were dried (Na2SO4), filtered, and concentrated by 
rotary evaporation.  Purification by silica flash chromatography (100% EtOAc) 
yielded the product (48) as a clear and colorless oil (2.570 g, 91%).   
 
IR (ATR): 3392, 3063, 2971, 2934, 2876, 2240, 1772, 1689, 1615, 1438, 1370, 
1343, 1213, 1163, 1035, 920, 774, 750.  1H-NMR (500 MHz; CDCl3): δ 7.75 
(d, J= 7.68, 1H), 7.49 (t, J=7.46, 1H), 7.40 (t, J= 7.57, 1H), 7.20 (d, J= 7.43, 
1H), 3.64 (m, 3H), 3.51 (p, J= 6.78, 1H), 3.04 (t, J= 6.87, 1H), 2.81 (m, 1H), 
1.93 (p, J= 6.39, 6.20, 2H), 1.56 (d, J=6.78, 6H), 1.14 (d, J= 6.58, 6H).  
13C-NMR (125 MHz; CDCl3): δ 202.27, 170.52, 138.81, 136.11, 131.64, 
128.48, 128.16, 126.15, 61.36, 51.29, 45.75, 36.78, 26.99, 20.26.  HRMS 
(ESI) m/z calcd for C17H26NO3 ([M+H]+) 292.1913; found 292.1934.   
 
 
 
2-(1,4-Dihydroxybutyl)-N,N-diisopropylbenzamide (49). Aryl ketone 48 (2 g, 
7.035 mmol, 1 equiv) was dissolved in MeOH (80 mL) and NaBH4 (397 mg, 
10.5 mmol, 1.5 equiv) added.  The reaction was stirred for 12 h at rt, then 
quenched with 1 M HCl (20 mL), diluted with saturated sodium chloride 
(75 mL), and extracted with ethyl acetate (5 x 50 mL).  The combined organic 
extracts were dried (Na2SO4), filtered, and concentrated by rotary evaporation 
afford the crude diol 49 (2.99 g, 145% crude yield), which was used without 
further purification. 	  
 
3-(3-Hydroxypropyl)isobenzofuranone (50).  Crude diol 49 was dissolved in 
toluene (230 mL) and p-toluenesulfonic acid (12 mg, 0.070 mmol, 0.01 equiv) 
was added.  The reaction was heated to reflux for 24 h, then cooled to rt and 
concentrated by rotary evaporation.  Purification by silica flash 
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chromatography (100% EtOAc) yielded the product (50) as a greasy white 
solid (1.53 g, 82% over two steps).  
IR (ATR): 3426, 3056, 2946, 2875, 2256, 1759, 1614, 1468, 1350, 1288, 1214, 
1058, 954, 754, 741. 1H-NMR (500 MHz; CDCl3): δ 7.88 (d, J=7.69, 1H), 7.68 
(t, J= 7.51, 1H), 7.53 (t, J= 7.50, 1H), 7.46 (d, J= 7.50, 1H), 5.55 (q, J= 3.55, 
3.98, 3.95, 1H), 3.91 (m, 2H), 2.24 (m, 1H), 1.96 (s, 1H), 1.78 (m, 3H). 
13C-NMR (125 MHz; CDCl3): δ 170.67, 149.89, 134.11, 129.17, 126.02, 
125.70, 121.82, 81.26, 62.03, 31.35, 31.21, 27.90.  HRMS (ESI) m/z calcd for 
C11H12O3Na ([M+Na]+) 215.0684; found 215.0689.   
 
 
 
3-(3-Oxo-1,3-dihydroisobenzofuran-1-yl)propanoic acid (51).   Alcohol 50 
(400 mg, 2.09 mmol, 1 equiv) was dissolved in acetone (20 mL), cooled 0 ºC, 
then jones reagent (prepared as previously described using CrO3 (1.044 g, 
10.459 mmol, 5 equiv.), H2O (13.3 mL), and conc. sulfuric acid (1.33 mL)) was 
added drop wise over 25 min until a deep red color persisted.   The reaction 
was stirred for 20 min, then quenched with isopropyl alcohol, diluted with H2O 
(80 mL), and extracted with ethyl acetate (5 x 80 mL).  The combined organic 
extracts were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (100% EtOAc with 1% AcOH) 
yielded the product (51) as a greasy white solid (380 mg, 89%). 
IR (ATR): 3058, 2931, 2663, 2255, 1760, 1614, 1599, 1467, 1416, 1349, 1288, 
1215, 1167, 1085, 1066, 1033, 938, 759, 741. 1H-NMR (500 MHz; CDCl3): δ 
10.59 (Br, 1H), 7.84 (d, J= 7.53, 1H), 7.63 (t, J= 7.53, 1H), 7.48 (t, J=7.53, 
1H), 7.40 (d, J= 7.59, 1H), 5.49 (q, J= 3.04, 5.75, 2.49, 1H), 2.56 (m, 1H), 2.43 
(m, 2H), 1.92 (m, 1H). 13C-NMR (125 MHz; CDCl3): δ 178.12, 170.25, 149.06, 
134.27, 129.48, 126.03, 125.93, 121.83, 29.70, 29.60, 29.19.  HRMS (ESI) 
m/z calcd for C11H10O4Na ([M+Na]+) 229.0477; found 229.0470.   	  	  	  	  
OH
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6-N-Bis-t-butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(N-[3-(3-oxo-1,3-
dihydroisobenzofuran-1-yl)propanoyl]sulfamoyl)adenosine (S5).  
Propionic acid 51 (40 mg, 0.194 mmol, 1 equiv), protected 5´-O-
sulfamoyladenosine 18 (141 mg, 0.291 mmol, 1.5 equiv), prepared as 
previously described,2,23 and DMAP (24 mg, 0.194 mmol, 1 equiv) dissolved in 
CH2Cl2 (4 mL) and EDCI (511.8 mg, 2.67 mmol, 3 equiv) added.  The reaction 
was stirred 14 h, then quenched with water (25 mL) and extracted with CH2Cl2 
(5 x 25 mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  Purification by silica flash 
chromatography (10% MeOH in CH2Cl2) yielded the product (S5) as a white 
solid (96 mg, 73%). 
 
 IR (ATR): 2982, 2932, 2854, 2254, 1763, 1601, 1579, 1496, 1454, 1371, 
1339, 1286, 1257, 1212, 1142, 1112, 1082, 1034, 951, 914, 850, 795, 777, 
734, 696, 647.  1H-NMR (600 MHz; CD3OD): δ 8.86 (d, J = 1.3, 1H), 8.78 (s, 
1H), 7.83 (d, J = 7.7, 1H), 7.74 (td, J = 7.5, 1.0, 1H), 7.62 (dd, J = 7.7, 0.8, 
1H), 7.56 (t, J = 7.5, 1H), 6.37 (d, J = 2.9, 1H), 5.63 (dd, J = 8.2, 3.5, 1H), 5.43 
(dd, J = 6.1, 2.9, 1H), 5.17 (dd, J = 6.1, 2.6, 1H), 4.57 (td, J = 4.2, 2.7, 1H), 
4.31 (qd, J = 10.7, 4.3, 2H), 2.44–2.33 (m, 3H), 1.98–1.93 (m, 1H), 1.59 (s, 
3H), 1.37 (s, 19H), 1.35 (s, 3H).  13C-NMR (150 MHz; CD3OD): δ 172.52, 
154.34, 153.29, 151.62,151.53, 151.1, 146.92, 135.72, 130.48, 130.42, 
127.02, 126.33, 123.65, 115.60, 92.21, 85.92, 85.68, 85.53, 83.04, 82.66, 
70.10, 35.13, 31.83, 28.05, 27.55, 25.58.  HRMS (ESI) m/z calcd for 
C34H43N6O13S ([M+H]+) 775.2609; found 775.2607.   
 
 
 
 
5´-O-(N-[3-(3-Oxo-1,3-dihydroisobenzofuran-1-yl)propanoyl]sulfamoyl) 
adenosine (8). Protected lactol analogue S5 (40 mg, 0.0593 mmol, 1 equiv) 
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was dissolved in CH2Cl2 (1.5 mL) and water (0.25 mL), cooled to 0 º C, and 
TFA (1.5 mL) added.  The reaction was stirred for 1 h at 0 ºC, then allowed to 
stir for 3 h while returning to rt.  Concentration by rotary evaporation, 
purification by preparative HPLC (5% → 95% MeCN in H2O with 0.01% TFA), 
and lyophilization yielded the product (8) as a fluffy white solid (28 mg, 88%).  
 
IR (ATR): 3344, 2921, 2852, 1752, 1685, 1603, 1470, 1420, 1364, 1292, 1208, 
1140, 1050, 842, 802, 724.  1H-NMR (600 MHz; CD3OD): δ 8.51 (s, 1H), 8.17 
(s, 1H), 7.82 (d, J = 7.7, 1H), 7.70 (td, J = 7.5, 1.0, 1H), 7.58 (dd, J = 7.7, 0.8, 
1H), 7.55 (t, J = 7.5, 1H), 6.07 (d, J = 5.8, 1H), 5.61 (dd, J = 8.3, 3.4, 1H), 4.64 
(t, J = 5.4, 1H), 4.38 (dd, J = 5.0, 3.3, 1H), 4.34 (dd, J = 11.7, 3.8, 1H), 4.29 
(dt, J = 7.9, 3.6, 2H), 3.34 (s, 1H), 2.46–2.33 (m, 3H), 1.96–1.91 (m, 1H).  
13C-NMR (150 MHz; CD3OD): δ 181.49, 172.68, 157.32, 153.70, 151.69, 
150.89, 141.18, 135.58, 130.37, 126.98, 126.25, 123.60, 120.19, 89.17, 84.65, 
82.85, 76.25, 72.34, 69.21, 35.45, 32.28.  HRMS (ESI) m/z calcd for 
C21H23O9N6S ([M+H]+) 535.1247; found 535.1238.  
 
 
 
 
H. Lactam analogue (9). 
 
 
 
2´,3´-O-TBS-5´-O-(N-[4-(2-methoxycarbonyl)-4-oxobutanoyl]sulfamoyl) 
adenosine (56).  4-(2-(Methoxycarbonyl)phenyl)-4-oxobutanoic acid (183 mg, 
0.774 mmol, 1 equiv), prepared as previously described, 2,23 protected 5´-O-
sulfamoyladenosine 18 (667 mg, 1.161 mmol, 1.5 equiv), prepared as 
previously described,2,23 and DMAP (95 mg, 0.774 mmol, 1 equiv) were 
dissolved in CH2Cl2 (25 mL) and EDCI (594 mg, 3.098 mmol, 4 equiv) added.  
The reaction was stirred for 12 h, quenched with water (25 mL), and extracted 
with CH2Cl2 (5 x 25 mL).  The combined organic extracts were dried (Na2SO4), 
filtered through a pad of celite, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (0% → 10% MeOH in CH2Cl2) 
yielded the product (56) as a white solid (370 mg, 60%). 
IR (ATR): 2954, 2931, 2858, 1702, 1654, 1599, 1575, 1473, 1414, 1363, 1285, 
1250, 1129, 1095, 1044, 992, 958, 865, 837, 779, 719, 675, 648.  1H-NMR 
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(600 MHz; acetone-d6): δ 8.31 (s, 1H), 8.23 (s, 1H), 7.87 (dd, J = 7.7, 0.6 Hz, 
1H), 7.66 (td, J = 7.5, 1.2 Hz, 1H), 7.58 (qd, J = 7.6, 1.0 Hz, 2H), 6.78 (s, 2H), 
6.06 (d, J = 5.9 Hz, 1H), 5.09 (dd, J = 5.8, 4.4 Hz, 1H), 4.77-4.61 (m, 2H), 4.56 
(t, J = 3.4 Hz, 1H), 4.35 (q, J = 3.7 Hz, 1H), 3.83 (s, 3H), 3.19 (t, J = 6.5 Hz, 
2H), 2.85 (t, J = 6.4 Hz, 2H), 0.95 (s, 9H), 0.78 (s, 9H), 0.18 (s, 3H), 0.15 (s, 
3H), -0.00 (s, 3H), -0.25 (s, 3H).  13C-NMR (151 MHz; acetone-d6): δ 203.9, 
167.7, 157.2, 153.7, 150.8, 143.7, 140.8, 133.2, 130.8, 130.4, 129.5, 127.6, 
120.89, 120.85, 89.1, 83.5, 75.4, 73.5, 52.9, 37.5, 26.30, 26.15, 18.64, 18.46, 
-4.23, -4.35, -4.51, -5.0.  HRMS (ESI) m/z calcd for C34H53N6O10SSi2 ([M+H]+) 
793.3082; found 793.3007. 
 
 
5´-O-(N-[3-(1-Hydroxy-3-oxoisoindolin-1-yl)propanoyl]sulfamoyl) 
adenosine (9). Protected MeOSB-AMS 56 (55 mg, 0.0694 mmol, 1 equiv) 
placed in a 15 mL pressure vessel and cooled to –78 ºC.  Anhydrous ammonia 
(5 mL) was then condensed into the pressure vessel and sealed, then 
returned to rt and stirred for 2 h.  The reaction was then cooled to –78 ºC, 
placed under cycling nitrogen, and allowed to slowly return to rt to remove the 
ammonia.   The reaction was placed under high vacuum for 30 minutes, then 
suspended in THF (5 mL) and cooled to 0 ºC.  TBAF (0.208 mL, 0.208 mmol, 
3.0 equiv, 1.0 M in THF) was added and stirred for 1 h, before  phosphate 
buffer (1 mL, 1M, pH 7.2), and 5 mL toluene were added before being 
concentrated by rotary evaporation.  Purification by silica flash 
chromatography (10% → 20% MeOH in EtOAc) yielded the product (10) as 
the tetrabutylammonium salt (15 mg, 40% over two steps).   
 
Assignment of 9 as the cyclic lactam isomer, as opposed to the open-chain 
keto amide isomer, was based on HMBC analysis of the analogous isolated 
side chain (see below) and correlation of the following diagnostic peaks: 
succinyl b-hydrogens C3-H2 (d 2.49-2.23), hemiaminal C4 (d 89.18), lactam 
NH (DMSO-d6: d 8.05), side chain OH (DMSO-d6: d 5.9).  This was necessary 
due to the inherently short half-life of 9 in its protonated sulfamate form, which 
requires isolation as the corresponding tetrabutylammonium salt, thereby 
precluding efficient multidimensional NMR analysis.  
 
IR (ATR): 3328, 3190, 2964, 2876, 1707, 1654, 1599, 1471, 1420, 1364, 1298, 
1223, 1148, 1088, 944, 884, 835, 801, 747, 718, 642.  1H-NMR (600 MHz; 
CD3OD): δ 8.52 (s, 1H), 8.19 (s, 1H), 7.69–7.67 (m, 1H), 7.62 (tdd, J = 7.4, 
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2.2, 1.1, 1H), 7.59 (d, J = 7.5, 1H), 7.49 (tt, J = 7.4, 1.1, 1H), 6.09–6.08 (m, 
1H), 4.64 (td, J = 5.4, 3.3, 1H), 4.37 (dd, J = 5.0, 3.2, 1H), 4.31-4.23 (m, 3H), 
3.24–3.21 (m, 12H), 2.49–2.43 (m, 1H), 2.35–2.23 (m, 2H), 2.13–2.05 (m, 1H), 
1.67–1.62 (m, 12H), 1.40 (sextet, J = 7.4, 12H), 1.01 (t, J = 7.4, 18H). 
13C-NMR (150 MHz; CD3OD): δ 181.98, 171.55, 161.54, 157.35, 153.92, 
150.96, 150.59, 141.15, 134.00, 132.45, 130.49, 124.06, 123.49, 120.17, 
89.18, 84.72, 76.41, 72.39, 68.88, 59.53, 36.17, 35.24, 24.85, 20.79, 14.02.  
HRMS (ESI) m/z calcd for C21H24N7O9S ([M+H]+) 550.1356; found 550.1362.   
 
 
 
 
To assign the structure of lactam analogue 9 as the cyclic lactam isomer, as 
opposed to the corresponding open-chain keto amide isomer, the 
corresponding OSB side chain analogue, which could be isolated and 
characterized by multidimensional NMR analysis, was prepared.  Thus, the 
known ketodiester, prepared as previously described,2,23 was treated with 
ammonia to afford the lactam product.  In acetone-d6, the hemiaminal C4 
(d 87.9) of the product shifted upfield compared to the ketone C4 (d 204.2) of 
the starting material.  In the product, the succinyl β-protons C3-H2 (d 2.44-
2.25) were also shifted upfield compared to those in the starting material  
(d 3.10).  Finally, HMBC correlations were observed between the NH (d 7.83) 
and C3 (d 35.0), C4 (d 87.9), and C5 (d 149.7), as well as between the OH 
(d 5.36) and C3, C4, and C5, consistent with the cyclic lactam structure shown 
and not the open-chain keto amide isomer nor the cyclic imidate isomer.  In 
contrast, the open-chain keto amide isomer would not be expected to show 
HMBC correlations between the primary carboxamide NH2 protons and C3 (6-
bond), C4 (5-bond), or C6 (4-bond).  This preference for the cyclic lactam 
isomer as opposed to the open-chain keto amide isomer is consistent with 
literature reports.24-26 
 
IR (ATR): 3290, 2979, 2934, 1701, 1616, 1469, 1422, 1368, 1313, 1266, 1154, 
1098, 1077, 969, 847, 766, 7337, 699, 630. 1H-NMR (600 MHz; acetone-d6): δ  
7.83 (s, 1H), 7.65-7.60 (m, 3H), 7.52 (td, J = 7.2, 1.2 Hz, 1H), 5.36 (s, 1H), 
2.44-2.37 (m, 1H), 2.32-2.25 (m, 2H), 2.15-2.07 (m, 1H), 1.38 (s, 9H). 
13C-NMR (150 MHz; acetone-d6): δ 172.6, 168.7, 149.7, 133.2, 132.7, 130.1, 
123.6, 123.1, 87.9, 80.5, 35.0, 31.1, 28.2. HRMS (ESI) m/z calcd for 
C15H20NO4 ([M+H]+) 278.1392; found 278.1405 
 
O
O
O
O
O
C5 C4
N
O
O C3
C2 C1
O
O
NH3,
–78 º C to rt, 2 h, 
75% yield
H
H
	   83	  
I. Difluoroindanediol analogue (9). 
 
 
 
 
2,2-Difluoro-indene-1,3-dione (69).  Selectfluor (24.24 g, 68.43 mmol, 2 
equiv), 1,3 indandione 68 (5.0 g, 34.2 mmol, 1.0 equiv) and sodium dodecyl 
sulfate (99 mg, 0.342 mmol, 0.01equiv) were suspended in water (80 mL).  
The reaction was heated to 80 ºC for 8 h, then cooled to rt and extracted with 
Et2O (5 x 80 mL).  The combined organic extracts were dried (Na2SO4), filtered, 
and concentrated by rotary evaporation.  Purification by sublimation (200 
mTorr, 150 ºC) yielded the product 69 as bright white crystals (5.82 g, 93%).  
   
IR (NaCl, Film): 3479, 3098, 1728, 1583, 1302, 1185, 1090, 1088, 733.  
1H-NMR (500 MHz; CDCl3): δ 8.16 (dtdd, J = 5.1, 3.2, 2.3, 0.0 Hz, 2H), 8.11–
8.07 (m, 2H).  13C-NMR (125 MHz; CDCl3): δ 185.923, 139.372, 138.276, 
125.088, 102.538.  19F-NMR (471 MHz; CDCl3): δ –124.843. HRMS (ESI) m/z 
calcd for C9H5F2O2 ([M+H]+) 183.0258; found 183.0232.   
 
      
 
 
tert-Butyl 3-(2,2-difluoro-1-hydroxy-3-oxo-2,3-dihydro-indenyl)propiolate 
(70). LiHMDS (13.72 mL, 13.72 mmol, 1.25 equiv, 1.0 M in THF) was cooled to 
–78 ºC and t-butyl propiolate (1.522 g, 12.07 mmol, 1.1 equiv) in THF (10 mL) 
was added drop wise over 10 min.  The reaction was stirred for 1 h, then 
added via cannula over 30 min to a stirring solution of di-ketone 69 (2 g, 10.98 
mmol, 1 equiv) in THF (10 mL) at –78 ºC.  The reaction was stirred for 1 h, 
then quenched with saturated ammonium chloride (50 mL) and extracted with 
CH2Cl2 (5 x 50 mL).  The combined organic extracts were dried (Na2SO4), 
filtered, and concentrated by rotary evaporation.  Purification by silica flash 
chromatography (20% EtOAc in hexanes) yielded the product (70) as a clear 
and colorless oil (2.767g, 82%).   
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IR (ATR): 2988, 2211, 1757, 1712, 1606, 1475, 1401, 1375, 1262, 1221, 1155, 
1021, 901, 843, 758, 718, 652.  1H-NMR (500 MHz; CDCl3): δ 7.93 (dd, J = 
7.6, 0.9 Hz, 1H), 7.90–7.87 (m, 2H), 7.67 (td, J = 7.5, 0.9 Hz, 1H), 4.17 (s, 
1H), 1.50 (s, 9H).  13C-NMR (125 MHz; CDCl3): δ 187.830, 157.996, 151.862, 
148.999, 138.156, 131.910, 131.165, 126.282, 125.159, 85.122, 82.060, 
77.523, 71.065, 27.933.  19F-NMR (471 MHz; CDCl3): δ –111.190, –111.762, –
125.772, –126.348.  HRMS (ESI) m/z calcd for C16H15F2O4Na ([M+Na]+) 
331.0758; found 331.0764.   
 
        
 
 
3-(2,2-Difluoro-1-hydroxy-3-oxo-2,3-dihydro-indenyl)propiolic acid (71). t-
Butyl ester 70 (400 mg, 1.298 mmol, 1 equiv) was dissolved in CH2Cl2/H2O 
(5 mL, 10:1) and cooled to 0 ºC, then TFA (5 mL) was added.  The reaction 
was stirred for 2 h, then concentrated by rotary evaporation.  Purification by 
silica flash chromatography (10% MeOH in CH2Cl2) yielded the product (71) as 
a white semi-solid (225 mg, 69%). 
 
IR (ATR): 3410, 1752, 1690, 1605, 1370, 1277, 1201, 1141, 1082, 1024, 938, 
903, 852, 768, 716, 649.  1H-NMR (500 MHz; DMSO-d6): δ 8.06–8.03 (m, 1H), 
7.96–7.94 (m, 2H), 7.80–7.77 (m, 1H).  13C-NMR (125 MHz; DMSO-d6): δ 
188.385, 153.757, 150.586, 138.920, 131.916, 129.758, 126.061, 124.830, 
113.974, 83.152, 77.101, 70.006. 19F-NMR (471 MHz; CDCl3): δ -113.646, -
114.207, -128.356, -128.915. HRMS (ESI) m/z calcd for C24H11F4O8 ([2M-H]-) 
503.0390; found 503.0394.   
        
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(N-[3-(2,2-difluoro-1-
hydroxy-3-oxo-2,3-dihydro-indenyl)propioloyl]sulfamoyl)adenosine (72). 
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Propiolic acid 71 (110 mg, 0.4362 mmol, 1 equiv), protected 5´-O-
sulfamoyladenosine 18 (265 mg, 0.5452 mmol, 1.25 equiv), prepared as 
previously described,2,23 and DMAP (53 mg, 0.4362 mmol, 1.0 equiv.) were 
dissolved in CH2Cl2 (5 mL) and EDCI (335 mg, 1.7448 mmol, 4.0 equiv) was 
added.  The reaction was stirred for 4 h, then quenched with 30 mL water, and 
extracted with CH2Cl2 (5 x 25 mL).  The combined organic extracts were dried 
(Na2SO4), filtered, and concentrated by rotary evaporation to afford the crude 
product 72 (427 mg, 136% crude yield), which was used without further 
purification. 
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(N-[3-(2,2-difluoro-1,3-
dihydroxy-2,3-dihydro-1H-inden-1-yl)propanoyl]sulfamoyl)adenosine 
(73).  Crude product 72 from previous step and 10% Pd/C (463.5 mg, 0.435 
mmol, 1 equiv) were suspended in solution of MeOH/NEt3 (40 mL, 9:1).  The 
reaction was then stirred vigorously under H2 balloon for 1 h before being 
diluted with EtOAc (50 mL), filtered through a celite pad, and concentrated by 
rotary evaporation to afford the crude product 73 (510 mg, 151% crude yield), 
which was used without further purification. 
 
 
 
 
5´-O-(N-[3-(2,2-Difluoro-1-hydroxy-3-oxo-2,3-dihydro-indenyl)propioloyl] 
sulfamoyl)adenosine (74).   Crude product 73 was suspended in CH2Cl2 (5 
mL) and water (0.25 mL), then cooled to 0 ºC and TFA (5 mL) added. The 
reaction was stirred for 1 h at 0 ºC, then allowed to stir for 3 h while returning 
to rt.  Concentration by rotary evaporation, purification by preparative HPLC 
(5% → 95% MeCN in H2O with 0.01% TFA), and lyophilization yielded the 
product (74) as a fluffy white solid (71 mg, 28% over 3 steps). 
O
O O
N
NN
NHBoc
O NSN
H
O OO
OH
HO F F
O
HO OH
N
NN
NH2
O NSN
H
O OO
OH
FFHO
	   86	  
 
IR (ATR): 3173, 2927, 1693, 1664, 1466, 1415, 1357, 1189, 1134, 1072, 872, 
791, 717.  1H-NMR (500 MHz; CH3OD): δ 8.47 (s, 1H), 8.35 (d, J = 1.8 Hz, 
1H), 7.45–7.37 (m, 4H), 6.11–6.09 (m, 1H), 5.13–5.10 (m, 1H), 4.65–4.62 (m, 
1H), 4.58–4.50 (m, 2H), 4.42–4.39 (m, 1H), 4.32–4.30 (m, 1H), 2.63 (td, J = 
7.8, 2.8 Hz, 2H), 2.32–2.13 (m, 2H).  13C-NMR (150 MHz; CH3OD): δ 173.449, 
150.229, 147.018, 143.991, 143.408, 140.036, 139.286, 130.700, 130.631, 
127.093, 126.441, 124.932, 120.495, 90.396, 83.610, 79.622, 75.770, 74.931, 
72.261, 71.609, 31.317, 31.146.  19F-NMR (471 MHz; CH3OD): δ –120.084, –
120.581, –130.679, –131.147. HRMS (ESI) m/z calcd for C22H25F2N6O9S 
([M+H]+) 587.1372; found 587.1349.     
 
 
 
J.  MenE Biochemical Assay 
 
Enzyme inhibition studies were performed in 20 mM NaHPO4 buffer (pH 7.4) 
containing 150 mM NaCl and 1 mM MgCl2 using a MenE-MenB coupled assay 
in which MenE is rate-limiting. IC50 values were determined in reaction 
mixtures containing OSB (60 μM), ATP (240 μM), CoA (240 μM), mtMenB (2.5 
μM), and varying inhibitor concentrations (5−250 μM). Reactions were initiated 
by addition of ecMenE  (50 nM), and the production of DHNA-CoA was 
monitored at 392 nm (ε392  = 4000 M−1 cm−1). 
 
 
K. Antimicrobial Assays 
 
Minimum inhibitory concentrations (MICs) were determined using visual 
growth inspection of cells grown in transparent 96-well plates. E. coli , B. 
subtilis  (ATCC 6051), MRSA (ATCC BAA-1762), and M. tuberculosis (H37Rv) 
were grown to mid-log phase (OD600  of 0.6−0.8) in  synthetic broth, or 7H9 
with 0.5% glycerol, 0.05% Tween, and 10% OADC medium at 37 ° C in an 
orbital shaker. A final inoculum concentration of 1−2 x 106 cells per well was 
treated with inhibitor at final concentrations ranging from 0.5 to 500 μg/mL. 
The MIC was defined as the minimum concentration at which a well showed 
no obvious growth by visual inspection (MIC-99). Growth rescue studies were 
performed by supplementing minimal medium (synthetic broth) with 10 μM 
menaquinone-4 (MK4) and following the same procedure in a 96-well plates. 
To determine the MK4-rescue MIC, 10% of the solution in each well was 
plated on synthetic agar plate and allowed to grow for 48 hours in 37 oC. 
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Colony forming units (CFUs) were counted and compared to plates with 
untreated wells. Rescue MICs were defined as the minimum inhibitor 
concentration at which a plate showed ~90% growth after supplementation 
with MK4.    
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CHAPTER 3 
STEREOSELECTIVE SYNTHESIS, DOCKING, AND EVALUATION OF 
DIFLUOROINDANEDIOL-BASED MENE INHIBITORS* 
 
3.1. Introduction 
In our efforts to improve the antimicrobial activity of MenE inhibitor 
platform, we investigated the keto-acid/lactol equilibrium of OSB-AMS (1, 
Figure 3.1),1 through the synthesis and evaluation of keto-acid and lactol form 
bioisosteres of OSB-AMS.2   In so doing, we discovered the difluoroindanediol 
analogue 2, which exhibited a promising but unusual activity profile.   
 
Figure 3.1. Previously reported analogues OSB-AMS (1) and difluoroindanediol 
analogue 2, with reported biochemical and antimicrobial activities.  
The difluoroindanediol analogue 2 exhibited an IC50 against MenE of 
1.5 µM in biochemical assays (vs. OSB-AMS MenE IC50 = 25 nM), and an 
antimicrobial activity (MIC) of 15.6 µg/mL against both methicillin-resistant 
Staphylococcus aureus (MRSA) and M. tuberculosis (vs. OSB-AMS: MRSA 
                                            
* Adapted from: Evans, C. E.; Matarlo, J. S.; Tonge, P. J.; Tan, D. S., 
Stereoselective Synthesis, Docking, and Biological Evaluation of 
Difluoroindanediol-Based MenE Inhibitors as Antibiotics." Org. Lett. 2016, 
6384–6387. 
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MIC = 31.25 µg/mL, M. tuberculosis MIC = 125 µg/mL).  We also noted rescue 
of difluoroindanediol analogue-treated MRSA when coadministered with 
exogenous menaquinone-4 (MK-4), suggesting that the difluoroindanediol 
inhibits menaquinone production.   However, as was discussed in Chapter 2 
(section 2.4), the hypothesis that the difluoroindanediol analogue inhibits cell 
growth through inhibition of MenE does not align well with our current 
understanding of OSB-AMS and acyl-AMS inhibitor permeability and 
selectivity.  Therefore, it was necessary to investigate the unusual activity of 
the difluoroindanediol analogue to gain insight into the mechanism behind this 
activity and if it can be leveraged to increase the potency of our OSB-AMS 
based platform.   
 
Figure 3.2. Diastereomers of the difluoroindanediol analogue 2.  
The original synthetic route to the difluoroindanediol analogue 
discussed in Chapter 2 resulted in a mixture of four diastereomers around the 
benzannulated five membered ring of the difluoroindanediol scaffold (Figure 
3.2).  While this approach allowed for expedient synthesis of the 
difluoroindanediol analogue to test for initial activity, in order to investigate the 
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scaffold further it was necessary to synthesize and evaluate the biochemical 
and antimicrobial activity of each of the diastereomers individually.   
 
3.2. Initial attempts towards the stereoselective synthesis of the 
diastereomeric difluoroindanediols  
 Our original synthetic route to the difluoroindanediol analogue involved 
two main steps that led to the epimeric centers around the difluoroindanediol 
core.  The first stereogenic center at C1 was established through addition of 
tert-butylpropiolate to the 2,2-difluoro-1,3-indandione intermediate 3 
(Figure 3.3).  The second stereogenic center at C3 was established through a 
late-stage palladium–catalyzed hydrogenation of the α-difluoroketone 
intermediate 5.    
 
Figure 3.3. Key stereocenter forming steps in original synthesis of the 
difluoroindanediol analogue 2.  Blue circles = C1 position of indanol core at key 
stereocenter forming step.  Green circles = C3 position of indandol core at key stereocenter 
forming step.  
To access the individual diastereomers of the difluoroindanediol 
analogue in a stereoselective manner, we proposed two alternative 
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retrosynthetic approaches.  In both approaches, the C1 and C3 stereocenters 
would be in place on the difluoroindanediol acyl chain 8 prior to coupling to the 
protected AMS scaffold 7.  This would allow access to a greater diversity of 
chemical transformations without concern for decomposition of the relatively 
labile acyl-sulfamate bond.  
 
Figure 3.4. Proposed retrosynthetic approaches to diastereomeric difluoroindanediol 
analogues 2.  PG = protecting group. Red circles indicate key stereocenters. 
In the first approach (route 1, Figure 3.4), the C3 stereochemistry would 
be set via diastereoselective ketone reduction of intermediate 9, with absolute 
stereochemistry at C1 being set by enantioselective alkynylation of 2,2-
difluoro-1,3-indandione (3).  Intermediate 3 can then be quickly and nearly 
quantitatively obtained from commercially available 1,3-indandione using our 
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previously published methods.2  In the second approach (route 2, Figure 3.4), 
C1 stereochemistry would be set via diastereoselective alkynylation of the 
protected difluorohydroxyindanone scaffold 11, with absolute stereochemistry 
at C3 being established through an enantioselective reduction of the 
corresponding difluoroindandione 3.  In both routes, the key challenge was the 
initial establishment of absolute stereochemistry on the highly activated and 
symmetric 2,2-difluoro-1,3-indandione (3).  
Work towards the diastereomeric difluoroindanediol analogues in the 
first approach began by first investigating the key step of the sequence, the 
alkynylation of the ketone intermediate 3.  Literature reports of 
enantioselective alkynylation of carbonyls rely on first forming an alkynyl-metal 
species, typically lithium or zinc, which is coordinated by a chiral ligand to 
allow for enantioselective addition into the desired carbonyl moiety.  There are 
a wide assortment of chiral ligands reported to catalyze enantioselective 
alkynylation reactions (Figure 3.5) such as camphorsulfonamide derivatives 
12,3-4 phenethylamine derivatives 13,5-6 napthol derivatives 14,7-9 or Schiff 
base derivatives 14.10-11 However, the majority of the reported enantioselective 
alkynylation reactions focus on addition of an alkyne into an aryl aldehyde.  
Instances in the literature of ketone alkynylation most often report poor 
enantioselectivity and/or very limited substrate scope.  One notable exception 
reported by Dr. Lushi Tan and coworkers at Merck Research Laboratories, is a 
highly enantioselective addition of cyclopropylacetylene (16) into 
trifluoromethylacetophenone 15 en route to the antiretroviral drug, efavirenz.6 
However, using these conditions with difluoroindandione intermediate 3 and 
related acetylenes 19, we observed poor chemoselectivity, enantioselectivity, 
and yields.  Additional methods using the other previously described ligand 
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systems were also screened with identical results, suggesting the                     
α-difluoroketone moiety is not amenable to enantioselective alkynylation.  We 
also explored chiral resolution of the racemic difluorohydroxyindanone 
intermediate 8 (Figure 3.4), through recrystallization with optically pure chiral 
amines, or through chromatographic separation of a chiral amine-derived 
Schiff bases from intermediate 9.  However, both methods failed to provide the 
suitable enantioenrichment of the corresponding material.  
 
Figure 3.5. Alkynylation of aryl ketones. A) Common chiral ligands for enantioselective 
alkynylation reactions. B) Reported alkynylation en route to Efavirenz.6 C) Alkynylation of 
difluoroindandione 3.  TBS = tert-butyldimethylsilyl. 
 As our scaffold was not amenable to enantioselective alkynylation, we 
began work towards the diastereomeric difluoroindanediol analogues through 
our second proposed retrosynthetic approach.  This synthetic route relies on a  
OH
SO2NHBn
N
OH
OH
OH
Ph
Ph
N
Ph OH
PhPh
Cl CF3
O
NH2
CF3CH2OH, 13, ZnEt2
Li
THF Cl OH
NH2
F3C
18, 95% ee
O
F
F
HO
O
O
F
F
A)
B)
R CF3CH2OH, 2, ZnEt2
THF
R
R = CO2t-Bu, CO2Et,
       CH2OH, CH2OTBS
20, < 10% ee
12 13 14 15
C)
16 17
3 19
 97 
 
 
Figure 3.6. Enantioselective reduction of ketones. A) Known chiral systems for 
enantioselective reduction of aryl-ketones.  B) Reduction of difluoroindandione 3 to give 
reduced product 26 and over-reduced product 27.  
successful enantioselective reduction of the C3 position of difluoroindandione 
3.  There are a large number of literature precedents for enantioselective 
reductions of aryl ketones.12  Most examples focus on the use of chiral 
boranes such as DIP-Cl (B-Chlorodiisopinocampheylborane, 21, Figure 3.6),13 
oxazaborolidine 22,14-16 and alpine borane 23,16-17 or chiral hydride sources 
such as BINAL-H (1,1'-Bi-2-naphthol-ethoxy-aluminum hydride, 24),18 or 
transition-metal catalyzed hydrogenations using chiral ligands such as 
Ru2Cl4[BINAP]2 (25).19-22  These systems were screened for enantioselective 
reduction of the difluoroindandione intermediate 3.  While we consistently 
observed efficient reduction of the starting material with the reaction conditions 
screened, the conditions gave no appreciable enantioselectivity as well as 
poor chemoselectivity, often affording the fully reduced product 27.  Attempts 
at kinetic resolution of the racemic difluorohydroxyindanone 26 or 
functionalization with chiral acids to allow for chromatographic separation of 
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the corresponding diastereomers failed to give the suitable enantioenrichment 
to proceed with the synthetic route.    
3.2. Stereoselective synthesis of the diastereomeric difluoroindanediols.  
 The results from our initial attempts towards an enantioselective 
synthesis of the diastereomeric difluoroindanediols indicated that the 
fluorinated intermediates were unsuitable for enantioselective reactions 
primarily due to their high reactivity, poor ability to coordinate the chiral 
ligands, and relative instability.  Thus, we next pursued establishment  
absolute stereochemistry before introduction of fluorine to the indanol scaffold.  
  
Figure 3.7. Stereoselective retrosynthesis of diastereomeric difluoroindanediol 
analogues 2. PG = protecting group. Red circles indicate key stereocenters.   
 
Our revised retrosynthetic route retained the concept of stereocenters 
at C1 and C3 being set before the acyl chain was coupled onto the protected 
AMS scaffold.  Stereochemistry at C1 would be set via a diastereoselective 
alkynylation of the corresponding protected difluorohydroxyindanone 11, and 
absolute stereochemistry at C3 established in 3-hydroxyindanone 28.    
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To access both (3R)-3-hydroxyindanone (28) and (3S)-3-
hydroxyindanone (28) in high enantiopurity, we used a methodology previously 
reported by Nair and coworkers in which enzymatic kinetic resolution of 3-
hydroxyindanone was achieved using Amano Lipase PS (Burkholderia 
cepacia) in vinyl acetate.23  This method provided 3-hydroxyindanone (3S)-
(28) in 46% yield with > 98% ee, and the enantiomeric acetate (3R)-29 in 43% 
yield and >98% ee (Figure 3.8, determined by LCMS with Chiracel OB-H 
column, E value > 200).24   With our desired C3 stereochemistry in place, we 
converted acetate (3R)-29 to silyl ether (3R)-30.  This protection step was 
necessary to prevent retro-aldol epimerization of the C3 stereocenter and add 
steric bulk to one side of the five-membered ring.  Intermediate (3R)-30 was 
treated with hexylamine to form the corresponding Schiff base, before 
fluorination using Selectfluor to provide the α-difluoroketone (3S)-31.  While 
this method for formation of α-difluoroketones is rarely seen in the literature, 
more typical methods for installation of fluorine require strong basic conditions 
such as NaH or lithium hexamethyldisilazide (LiHMDS), which are not 
compatible with the non-fluorinated hydroxyindanone scaffold.  The next key 
step involved the diastereoselective alkynylation of the α-difluoroketone (3S)-
31.  A number conditions using combinations of relevant bases (lithium 
diisopropylamide [LDA], LiHMDS, NaHMDS, KHMDS, n-BuLi), additives 
(hexamethylphohsphoramide, tetramethylethenediamine) and solvents 
(hexanes, THF, diethyl ether) were screened for optimal diastereoselective 
alkynylation of the α-difluoroketone (3S)-31.  Leveraging both the relatively 
poor nucleophilicity of the alkynyl-lithium species as well as the steric bulk of  
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Figure 3.8.  Synthesis of syn-difluoroindanediol inhibitors (1R,3S)-2 and (1S,3R)-2.  
Yields in parentheses are for synthesis of (1S,3R)-2, prepared analogously from alcohol (3S)-
28.  DMAP = N,N-dimethyl-4-aminopyridine; EDCI = 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide; HMDS = hexamethyldisilazide; Selectfluor = 1-chloromethyl-4-fluoro-1,4-diazoniabi-
cyclo[2.2.2]octane bis(tetrafluoroborate); TAS-F = tris(dimethylamino)sulfonium difluorotri-
methylsilicate; TBS = t-butyldimethylsilyl; TFA = 2,2,2-trifluoroacetic acid. 
the C3 silyl-ether, we achieved efficient conversion to the syn-diol intermediate 
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acid (1R,3S)-33, which was desilylated and crystallized to confirm absolute 
and relative stereochemistry by X-ray crystallographic analysis (CuKα 
radiation, see experimental section 3.6 for details).  The free acid intermediate 
(1R,3S)-33 was coupled to the protected AMS scaffold 34 before 
hydrogenation of the alkyne and global deprotection provided the syn-
difluoroindanediol analogue (1R,3S)-2.  The alternative syn-difluoroindanediol 
analogue (1S,3R)-2 was synthesized analogously from the enantiomeric 
alcohol (3S)-(28).   
 In order to synthesize the anti-difluoroindanediol analogue (1R,3R)-2, 
we began by desilylating the syn-diol intermediate (1R,3S)-32 (Figure 3.9), to 
provide the corresponding free-diol (1R,3S)-37.  Oxidation to the ketone     
(1R)-38 followed by reduction with optimized conditions using sodium 
borohydride provided the anti-diol intermediate (1R,3R)-39 (>20:1 dr). In the 
course of the optimization of this reaction, we observed that rapid addition of 
reductant or use of an excess of hydride greatly diminished the 
diastereoselectivity.  Thus the diastereoselectivity in this reaction is likely due 
to a combination of increased sterics on the alkyne facing side of the ring, and 
the boronate first coordinating with the C1 hydroxyl of (1R)-38 before 
delivering the hydride from the syn-face of the ring to provide the anti-diol 
(1R,3R)-39.25  The tert-butyl ester was cleaved to provide the desired acid 
(1R,3R)-40, which was coupled to the protected AMS scaffold 34 before 
hydrogenation of the alkyne and global deprotection provided the anti-
difluoroindanediol analogue (1R,3R)-2.  The alternative anti-difluoroindanediol 
analogue (1S,3S)-2 was synthesized analogously from the enantiomeric syn-
diol intermediate (1S,3R)-32.   
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Figure 3.9. Synthesis of anti-difluoroindanediol inhibitors (1R,3S)-2 and (1S,3R)-2.  
Yields in parentheses are for synthesis of (1S,3R)-2, prepared analogously from alcohol (3S)-
28.  DMAP = N,N-dimethyl-4-aminopyridine; EDCI = 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide; TAS-F = tris(dimethylamino)sulfonium difluorotrimethylsilicate; TBS = t-butyldimethyl-
silyl; TFA = trifluoroacetic acid. 
3.3.  Computational docking of the diastereomeric difluoroindanediols to 
the OSB-AMS•MenE cocrystal structure  
 In parallel to the synthesis of the diastereomeric difluoroindanediols, we 
investigated in silico binding profiles for the individual diastereomers to MenE. 
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Using Glide (Schrödinger software suite), we docked the four 
difluoroindanediol diastereomers to our previously published cocrystal 
structure of OSB-AMS in complex with E. coli MenE (Figure 3.10, PDB: 5C5H, 
see experimental section 3.6 for complete details).  As a means to first confirm 
our docking model was functioning correctly, we docked OSB-AMS to the 
prepared MenE protein and found it to align nearly perfectly with that of the 
cocrystalized OSB-AMS (rmsd 0.2 Å).  We then proceeded to dock each of the 
four diasteromeric difluoroindanediols 2.  With each of the four diastereomers, 
the adenosine region of each molecule docked with high fidelity to the native 
OSB-AMS cocrystal structure, retaining key interactions with the protein and 
properly filling the binding pocket (Figure 3.10).  In contrast, there were 
significant levels of variability observed in the sidechain region of the 
difluoroindanediol diastereomers 2.  Only the syn-difluoroindanediol 
diastereomer (1R,3S)-2 fully filled the OSB binding pocket and overlapped well 
with the structure of the cocrystalized OSB-AMS.  The two benzannulated 
alcohols of the difluoroindanediol sidechain appear poised to engage in a 
hydrogen bonding network with a conserved water (H2O-666) and threonine 
(Thr-277) in the OSB binding pocket, both of which appear to interact with 
OSB in the MenE cocrystal structure (Figure 3.11).  In our docking studies, 
none of the diastereomers interact with the water molecules responsible for 
bridging interactions between the free carboxylate of OSB and Lys-195 (Arg-
195 in native enzyme).  This lack of the theoretical ionic interaction accounts 
for the difference in enthalpic binding modes observed between the 
difluoroindanediol  
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Figure 3.10.  Computational docking of diastereomeric difluoroindanediols 2.  
Difloroindanediols 2 (blue) to E. coli MenE R195K (cyan) (PDB: 5C5H), overlaid with co-
crystallized OSB-AMS (beige), with key binding residues (yellow) and conserved waters (red). 
Schro ̈dinger Glide docking scores shown for each diastereomer (arbitrary units).  OSB-AMS 
docked with a score of −13.9. 
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analogue and OSB-AMS during isothermal calorimetry titration experiments as 
was discussed during Chapter 2.   
As was discussed in Chapter 1, our original docking experiments with 
the unliganded crystal structure of S. aureus MenE identified Ser-302 (Thr-178 
in M. tuberculosis), whose sidechain was proposed to interact with the succinyl 
ketone of OSB.  While this residue is not conserved across species, and in the 
case of E. coli MenE is a glycine (Gly-268), its location in the docking studies 
 
 
 
Figure 3.11.  Specific interactions between MenE and (1R,3S)-2. Difloroindanediol 2 (blue) 
to E. coli MenE R195K (cyan) (PDB: 5C5H), with key binding residues (yellow) and conserved 
waters (red) in the OSB binding pocket. 
suggest that the sidechain in S. aureus and M. tuberculosis may interact with 
the tertiary alcohol of the difluoroindanediol diastereomer (1R,3S)-2.  Whether 
it would do so in addition to the conserved water or if the sidechain will exclude 
the molecule of water is unknown.  
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3.4.  Associated biochemical and antimicrobial activity of the 
diastereomeric difluoroindanediols  
 The four diastereomeric difluoroindanediol analogues 2 were then 
tested for biochemical inhibition of E. coli MenE by our collaborators in the 
laboratory of Professor Peter Tonge at Stony Brook University, using our 
previously discussed MenE-MenB coupled assay (see Chapter 2 for details).  
In results that closely mirrored the results from our docking studies, the        
syn-difluoroindanediol (1R,3S)-2 exhibited the most potent inhibition of MenE 
(Table 1), while the other three difluoroindanediol diastereomers [(1S,3R)-2, 
(1R,3R)-2, (1S,3S)-2] failed to inhibit MenE at concentrations up to 200 µM.   
Importantly, the difluoroindanediol diastereomer (1R,3S)-2 had an IC50 roughly 
¼ that of the mixture of all four diastereomers (synthesized from the original 
non-stereoselective route), suggesting that the (1R,3S)-2 diastereomer is 
solely responsible for the previously reported inhibition of MenE.   
Next, our collaborators evaluated the antimicrobial activity of the 
diastereometic difluoroindanediols 2 against B. subtilis, methicillin resistant S. 
aureus (MRSA), and M tuberculosis.   However, contrary to our expectations 
based on our biochemical inhibition results, we observe all four diastereomers 
exhibited MIC values similar to each other and to the mixture of diastereomers.   
To test whether the antimicrobial activity of the diastereomeric 
difluoroindanediols is due to inhibition of menaquinone production, we 
repeated the antimicrobial assays in the presence of exogenous 
menaquinone-4 (MK-4, 10 µg/mL).  When bacteria were coadministered MK-4 
and inhibitor at varying concentrations, we observed a 
   
 107 
 Table 3.1.  Biochemical and antimicrobial activity of difluoroindanediols 2.   
entry inhibitor 
MenE IC50 
[µM]a 
B. subtilis 
MIC [µg/mL]b 
MRSA             
MIC [ug/mL]b,c 
M. tuberculosis  
MIC [µg/mL]b 
1 2d 18.3 ± 3.7e 15.6 (62.5) 15.6 (62.5) 15.6 (62.5) 
2 (1R,3S)-2 5.0 ± 1.0 15.6 (31.2) 15.6 (31.2) 15.6 (62.5) 
3 (1S,3R)-2 > 200 15.6 (31.2) 31.2 (31.2) 31.2 (62.5) 
4 (1R,3R)-2 > 200 15.6 (15.6) 15.6 (15.6) 15.6 (31.2) 
5 (1S,3S)-2 > 200 15.6 (15.6) 15.6 (15.6) 31.2 (31.2) 
6 AMSf n.dg 3.9 (3.9) 1.9 (1.9) 0.16 (0.32) 
a E. coli MenE. b MIC values in parentheses determined with addition of exogenous 
menaquinone-4 (10 mg/mL). c MRSA = methicillin-resistant S. aureus. d Equimolar mixture of 
four diastereomers, prepared by the original synthetic route.2  e This IC50  is higher than the 1.5 
mM that we reported previously,2 due to batch-to-batch variability of the enyzme; IC50 values 
reported herein were all determined with the same batch of enzyme. f 5´-O-sulfamoyl-
adenosine. g n.d. = not determined. 
modest 4-fold increase in the MIC with the mixture of four difluoroindanediol 
diastereomers and a 2- to 4-fold increase in MIC for the biochemically active 
diastereomer (1R,3S)-2.  Some trace rescue was observed in bacteria co-
treated with the other syn-difluoroindanediol diastereomer (1S,3R)-2, and no 
rescue was observed with the two anti-difluoroindanediol diastereomers.  
While this does suggest that the antimicrobial activity of the biochemically 
active difluoroindanediol diastereomer is at least in part due to inhibition of 
menaquinone production, it does not explain the nearly identical nature of the 
antimicrobial activity observed across all the diastereomeric difluoroindanediol 
analogues.   
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 To interrogate the mechanism of action of the diastereomeric 
difluoroindanediol analogues further, we used LC-MS/MS quantification of 
endogenous menaquinone levels in MRSA treated with each of the four 
diastereomeric difluoroindanediol analogues.   While OSB-AMS was able 
induce a 2.5-fold reduction in endogenous menaquinone levels, no individual 
difluoroindanediol diastereomer was able to reduce endogenous menaquinone 
levels in a statistically significant manner.   Interestingly, the mixture of four 
diastereomeric difluroindanediols 2 did decrease endogenous menaquinone 
levels, albeit by a modest 31%, or roughly 10-fold less than that of OSB-AMS.   
 
 
Figure 3.12. Menaquinone-8 levels in methicillin-resistant Staphylococcus aureus 
treated with MenE inhibitors.  Standard error shown for two independent experiments.  
Statistical significance determined using one-tailed t test: * p ≤ 0.05, ** p ≤ 0.01. 
 109 
3.5.  Discussion and Conclusions.  
 To investigate the unusual activity of the difluoroindanediol analogue 2 
discovered in Chapter 2, we sought to synthesize each of the four 
diastereomeric difluoroindanediols and to test their biochemical and 
antimicrobial activity individually.  To this end we first developed a 
stereoselective synthesis of each of the four diastereomeric difluoroindanediol-
based inhibitors.  This was achieved through the use of enzymatic kinetic 
resolution to establish absolute stereochemistry at C3 of the indane scaffold, 
and diastereoselective alkynylation to establish relative stereochemistry at the 
C1 position of the scaffold.  Docking studies showed the syn-difluoroindanediol 
diastereomer (1R,3S)-2 docked to the MenE crystal structure with the best 
calculated score, as well as being best able to fit into the binding pocket while 
retaining key interactions with the protein.   In biochemical experiments, we 
identified the difluoroindanediol diastereomer (1R,3S)-2 as the only analogue 
to show inhibition of MenE, which mirrors our docking experiment data.  
However, in antimicrobial assays all four difluoroindanediol diastereomers 
exhibited nearly identical MICs against the B. subtilis, MRSA, and 
M.  tuberculosis, indicating that the antimicrobial mechanism of action of the 
difluoroindanediol diastereomers is not due to inhibition of MenE.  While 
modest rescue was observed upon supplementation of exogenous MK-4 in 
MRSA treated with the mixture of difluoroindanediol diastereomers and the 
difluoroindanediol diastereomer (1R,3S)-2, no appreciable rescue was 
observed with the other three diastereomers.  Finally, there was no statistically 
significant reduction of endogenous menaquinone production in MRSA treated 
with any of the four diastereomeric difluoroindanediols. 
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 In beginning this investigation of the diastereomeric difluoroindanediols, 
we had hoped to find that only one diastereomer was active in antimicrobial 
assays.  This would have lead to an inhibitor with low to sub-µM concentration 
antimicrobial activity.  However, all four diastereomers are essentially 
equivalent in their antimicrobial activity and do not inhibit production of 
menaquinone, suggesting the activity of the difluoroindanediol analogue is due 
primarily to an off-target mechanism of action.  The rescue experiments 
suggest that there is perhaps a more complicated mechanism of action than a 
simple, single off-target protein inhibition event, and that menaquinone might 
somehow play a part in this mechanism.  This hypothesis is further supported 
by the fact that the four diastereomers are, within the error of the antimicrobial 
experiments, equivalently active.  These results, when considered in isolation, 
suggest that if there is an off-target protein, it is not interacting in a specific 
manner with the difluoroindanediol sidechain.    However, if there was such a 
protein that bound with OSB-AMS type scaffolds in such a promiscuous 
manner, it is not unreasonable to suppose we would have observed 
antimicrobial activity with one of the other keto-acid or lactol analogues of 
OSB-AMS discussed in Chapter 2.  Therefore, the evidence suggests that the 
difluoroindanediol analogue 2 acts through some yet unknown, and possibly 
complex, mechanism of action.   Future investigations with this scaffold will 
focus on attempting to identify the mechanism of action behind the observed 
antimicrobial activity through the generation of resistant mutants, pull-down 
experiments, and other standards of target identification.  
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3.6.  Experimental Section 
 
A. Materials and Methods 
 Reagents were obtained from Aldrich Chemical (www.sigma-
aldrich.com) or Acros Organics (www.fishersci.com) and used without further 
purification. Optima or HPLC grade solvents were obtained from Fisher 
Scientific (www.fishersci.com), degassed with Ar, and purified on a solvent 
drying system. Reactions were performed in flame-dried glassware under 
positive Ar pressure with magnetic stirring.  
 
TLC was performed on 0.25 mm E. Merck silica gel 60 F254 plates and 
visualized under UV light (254 nm) or by staining with potassium 
permanganate (KMnO4), cerium ammonium molybdenate (CAM), or iodine (I2). 
Silica flash chromatography was performed on E. Merck 230–400 mesh silica 
gel 60. Preparative scale HPLC purification was carried out on a Waters 2545 
HPLC with 2996 diode array detector using a Sunfire Prep C18 reverse phase 
column (10 Å~ 150 mm, 5 μm) with UV detection at 254 nm. Samples were 
lyophilized using a Labconco Freezone 2.5 instrument. 
 
IR spectra were recorded on a Bruker Optics Tensor 27 FTIR spectrometer 
with Pike technologies MIRacle ATR (attenuated total reflectance, ZnSe 
crystal) accessory and peaks reported in cm–1. NMR spectra were recorded on 
a Bruker Avance III 500 instrument or Bruker Avance III 600 instrument at 24 
°C in CDCl3 unless otherwise indicated. Spectra were processed using Bruker 
TopSpin or nucleomatica iNMR (www.inmr.net) software, and chemical shifts 
are expressed in ppm relative to TMS (1H, 0 ppm) or residual solvent signals: 
CDCl3 (1H, 7.24 ppm; 13C, 77.23 ppm), CD3OD (1H, 3.31 ppm; 13C, 49.15 ppm), 
D2O (1H, 4.80 ppm); coupling constants are expressed in Hz. Mass spectra 
were obtained at the MSKCC Analytical Core Facility on a Waters Acuity SQD 
LC-MS by electrospray (ESI) ionization or atmospheric pressure chemical 
ionization (AP-CI). 
 
N.B.: 1H-NMR chemical shifts in these compounds were found to exhibit 
significant concentration dependence.  
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B. Enzymatic Kinetic Resolution of 3-Hydroxy-1-indanone (28). 
	
Figure 3.13. Enzymatic kinetic resolution of 3-hydroxy-1-indanone (6). The lipase 
catalyzes acetyl transfer from vinyl acetate to the R-alcohol (R)-28 enantioselectively, 
affording, at ideal 50% conversion, a 1:1 mixture of the R-acetate product (R)-29 and the 
unreacted S-alcohol starting material (S)-28, which are readily separable by silica flash 
chromatography. 
 
(+)-(S)-3-Hydroxy-1-indanone ((S)-28) and (–)-(R)-3-oxo-1-indanyl acetate 
((R)-29). Racemic 3-hydroxy-1-indanone (1 g, 6.7 mmol, 1 equiv) prepared as 
previously described,26 and Amano Lipase PS from Burkholderia cepacia (1.5 
g, Sigma Aldrich) were suspended in vinyl acetate (80 mL) and stirred at rt 
until the reaction had proceeded to 50% conversion as judged by LC-MS 
analysis (≈48 h).  Filtration through a pad of celite, concentration by rotary 
evaporation, and purification by silica flash chromatography (20 → 60% EtOAc 
in hexanes) yielded (S)-3-hydroxy-1-indanone ((S)-28) (455 mg, >98% ee, 
46% yield) as a red tinged semi-solid and (R)-3-oxo-1-indanyl acetate ((R)-29) 
(604 mg, >98% ee, 47% yield) as a yellow oil.   
 
Enantiomeric excess was determined by chiral HPLC (Chiralcel: OB-H, 
4.6 mm x 150 mm, 5 μm particle size, 5% isopropanol in hexanes, 1 
mL/minute), with samples prepared as 1 mg/mL solutions in 10% 
EtOH/hexanes:27,† 
 
 (S)-6: (S)-3-hydroxy-1-indanone  tret = 25 min 
 (R)-6: (R)-3-hydroxy-1-indanone  tret = 23 min 
 (R)-7: (R)-3-oxo-1-indanyl acetate tret = 20 min 
 (S)-7: (S)-3-oxo-1-indanyl acetate tret = 23 min 
 
                                            
† E=Ln[(1-c)(1-ee)]/Ln[(1-c)(1+ee)] 
O
OH
O
OH
O
O
O
(3S)-28 (3R)-2928
+
Amano Lipase PS 
from Burkholderia cepacia
vinyl acetate, rt, 48 h
3S 3R3
1
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(S)-6: : +132.0° (c 1, CHCl3). IR (ATR): 3393, 2917, 1698, 1605, 1465, 
1396, 1332, 1279, 1242, 1211, 1176, 1153, 1099, 1044, 993, 960, 903, 811, 
759, 728, 644. 1H-NMR (500 MHz; CDCl3): δ 7.75-7.68 (m, 3H), 7.51-7.48 (m, 
1H), 5.44 (d, J = 6.6 Hz, 1H), 3.12 (dd, J = 18.9, 6.8 Hz, 1H), 2.62 (dd, J = 
18.9, 2.9 Hz, 1H), 2.55 (s, 1H). 13C-NMR (126 MHz; CDCl3): δ 203.5, 155.1, 
136.4, 135.4, 129.5, 125.9, 123.3, 68.5, 47.2. HRMS (ESI) m/z calcd for 
C9H8O2Na ([M+Na]+) 171.0422; found 171.0419. 
 
(R)-7: : –11.9° (c 1, CHCl3). IR (ATR): 3075, 2936, 1718, 1605, 1466, 
1433, 1402, 1372, 1341, 1280, 1228, 1164, 1096, 1065, 989, 965, 945, 869, 
763, 734, 681, 634, 607.  1H-NMR (600 MHz; CDCl3): δ 7.78 (d, J = 7.7 Hz, 
1H), 7.70-7.67 (m, 2H), 7.55-7.52 (m, 1H), 6.36 (dd, J = 7.0, 2.6 Hz, 1H), 3.19 
(dd, J = 19.1, 7.0 Hz, 1H), 2.66 (dd, J = 19.1, 2.7 Hz, 1H), 2.14 (s, 3H).  
13C-NMR (151 MHz; CDCl3): δ 202.1, 171.0, 151.5, 137.1, 135.3, 130.0, 
126.9, 123.4, 69.9, 43.9, 21.1. HRMS (ESI) m/z calcd for C11H10O3Na ([M+H]+) 
213.0528; found 213.0522. 
 
 
 
C. Synthesis of 1R,3S-syn-Difluoroindanediol (1R,3S)-2 
 
 
(–)-(R)-3-Hydroxy-1-indanone ((R)-28).  (R)-3-Oxo-1-indanyl acetate (R)-29 
(550 mg, 2.891 mmol, 1 equiv.) was dissolved in 20 mL acetone then 6 M HCl 
(20 mL) was added.  The mixture was stirred at rt for 14 h, then poured into 
satd aq NaHCO3 (150 mL) and extracted with CH2Cl2 (4 x 75 mL).  The 
combined organic extracts were dried (Na2SO4), filtered, and concentrated by 
rotary evaporation.  Purification by silica flash chromatography (30% → 70% 
EtOAc in hexanes) yielded the alcohol (R)-28 as a pale yellow semi-solid (365 
mg, 85%).   
: –129.1° (c 1, CHCl3). IR (ATR): 3404, 2914, 1715, 1600, 1466, 1401, 
1340, 1275, 1243, 1203, 1152, 1037, 896, 759, 730.  1H-NMR (600 MHz; 
CDCl3): δ 7.75-7.68 (m, 3H), 7.51-7.48 (m, 1H), 5.44 (d, J = 4.5 Hz, 1H), 3.12 
(dd, J = 18.9, 6.8 Hz, 1H), 2.63 (dd, J = 18.9, 2.9 Hz, 1H), 2.53 (s, 1H).  
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13C-NMR (151 MHz; CDCl3): δ 203.4, 155.1, 136.4, 135.4, 129.5, 125.9, 
123.3, 68.6, 47.2.  HRMS (ESI) m/z calcd for C9H8O2Na ([M+Na]+) 171.0422; 
found 171.0428. 
 
 
(–)-(R)-3-((t-Butyldimethylsilyl)oxy)-1-indanone ((R)-30).  (R)-3-Hydroxy-1-
indanone ((R)-28) (310 mg, 2.092 mmol, 1 equiv.) was dissolved in 5 mL 
CH2Cl2 and imidazole (370 mg, 5.439 mmol, 2.6 equiv.) was added.  TBSCl 
(410 mg, 2.719 mmol, 1.3 equiv.) was added and the reaction mixture was 
stirred at rt for 12 h, then diluted with 50 mL water and extracted with CH2Cl2 
(4 x 50 mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  Purification by silica flash 
chromatography (0% → 30% EtOAc in hexanes) yielded the silyl ether (R)-30 
as a yellow tinged oil (510 mg, 93%). 
: –110.3° (c 1, CHCl3). IR (ATR): 2955, 2930, 2886, 1857, 1720, 1605, 
1464, 1390, 1351, 1279, 1254, 1216, 1161, 1106, 1078, 1046, 1006, 961, 933, 
856, 837, 809, 776, 759, 741, 720, 668.  1H-NMR (600 MHz; CDCl3): δ 7.74 
(d, J = 7.7 Hz, 1H), 7.68-7.66 (m, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.46 (t, J = 7.4 
Hz, 1H), 5.39 (dd, J = 6.6, 3.4 Hz, 1H), 3.07 (dd, J = 18.3, 6.7 Hz, 1H), 2.60 
(dd, J = 18.3, 3.4 Hz, 1H), 0.96 (s, 9H), 0.23 (s, 3H), 0.19 (s, 3H).  13C-NMR 
(151 MHz; CDCl3): δ 203.1, 156.0, 136.3, 135.1, 129.0, 125.8, 123.0, 68.9, 
47.9, 25.8, 18.2, –4.4, –4.6. HRMS (ESI) m/z calcd for C15H22O2NaSi 
([M+Na]+) 285.1287; found 285.1280. 
 
 
(–)-(S)-3-((t-Butyldimethylsilyl)oxy)-2,2-difluoro-1-indanone ((S)-31).  
Ketone (R)-30 (266 mg, 1.013 mmol, 1 equiv.) was dissolved in 25 mL 
toluene, then hexylamine (0.535 mL, 4.052 mmol, 4 equiv.) was added and the 
reaction mixture was heated to reflux for 14 h.  The reaction was then cooled 
to rt, concentrated by rotary evaporation, and placed under high vacuum (~60 
O
OTBS
(3R)
  
€ 
[α]D19
O
OTBS
F
F
(3S)
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mTorr) for 1 h.  The crude imine was dissolved in acetonitrile (10 mL) and 
Selectfluor (753 mg, 2.125 mmol, 2.1 equiv.) and sodium sulfate (144 mg, 
1.012 mmol, 1 equiv.) were added, then the reaction mixture was heated to 
reflux.  The reaction was stirred for 12 h, then cooled to rt, diluted with 1 M HCl 
(50 mL) and extracted with CH2Cl2 (4 x 50 mL).  The combined organic 
extracts were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (25% → 75% CH2Cl2 in hexanes) 
yielded the difluoroindanone (S)-31 as a deep yellow tinged oil (180 mg, 60%).   
: –140.4° (c 1, CHCl3).  IR (ATR): 2956, 2932, 2888, 2860, 1745, 1608, 
1472, 1362, 1299, 1256, 1230, 1184, 1143, 1101, 1075, 1007, 927, 895, 838, 
780, 740, 698, 670, 648.  1H-NMR (500 MHz; CDCl3): δ 7.86 (d, J = 7.7 Hz, 
1H), 7.81 (td, J = 7.6, 1.1 Hz, 1H), 7.64 (dd, J = 7.8, 0.8 Hz, 1H), 7.57 (t, J = 
7.5 Hz, 1H), 5.24 (dd, J = 12.8, 3.5 Hz, 1H), 0.99 (s, 9H), 0.28 (s, 3H), 0.25 (s, 
3H).  13C-NMR (126 MHz; CDCl3): δ 189.6, 150.4, 137.5, 132.3, 130.4, 126.2, 
124.7, 114.9, 71.8, 25.7, 18.4, –4.6, –5.1.  19F-NMR (471 MHz; CDCl3): δ -
116.50 (d, J = 279.4 Hz, 1F), -123.44 (d, J = 279.8 Hz, 1F).  HRMS (ESI) m/z 
calcd for C15H20O3F2SiNa ([M+Na]+) 321.1098; found 321.1094. 
 
 
(+)-t-Butyl 3-((1R,3S)-3-(t-butyldimethylsilyloxy)-2,2-difluoro-1-hydroxy-1-
indanyl)propiolate ((1R,3S)-32). Lithium bis(trimethylsilyl)amide (6.5 mL, 
6.492 mmol, 1.0 M in THF, 1.55 equiv.) was cooled to –78 ºC, then t-butyl 
propiolate (793 mg, 6.283 mmol, 1.5 equiv.) in 3 mL THF was added and the 
mixture was stirred for 45 min.  The solution was then added via cannula over 
10 min to ketone (3R)-31  (1.25 g, 4.189 mmol, 1 equiv.) in 5 mL THF at –78 
ºC and stirred for 2 h.  The reaction was quenched with satd aq NH4Cl (50 
mL), warmed to rt, and extracted with EtOAc (4 x 50 mL).  The combined 
organic extracts were dried (Na2SO4), filtered, and concentrated by rotary 
evaporation.  Purification by silica flash chromatography (50% → 100% 
CH2Cl2 in hexanes) yielded the ester (1R,3S)-32 as a yellow tinged oil (1.778 g, 
82%). 
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: +30.0° (c 1, CHCl3).  IR (ATR): 3394, 2956, 2932, 2888, 2859, 2245, 
1762, 1473, 1395, 1371, 1258, 1205, 1153, 1113, 1040, 1013, 909, 888, 839, 
791, 751, 732, 695, 672, 657.  1H-NMR (500 MHz; CDCl3): δ 7.63-7.60 (m, 
1H), 7.48-7.44 (m, 2H), 7.39-7.37 (m, 1H), 5.19 (dd, J = 8.0, 6.4 Hz, 1H), 1.49 
(s, 9H), 0.95 (s, 9H), 0.24 (s, 6H).  13C-NMR (126 MHz; CDCl3): δ 151.8, 
139.4, 139.1, 130.9, 130.3, 124.9, 124.4, 124.2, 84.2, 80.6, 78.2, 74.9, 74.4, 
28.0, 25.7, 18.2, –4.6, –4.9.  19F-NMR (471 MHz; CDCl3): δ -115.04 (d, J = 
222.3 Hz, 1F), -128.51 (d, J = 223.3 Hz, 1F).  HRMS (ESI) m/z calcd for 
C22H30O4F2SiNa ([M+Na]+) 441.1779; found 447.1774.   
 
 
(+)-3-((1R,3S)-3-(t-Butyldimethylsilyloxy)-2,2-difluoro-1-hydroxy-1-
indanyl)propiolic acid ((1R,3S)-33).  Ester (1R,3S)-32  (485 mg, 1.142 mmol, 
1 equiv.) was dissolved in 5 mL CH2Cl2 and cooled to 0 ºC, then 5 mL TFA 
was added and the reaction mixture was stirred for 3 h.  Concentration by 
rotary evaporation at 0 ºC and purification by silica flash chromatography (0% 
→ 20% MeOH in CH2Cl2) yielded the acid (1R,3S)-33  as a white cotton type 
solid (245 mg, 58%) as well as the corresponding desilated diol (1R,3S)-40 as 
a white solid (100 mg, 34%). 
(1R,3S)-33: : +27.6° (c 1, CHCl3).  IR (ATR): 2957, 2932, 2887, 2860, 
2249, 1700, 1472, 1364, 1247, 1150, 1095, 1010, 910, 892, 839, 782, 760, 
733, 687, 652, 625.  1H-NMR (500 MHz; CDCl3): δ 7.62-7.60 (m, 1H), 7.50-
7.45 (m, 2H), 7.40-7.38 (m, 1H), 5.18 (dd, J = 8.2, 5.8 Hz, 1H), 0.95 (s, 9H), 
0.24 (s, 6H).  13C-NMR (126 MHz; CDCl3): δ 156.1, 139.2, 139.0, 131.2, 130.4, 
125.1, 124.5, 124.0, 83.3, 78.5, 75.1, 74.5, 25.7, 18.2, –4.7, –4.9.  19F-NMR 
(471 MHz; CDCl3): δ -114.45 (d, J = 227.1 Hz, 1F), -128.02 (d, J = 224.9 Hz, 
1F).  HRMS (ESI) m/z calcd for C18H22F2O4SiNa ([M+H]+) 391.1153; found 
391.1110. 
 
(1R,3S)-40: : +3.4° (c 1, CHCl3).  IR (ATR): 3374, 2521, 2246, 1698, 1466, 
1369, 1271, 1228, 1178, 1159, 1109, 1067, 1001, 910, 886, 582, 796, 758, 
731, 682, 656, 632.  1H-NMR (500 MHz; MeOD): δ 7.56-7.54 (m, 1H), 7.50-
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7.46 (m, 3H), 5.19 (t, J = 8.6 Hz, 1H).  13C-NMR (126 MHz; CDCl3): δ 155.6, 
141.0, 140.0, 131.6, 131.1, 126.8, 126.0, 124.9, 83.3, 80.4, 75.1, 74.6.  19F-
NMR (471 MHz; CDCl3): δ -118.63 (d, J = 224.7 Hz, 1F), -131.89 (d, J = 221.8 
Hz, 1F).  HRMS (ESI) m/z calcd for C12H8F2O4Na ([M+H]+) 277.0288; found 
277.0291. 
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1R,3S)-3˝´-(t-Butyldimethyl 
silyloxy)-2˝´,2˝´-difluoro-1˝´-hydroxy-1˝´-indanyl)propioloyl]sulfamoyl) 
adenosine ((1R,3S)-35).  Propiolic acid (1R,3S)-33  (245 mg, 0.665 mmol, 1 
equiv), protected 5´-O-sulfamoyladenosine 34 (573 mg, 0.997 mmol, 1.5 
equiv) prepared as previously described,28 and DMAP (81 mg, 0.665 mmol, 
1.0 equiv.) was dissolved in CH2Cl2 (5 mL) and EDCI (510 mg, 2.659 mmol, 
4.0 equiv) was added.  The reaction was stirred for 12 h, quenched with 25 mL 
1 M KHSO4, and extracted with CH2Cl2 (5 x 25 mL).  The combined organic 
extracts were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
The reside was reconstituted in CH2Cl2, loaded into a pad of silica and washed 
with 100 mL CH2Cl2, then eluted with 15% MeOH/ CH2Cl2 (200 mL) to afford 
the crude propiolyl-sulfamate (1R,3S)-35  (499 mg), which was used without 
further purification. 
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1R,3S)-3˝´-(t-Butyldimethyl 
silyloxy)-2˝´,2˝´-difluoro-1˝´-hydroxy-1˝´-indanyl)propanoyl]sulfamoyl) 
adenosine ((1R,3S)-36).  Crude propiolyl-sulfamate (1R,3S)-35 (499 mg, 
0.540 mmol, 1 equiv.) from previous step and 10% Pd/C (575 mg, 0.540 
mmol, 1 equiv) were suspended in solution of MeOH/NEt3 (50 mL, 9:1).  The 
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reaction was then stirred vigorously under H2 balloon for 2 h, then diluted with 
EtOAc (50 mL), filtered through a celite pad, and concentrated by rotary 
evaporation to afford the crude propanoyl-sulfamate (1R,3S)-36  (500 mg), 
which was used without further purification. 
 
 
(–)-5´-O-(N-[3˝-((1R,3S)-2˝´,2˝´-difluoro-1˝´,3˝´-dihydroxy-1˝´-indanyl) 
propanoyl]sulfamoyl)adenosine ((1R,3S)-2).  Crude propanoyl-sulfamate 
(1R,3S)-36 (500 mg, 0.538 mmol, 1 equiv.) was suspended in DMF (5 mL), 
then TASF (592 mg, 2.151 mmol, 4.0 equiv.) was added and the reaction 
mixture was stirred for 12 h at 50 ºC.  Concentration by rotary evaporation, 
purification by preparative HPLC (5% → 30% MeCN in H2O with 0.1% TFA), 
and lyophilization yielded the syn-difluoroindanediol (1R,3S)-2 as a fluffy white 
solid (144 mg, 37% over 3 steps).  N.B.: HPLC fractions were stored at 0 °C 
until just prior to pooling and freezing (dry-ice bath) for lyophilization. 
: –19.16° (c 0.5, MeOH). IR (ATR): 3340, 2504, 2245, 2074, 1684, 1558, 
1474 1421, 1377, 1201, 1140, 1043, 979, 882, 842, 800, 724, 645.  1H-NMR 
(500 MHz; CD3OD): δ 8.46 (s, 1H), 8.35 (s, 1H), 7.44-7.37 (m, 4H), 6.09 (d, J 
= 4.8 Hz, 1H), 5.12 (dd, J = 11.6, 7.5 Hz, 1H), 4.63 (t, J = 5.0 Hz, 1H), 4.54-
4.48 (m, 2H), 4.39 (t, J = 4.9 Hz, 1H), 4.30-4.28 (m, 1H), 2.61 (ddd, J = 16.2, 
10.0, 5.9 Hz, 1H), 2.47 (ddd, J = 16.3, 9.9, 6.1 Hz, 1H), 2.16-2.09 (m, 1H), 
1.83 (ddd, J = 14.7, 9.4, 5.6 Hz, 1H). 13C-NMR (126 MHz; CD3OD): δ 173.2, 
150.2, 147.05, 147.03, 143.4, 142.9, 139.3, 130.4, 130.1, 125.2, 124.8, 120.5, 
90.3, 83.6, 79.4, 75.8, 74.2, 72.3, 71.6, 49.5, 31.6, 30.9.  19F-NMR (471 MHz; 
CD3OD): δ -128.07 (d, J = 225.3 Hz, 1F), -130.99 (d, J = 225.2 Hz, 1F).  
HRMS (ESI) m/z calcd for C22H25N6O9F2S ([M+H]+) 587.1372; found 587.1364. 
 
 
 
 
 
 
O
HO OH
N
NN
NH2
O NSN
H
O OO
OH
HO F F
(1R)(3S)
  
€ 
[α]D19
 119 
D. Synthesis of 1S,3R-syn-Difluoroindanediol (1R,3S)-2 
 
 
(+)-(S)-3-((t-Butyldimethylsilyl)oxy)-1-indanone ((S)-30).  (S)-3-Hydroxy-1-
indanone (S)-28 (720 mg, 4.859 mmol, 1 equiv.) was dissolved in 10 mL 
CH2Cl2 and imidazole (860 mg, 12.63 mmol, 2.6 equiv.) was added.  TBSCl 
(952 mg, 6.316 mmol, 1.3 equiv.) was added and the reaction mixture was 
stirred at rt for 12 h, then diluted with 50 mL water and extracted with CH2Cl2 
(4 x 50 mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  Purification by silica flash 
chromatography (0% → 30% EtOAc in hexanes) yielded the silyl ether (S)-30 
as a yellow tinged oil (1.13 g, 91%). 
: +109.4° (c 1, CHCl3).  IR (ATR): 2955, 2930, 2886, 2857, 1720, 1606, 
1464, 1390, 1361, 1279, 1254, 1216, 1161, 1106, 1079, 1046, 1006, 961, 
9334, 857, 837, 809, 776, 759, 719, 668. 1H-NMR (600 MHz; CDCl3): δ 7.74 
(d, J = 7.7 Hz, 1H), 7.74 (d, J = 7.7 Hz, 1H), 7.68-7.65 (m, 1H), 7.61 (d, J = 7.7 
Hz, 1H), 7.46 (t, J = 7.4 Hz, 1H), 5.39 (dd, J = 6.6, 3.4 Hz, 1H), 3.06 (dd, J = 
18.3, 6.7 Hz, 1H), 2.60 (dd, J = 18.3, 3.4 Hz, 1H), 0.96 (s, 9H), 0.23 (s, 3H), 
0.19 (s, 3H). 13C-NMR (151 MHz; CDCl3): δ 203.1, 156.0, 136.3, 135.1, 129.0, 
125.8, 123.0, 68.9, 47.9, 25.8, 18.2, -4.4, -4.6.  HRMS (ESI) m/z calcd for 
C15H23O2Si ([M+H]+) 263.1467; found 263.1465. 
 
 
(+)-(R)-3-((t-Butyldimethylsilyl)oxy)-2,2-difluoro-1-indanone ((R)-31).  
Ketone (S)-30 (1 g, 3.814 mmol, 1 equiv.) was dissolved in 80 mL 
cyclohexane, then hexylamine (2 mL, 15.25 mmol, 4 equiv.) and trifluoroacetic 
acid (0.015 mL, 0.19 mmol, 0.05 equiv.) were added and the reaction mixture 
was heated to reflux for 14 h.  The reaction was then cooled to rt, diluted with 
75 mL toluene, concentrated by rotary evaporation, and placed under high 
vacuum (~60 mTorr) for 1 h.  The crude imine was dissolved in acetonitrile (50 
mL), then Selectfluor (2.83 g, 7.99 mmol, 2.1 equiv.) and sodium sulfate (378 
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mg, 2.663 mmol, 0.7 equiv.) were added and the reaction mixture was heated 
to reflux for 12 h.  The reaction was cooled to rt, diluted with 1 M HCl (150 mL) 
and extracted with CH2Cl2 (4 x 100 mL).  The combined organic extracts were 
dried (Na2SO4), filtered, and concentrated by rotary evaporation.  Purification 
by silica flash chromatography (25% → 75% CH2Cl2 in hexanes) yielded the 
difluoroindanone (R)-31 as a yellow tinged oil (710 mg, 63%). 
: +138.7° (c 3.3, CHCl3).  IR (ATR): 2958, 2933, 2890, 2862, 1748, 1610, 
1474, 1364, 1301, 1258, 1232, 1186, 1145, 1103, 1076, 1008, 929, 897, 840, 
782, 741, 700, 672, 650.  1H-NMR (500 MHz; CDCl3): δ 7.86 (d, J = 7.8 Hz, 
1H), 7.81 (td, J = 7.6, 1.0 Hz, 1H), 7.64 (dd, J = 7.8, 0.7 Hz, 1H), 7.57 (t, J = 
7.5 Hz, 1H), 5.24 (dd, J = 12.8, 3.5 Hz, 1H), 0.99 (s, 10H), 0.28 (s, 3H), 0.25 
(s, 3H).  13C-NMR (126 MHz; CDCl3): δ 189.6, 150.4, 137.6, 132.3, 130.4, 
126.2, 124.6, 114.93, 114.91, 71.8, 25.68, 18.3, –4.6, –5.1.  19F-NMR (471 
MHz; CDCl3): δ -116.50 (d, J = 279.6 Hz, 1F), -123.45 (d, J = 279.8 Hz, 1F). 
HRMS (ESI) m/z calcd for C15H20O3F2SiNa ([M+Na]+) 321.1098; found 
321.1103. 
 
 
(–)-t-Butyl 3-((1S,3R)-3-(tert-butyldimethylsilyloxy)-2,2-difluoro-1-
hydroxy-1-indanyl)propiolate ((1S,3R)-32).  Lithium bis(trimethylsilyl)amide 
(4.95 mL, 4.95 mmol, 1.0 M in THF, 1.55 equiv.) was cooled to –78 ºC, then t-
butyl propiolate (604 mg, 4.789 mmol, 1.5 equiv.) in 3 mL THF was added and 
the reaction mixture was stirred for 45 min.  The solution was then added via 
cannula over 10 min to ketone (R)-31  (953 mg, 3.193 mmol, 1 equiv.) in 5 mL 
THF at –78 ºC and stirred for 2 h.  The reaction was quenched with satd aq 
NH4Cl (50 mL), warmed to rt, and extracted with EtOAc (4 x 50 mL).  The 
combined organic extracts were dried (Na2SO4), filtered, and concentrated by 
rotary evaporation.  Purification by silica flash chromatography (50% → 100% 
CH2Cl2 in hexanes) yielded the ester (1S,3R)-32 as a clear viscous oil (1.05 g, 
78%). 
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: –28.1° (c 1, CHCl3).  IR (ATR): 3400, 2956, 2932, 2888, 2860, 2248, 
1710, 1473, 1395, 1371, 1258, 1204, 1153, 1114, 1039, 1013, 909, 888, 838, 
781, 751, 732, 695, 672, 657. 1H-NMR (500 MHz; CDCl3): δ 7.63-7.60 (m, 
1H), 7.47-7.45 (m, 2H), 7.38-7.37 (m, 1H), 5.19 (dd, J = 8.0, 6.3 Hz, 1H), 2.96 
(d, J = 2.3 Hz, 1H), 1.49 (s, 9H), 0.95 (s, 9H), 0.24 (s, 6H). 13C-NMR (126 
MHz; CDCl3): δ 151.8, 139.5, 139.1, 130.9, 130.3, 124.9, 124.4, 124.2, 84.2, 
80.6, 78.2, 74.9, 74.4, 28.0, 25.7, 18.2, –4.65, –4.84. 19F-NMR (471 MHz; 
CDCl3): δ -115.05 (d, J = 224.7 Hz, 1F), -128.46 (d, J = 224.6 Hz, 1F). HRMS 
(ESI) m/z calcd for C22H30O4F2SiNa ([M+Na]+) 441.1779; found 441.1785. 
 
 
(–)-3-((1S,3R)-3-(t-Butyldimethylsilyloxy)-2,2-difluoro-1-hydroxy-1-
indanyl)propiolic acid ((1S,3R)-33).  Ester (1S,3R)-32 (950 mg, 2.26mmol, 1 
equiv.) was dissolved in 10 mL CH2Cl2 and cooled to 0 ºC, then 10 mL TFA 
was added and the reaction mixture was stirred for 3 h.  Concentration by 
rotary evaporation at 0 ºC and purification by silica flash chromatography (0% 
→ 20% MeOH in CH2Cl2) yielded the acid (1S,3R)-33 as a white cotton type 
solid (465 mg, 56%), along with the corresponding desilated congener 
(1S,3R)-40  as a white solid (176 mg, 31%). 
(1S,3R)-33: : –27.9° (c 1, CHCl3).  IR (ATR): 2958, 2934, 2893, 2862, 
2253, 1701, 1474, 1365, 1249, 1152, 1095, 1010, 912, 893, 841, 783, 764, 
733, 688, 653, 626.  1H-NMR (500 MHz; CDCl3): δ 7.61-7.60 (m, 1H), 7.50-
7.45 (m, 2H), 7.40-7.38 (m, 1H), 5.18 (dd, J = 8.2, 5.8 Hz, 1H), 0.94 (s, 9H), 
0.24 (s, 6H).  13C-NMR (126 MHz; CDCl3): δ 156.3, 139.2, 139.0, 131.2, 130.5, 
125.1, 124.5, 124.0, 83.4, 78.5, 75.1, 74.5, 25.7, 18.2, –4.66, –4.85.  19F-NMR 
(471 MHz; CDCl3): 114.45 (d, J = 224.6 Hz, 1F), -127.98 (d, J = 224.6 Hz, 1F).  
HRMS (ESI) m/z calcd for C18H22O4F2NaSi ([M+H]+) 391.1153; found 
391.1154. 
 
(1S,3R)-40: : –3.6° (c 1, CHCl3).  IR (ATR): 3354, 2502, 2246, 1697, 1466, 
1271, 1228, 1178, 1159, 1109, 1066, 1000, 974, 909, 886, 851, 795, 759, 730, 
683, 655, 631.  1H-NMR (500 MHz; MeOD): δ 7.56-7.54 (m, 1H), 7.50-7.46 (m, 
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3H), 5.18 (t, J = 8.6 Hz, 1H).  13C-NMR (126 MHz; MeOD): δ 155.6, 141.0, 
140.0, 131.6, 131.1, 126.9, 126.0, 124.9, 83.3, 80.4, 75.1, 74.5.  19F-NMR 
(471 MHz; MeOD): δ -118.67 (d, J = 221.5 Hz, 1F), -131.92 (d, J = 224.7 Hz, 
1F).  HRMS (ESI) m/z calcd for C24H16O8F4 ([2M-H]-) 507.0703; found 
507.0704. 
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1S,3R)-3˝´-(t-Butyldimethyl 
silyloxy)-2˝´,2˝´-difluoro-1˝´-hydroxy-1˝´-indanyl)propioloyl]sulfamoyl) 
adenosine ((1S,3R)-35).  Propiolic acid (1S,3R)-33 (250 mg, 0.678 mmol, 1 
equiv), protected 5´-O-sulfamoyladenosine 34 (585 mg, 1.017 mmol, 1.5 
equiv) prepared as previously described,3 and DMAP (83 mg, 0.678 mmol, 1.0 
equiv.) was dissolved in CH2Cl2 (5 mL) and EDCI (520 mg, 2.714 mmol, 4.0 
equiv) was added.  The reaction was stirred for 12 h, then quenched with 
25 mL 1 M KHSO4, and extracted with CH2Cl2 (5 x 25 mL).  The combined 
organic extracts were dried (Na2SO4), filtered, and concentrated by rotary 
evaporation.  The reside was reconstituted in CH2Cl2, loaded into a pad of 
silica and washed with 100 mL CH2Cl2, then eluted with 15% MeOH/ CH2Cl2 
(200 mL) to afford the crude propiolyl-sulfamate (1S,3R)-35 (480 mg), which 
was used without further purification. 
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1S,3R)-3˝´-(t-Butyldimethyl 
silyloxy)-2˝´,2˝´-difluoro-1˝´-hydroxy-1˝´-indanyl)propanoyl]sulfamoyl) 
adenosine ((1S,3R)-36).  Crude propiolyl-sulfamate (1S,3R)-35 (480mg, 
0.519 mmol, 1 equiv.) from previous step and 10% Pd/C (552 mg, 0.519 
mmol, 1 equiv) were suspended in solution of MeOH/NEt3 (50 mL, 9:1).  The 
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reaction was then stirred vigorously under H2 balloon for 2 h, then diluted with 
EtOAc (50 mL), filtered through a celite pad, and concentrated by rotary 
evaporation to afford the crude propanoyl-sulfamate (1S,3R)-36 (428 mg), 
which was used without further purification. 
 
 
(+)-5´-O-(N-[3˝-((1S,3R)-2˝´,2˝´-difluoro-1˝´,3˝´-dihydroxy-1˝´-
indanyl)propanoyl]sulfamoyl)adenosine ((1S,3R)-2).  Crude propanoyl-
sulfamate (1S,3R)-36 (480 mg, 0.461 mmol, 1 equiv.) was suspended in DMF 
(5 mL), then TASF (507 mg, 1.841 mmol, 4.0 equiv.) was added and the 
reaction mixture was stirred for 12 h at 50 ºC.  Concentration by rotary 
evaporation, purification by preparative HPLC (5% → 30% MeCN in H2O with 
0.1% TFA), and lyophilization yielded the syn-difluoroindanediol (1S,3R)-2 as 
a fluffy white solid (123 mg, 31% over 3 steps).  N.B.: HPLC fractions were 
stored at 0 °C until just prior to pooling and freezing (dry-ice bath) for 
lyophilization. 
: +5.7° (c 0.5, MeOH). IR (ATR): 3368, 2512, 2241, 2077, 1687, 1478, 
1425, 1379, 1202, 1141, 1045, 980, 882, 803, 726, 645.  1H-NMR (500 MHz; 
CD3OD): δ 8.42 (s, 1H), 8.34 (s, 1H), 7.42-7.36 (m, 4H), 6.07-6.06 (m, 1H), 
5.15-5.10 (m, 1H), 4.63-4.60 (m, 1H), 4.54-4.46 (m, 2H), 4.40-4.37 (m, 1H), 
4.30-4.27 (m, 1H), 2.66-2.60 (m, 1H), 2.49-2.42 (m, 1H), 2.18-2.12 (m, 1H), 
1.81-1.75 (m, 1H).  13C-NMR (126 MHz; CD3OD): δ 173.2, 150.2, 147.01, 
146.86, 143.4, 142.9, 139.3, 130.4, 130.1, 125.2, 124.9, 120.5, 90.3, 83.6, 
79.4, 75.8, 74.2, 72.3, 71.6, 49.9, 31.6, 30.9.  19F-NMR (471 MHz; CD3OD): δ 
-128.11 (d, J = 225.3 Hz, 1F), -131.06 (d, J = 224.7 Hz, 1F).  HRMS (ESI) m/z 
calcd for C22H25N6O9F2S ([M+H]+) 587.1372; found 587.1353. 
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E. Synthesis of 1R,3R-anti-Difluoroindanediol (1R,3S)-2 
 
 
(–)-t-Butyl 3-((1R,3S)-2,2-difluoro-1,3-dihydroxy-1-indanyl)propiolate 
((1R,3S)-37).  Silyl ether (1R,3S)-32 (470 mg, 1.107 mmol, 1.0 equiv.) was 
dissolved in 2 mL THF and cooled to 0 ºC, then tetrabutylammonium fluoride 
(1.217 mL, 1.217 mmol, 1.0 M in THF, 1.1 equiv.) was added, and the reaction 
mixture was stirred for 1 h.  Concentration by rotary evaporation and 
purification by silica flash chromatography (30% → 60% EtOAc in hexanes) 
yielded the diol (1R,3S)-37 as a white solid (285 mg, 83%). 
 
Enantiomeric excess was confirmed by chiral HPLC (Chiralcel: OB-H, 4.6 mm 
x 150 mm, 5 μm particle size, 5% isopropanol in hexanes, 1 mL/minute), with 
samples prepared as 1 mg/mL solutions in 10% EtOH/hexanes:  
 
 (1R,3S)-37: tret = 17 min, >98% ee 
 (1S,3R)-37: tret = 21 min 
 
: –5.3° (c 1, CHCl3).  IR (ATR): 3377, 2984, 2936, 2249, 1707, 1459, 
1396, 1372, 1281, 1232, 1152, 1110, 1067, 1003, 909, 838, 798, 754, 732, 
682, 660, 649.  1H-NMR (500 MHz; CDCl3): δ 7.65-7.62 (m, 1H), 7.54-7.48 (m, 
3H), 5.11 (dd, J = 8.7, 4.0 Hz, 1H), 3.10 (s, 2H), 1.49 (s, 9H).  13C-NMR (126 
MHz; CDCl3): δ 151.8, 139.5, 138.7, 131.3, 130.8, 125.8, 124.8, 123.6, 84.5, 
80.9, 77.9, 74.8, 74.3, 28.0.  19F-NMR (471 MHz; CDCl3): δ  -114.40 (d, J = 
233.2 Hz, 1F), -129.02 (d, J = 231.4 Hz, 1F).  HRMS (ESI) m/z calcd for 
C16H16O4F2Na ([M+H]+) 333.0914; found 333.0916. 
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(–)-(R)-t-Butyl 3-(2,2-difluoro-1-hydroxy-3-oxo-1-indanyl)propiolate 
((R)-38).  DMSO (227 mg, 2.9 mmol, 3.0 equiv.) was dissolved in 4 mL 
CH2Cl2, cooled to –78 ºC, and oxalyl chloride (184 mg, 1.450 mmol, 1.5 equiv.) 
was added and the reaction mixture was stirred for 10 min.  Diol (1R,3S)-37 
(300 mg, 0.967 mmol, 1.0 equiv.) in 1.5 mL CH2Cl2 was added dropwise, then 
the reaction mixture was stirred for 40 min.  Triethylamine (0.675 mL, 4.834 
mmol, 5.0 equiv.) was added and the reaction mixture was stirred for 40 min, 
then removed from the dry-ice bath and stirred for 10 min.  The reaction was 
then quenched with satd aq NH4Cl (30 mL), extracted with CH2Cl2 (4 x 20 mL), 
the combined organic extracts were dried (Na2SO4), filtered, and concentrated 
by rotary evaporation.  Purification by silica flash chromatography (5% → 25% 
EtOAc in hexanes) yielded the ketoalcohol (R)-38 as a clear oil (272 mg, 91%). 
: –24.4° (c 1, CHCl3).  IR (ATR): 3410, 2985, 2938, 2244, 1752, 1712, 
1604, 1471, 1397, 1372, 1286, 1222, 1193, 1152, 1101, 1041, 1017, 934, 910, 
877, 837, 770, 755, 736, 712, 693, 649.  1H-NMR (500 MHz; CDCl3): δ 7.94-
7.88 (m, 3H), 7.68 (td, J = 7.5, 1.0 Hz, 1H), 3.59 (s, 1H), 1.51 (s, 9H). 
13C-NMR (126 MHz; CDCl3): δ 187.6, 151.6, 148.8, 138.1, 132.0, 131.3, 
126.3, 125.2, 113.5, 85.0, 82.2, 77.1, 71.1, 28.0. 19F-NMR (471 MHz; CDCl3): 
δ -111.61 (d, J = 269.2 Hz, 1F), -125.99 (d, J = 270.5 Hz, 1F).  HRMS (ESI) 
m/z calcd for C16H14O4F2Cl ([M+Cl]-) 343.0549; found 343.0565. 
 
 
(+)-t-Butyl 3-((1R,3R)-2,2-difluoro-1,3-dihydroxy-1-indanyl)propiolate 
((1R,3R)-39).  Ketone (R)-38  (300 mg, 0.941 mmol, 1 equiv.) was dissolved in 
5 mL MeOH and cooled to 0 ºC, then NaBH4 (11 mg, 0.282 mmol, 0.3 equiv.) 
was added in 4 portions over 5 min and the reaction mixture was stirred for 30 
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min.  Acetone (0.1 mL) was added and the reaction mixture was stirred for 10 
min, then 1 M phosphate buffer (pH 7.0, 20 mL) was added and the reaction 
mixture was stirred for an additional 10 min.  The reaction was then extracted 
with EtOAc (4 x 15 mL), the combined organic extracts were dried (Na2SO4), 
filtered, and concentrated by rotary evaporation.  Purification by silica flash 
chromatography (0% → 100% EtOAc in CH2Cl2) yielded the anti-diol 
(1R,3R)-39 as a white solid (263 mg, 90%). 
 
Enantiomeric excess was confirmed by chiral HPLC (Chiralcel: OB-H, 4.6 mm 
x 150 mm, 5 μm particle size, 5% isopropanol in hexanes, 1 mL/minute), with 
samples prepared as 1 mg/mL solutions in 10% EtOH/hexanes:  
 
 (1R,3R)-39: tret = 21 min, >98% ee 
 (1S,3S)-39: tret = 27 min 
 
: +9.6° (c 1, CHCl3).  IR (ATR): 3371, 2983, 2930, 2241, 1684, 1395, 
1371, 1230, 1300, 1152, 1111, 1078, 1032, 1003, 913, 834, 752, 731, 649, 
574.  1H-NMR (500 MHz; CDCl3): δ 7.63 (d, J = 7.4 Hz, 1H), 7.52-7.49 (m, 
2H), 7.48-7.45 (m, 1H), 5.41 (td, J = 10.3, 6.4 Hz, 1H), 3.11 (d, J = 1.5 Hz, 
1H), 2.38 (dd, J = 10.7, 2.1 Hz, 1H), 1.51 (s, 9H).  13C-NMR (126 MHz; CDCl3): 
δ 151.8, 139.0, 137.6, 131.5, 130.2, 124.94, 124.74, 123.7, 84.6, 80.8, 77.8, 
74.17, 74.06, 28.0.  19F-NMR (471 MHz; CDCl3): δ -123.33 (d, J = 225.3 Hz, 
1F), -125.61 (d, J = 226.3 Hz, 1F).  HRMS (ESI) m/z calcd for C16H16O4F2Na 
([M+H]+) 333.0914; found 333.0920. 
 
 
3-((1R,3R)-2,2-difluoro-1,3-dihydroxy-1-indanyl)propiolic acid 
((1R,3R)-40).  Ester (1R,3R)-39 (185 mg, 0.593 mmol, 1 equiv.) was dissolved 
in 5 mL CH2Cl2 and cooled to 0 ºC, then 5 mL TFA was added and the 
reaction mixture was stirred for 3 h.  Concentration by rotary evaporation at 
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0 ºC gave crude acid (1R,3R)-40 (170 mg), which was used directly in the next 
step without further purification.  
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1R,3R)-2˝´,2˝´-difluoro-1˝´,3˝´-
dihydroxy-1˝´-indanyl)propioloyl]sulfamoyl)adenosine ((1R,3R)-41).  
Propiolic acid (1R,3R)-40 (assumed quantitative yield from previous step: 151 
mg, 0.594 mmol, 1 equiv), protected 5´-O-sulfamoyladenosine 34 (427 mg, 
0.723 mmol, 1.25 equiv) prepared as previously described,3 and DMAP (73 
mg, 0.594 mmol, 1.0 equiv.) was dissolved in CH2Cl2:MeCN (5 mL, 2:1) and 
EDCI (456 mg, 2.376 mmol, 4.0 equiv) was added.  The reaction was stirred 
for 12 h, quenched with 15 mL 1 M KHSO4, and extracted with EtOAc (5 x 15 
mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  The reside was reconstituted in CH2Cl2, 
loaded into a pad of silica and washed with 100 mL CH2Cl2, then eluted with 
15% MeOH/ CH2Cl2 (150 mL) to afford the crude propiolyl-sulfamate 
(1R,3R)-40 (294 mg), which was used directly in the next step without further 
purification. 
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1R,3R)-2˝´,2˝´-difluoro-1˝´,3˝´-
dihydroxy-1˝´-indanyl)propanoyl]sulfamoyl)adenosine ((1R,3R)-42).  
Crude propiolyl-sulfamate (1R,3R)-41 (294 mg, 0.363 mmol, 1 equiv.) from 
previous step and 10% Pd/C (386 mg, 0.363 mmol, 1 equiv) were suspended 
in solution of MeOH/NEt3 (40 mL, 9:1).  The reaction was then stirred 
vigorously under H2 balloon for 2 h, then diluted with EtOAc (15 mL), filtered 
through a celite pad, and concentrated by rotary evaporation to afford the 
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crude propanoyl-sulfamate (1R,3R)-42 (300 mg), which was used directly in 
the next step without further purification. 
 
 
(+)-5´-O-(N-[3˝-((1R,3R)-2˝´,2˝´-difluoro-1˝´,3˝´-dihydroxy-1˝´-
indanyl)propanoyl]sulfamoyl)adenosine ((1R,3R)-2).  Crude propanoyl-
sulfamate (1R,3R)-42 (300 mg, 0.370 mmol, 1 equiv.) was suspended in DMF 
(1.5 mL), then TASF (306 mg, 1.109 mmol, 3.0 equiv.) was added and the 
reaction mixture was stirred for 12 h at 50 ºC.  Concentration by rotary 
evaporation, purification by preparative HPLC (5% → 30% MeCN in H2O with 
0.1% TFA), and lyophilization yielded the anti-difluoroindanediol (1R,3R)-2 as 
a fluffy white solid (75 mg, 35% over 4 steps).  N.B.: HPLC fractions were 
stored at 0 °C until just prior to pooling and freezing (dry-ice bath) for 
lyophilization. 
: +4.0° (c 0.5, MeOH). IR (ATR): 3343, 2942, 2865, 2509, 2076, 1692, 
1473, 1420, 1378, 1198, 1134, 976, 885, 835, 800, 765, 723, 680, 638.  
1H-NMR (500 MHz; CD3OD): δ 8.47 (s, 1H), 8.34 (s, 1H), 7.45-7.40 (m, 4H), 
6.10 (d, J = 4.8 Hz, 1H), 5.12 (dd, J = 9.7, 5.9 Hz, 1H), 4.64 (t, J = 5.0 Hz, 1H), 
4.57-4.51 (m, 2H), 4.41 (t, J = 4.9 Hz, 1H), 4.31 (q, J = 3.9 Hz, 1H), 2.63 (t, J = 
7.9 Hz, 2H), 2.32-2.13 (m, 2H). 13C-NMR (126 MHz; CD3OD): δ 173.4, 150.2, 
147.5, 147.3, 143.8, 143.3, 140.0, 130.70, 130.63, 126.4, 124.9, 120.5, 90.3, 
83.6, 79.6, 75.8, 74.9, 72.3, 71.6, 49.3, 31.31, 31.13.  19F-NMR (471 MHz; 
CD3OD): δ -120.31 (d, J = 230.1 Hz, 1F), -130.90 (d, J = 233.2 Hz, 1F).  
HRMS (ESI) m/z calcd for C22H25N6O9F2S ([M+H]+) 587.1372; found 587.1370. 
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F. Synthesis of 1S,3S-anti-Difluoroindanediol (1R,3S)-2 
 
 
(+)-t-Butyl 3-((1S,3R)-2,2-difluoro-1,3-dihydroxy-1-indanyl)propiolate 
((1S,3R)-37).  Silyl ether (1S,3R)-32 (681 mg, 1.604 mmol, 1.0 equiv.) was 
dissolved in 4 mL THF and cooled to 0 ºC, then tetrabutylammonium fluoride 
(1.764 mL, 1.764 mmol, 1.0 M in THF, 1.1 equiv.) was added and the reaction 
mixture was stirred for 1 h.  Concentration by rotary evaporation and 
purification by silica flash chromatography (30% → 60% EtOAc in hexanes) 
yielded the diol (1S,3R)-37 as a white solid (405 mg, 81%). 
 
Enantiomeric excess was confirmed by chiral HPLC (Chiralcel: OB-H, 4.6 mm 
x 150 mm, 5 μm particle size, 5% isopropanol in hexanes, 1 mL/minute), with 
samples prepared as 1 mg/mL solutions in 10% EtOH/hexanes:  
 
 (1R,3S)-37: tret = 17 min 
 (1S,3R)-37: tret = 21 min, >98% ee 
 
: +5.7° (c 1, CHCl3).  IR (ATR): 3395, 2984, 2936, 2249, 1708, 1459, 
1397, 1372, 1281, 1232, 1152, 1110, 1068, 1003, 909, 882, 839, 798, 756, 
732, 696, 682, 659, 649.  1H-NMR (500 MHz; CDCl3): δ 7.64-7.61 (m, 1H), 
7.53-7.47 (m, 3H), 5.11 (dd, J = 8.7, 4.0 Hz, 1H), 3.05 (s, 2H), 1.48 (s, 9H). 
13C-NMR (126 MHz; CDCl3): δ 151.8, 139.5, 138.7, 131.3, 130.8, 125.8, 
124.8, 123.6, 84.6, 80.9, 77.9, 74.8, 74.3, 28.0.  19F-NMR (471 MHz; CDCl3): δ 
-114.41 (d, J = 228.7 Hz, 1F), -129.08 (d, J = 228.8 Hz, 1F). HRMS (ESI) m/z 
calcd for C16H16O4F2Na ([M+H]+) 374.0914; found 374.1198. 
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(+)-(S)-t-Butyl 3-(2,2-difluoro-1-hydroxy-3-oxo-1-indanyl)propiolate 
((S)-38).  DMSO (147 mg, 1.885 mmol, 3.0 equiv.) was dissolved in 2.5 mL 
CH2Cl2, cooled to –78 ºC, and oxalyl chloride (120 mg, 0.943 mmol, 1.5 equiv.) 
was added and the reaction mixture was stirred for 10 min.  Diol (1S,3R)-37 
(195 mg, 0.628 mmol, 1.0 equiv.) in 1 mL CH2Cl2 was added and the reaction 
mixture was stirred for 40 min.  Triethylamine (0.438 mL, 3.142 mmol, 5.0 
equiv.) was added and the reaction mixture was stirred for 40 min, then 
removed from the dry-ice bath and stirred for 10 min.  The reaction was then 
quenched with satd aq NH4Cl (20 mL), extracted with CH2Cl2 (4 x 15 mL), the 
combined organic extracts were dried (Na2SO4), filtered, and concentrated by 
rotary evaporation.  Purification by silica flash chromatography (5% → 25% 
EtOAc in hexanes) yielded the ketoalcohol (S)-38 as a clear oil (180 mg, 93%). 
: +25.2° (c 1, CHCl3).  IR (ATR): 3411, 2986, 2939, 2246, 1753, 1713, 
1606, 1473, 1398, 1374, 1287, 1223, 1194, 1153, 1103, 1043, 1019, 936, 911, 
879, 839, 772, 756, 737, 713, 651.  1H-NMR (500 MHz; CDCl3): δ 7.94-7.87 
(m, 3H), 7.68 (td, J = 7.5, 1.1 Hz, 1H), 3.60 (s, 1H), 1.51 (s, 9H). 13C-NMR 
(126 MHz; CDCl3): δ 187.6, 151.6, 148.8, 138.1, 132.0, 131.2, 126.3, 125.2, 
113.5, 85.0, 82.2, 77.1, 71.1, 28.0. 19F-NMR (471 MHz; CDCl3): δ  -111.50 (d, 
J = 267.2 Hz, 1F), -126.10 (d, J = 270.5 Hz, 1F).  HRMS (ESI) m/z calcd for 
C16H14O4F2Na ([M+H]+) 331.0758; found 331.0750. 
 
 
(–)-t-Butyl 3-((1S,3S)-2,2-difluoro-1,3-dihydroxy-1-indanyl)propiolate 
((1S,3S)-39).  Ketone (S)-38 (200 mg, 0.649 mmol, 1 equiv.) was dissolved in 
3 mL MeOH and cooled to 0 ºC, then NaBH4 (7.4 mg, 0.195 mmol, 0.3 equiv.) 
was added in 4 portions over 5 min and the reaction mixture was stirred for 30 
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min.  Acetone (0.1 mL) was added and the reaction mixture was stirred for 10 
min, then 1 M phosphate buffer (pH 7.0, 15 mL) was added and the reaction 
mixture was stirred for an additional 10 min.  The reaction was then extracted 
with EtOAc (4 x 10 mL), the combined organic extracts were dried (Na2SO4), 
filtered, and concentrated by rotary evaporation.  Purification by silica flash 
chromatography (0% → 10% EtOAc in CH2Cl2) yielded the anti-diol (1S,3S)-39 
as a white solid (170 mg, 84%).   
 
Enantiomeric excess was confirmed by chiral HPLC (Chiralcel: OB-H, 4.6 mm 
x 150 mm, 5 μm particle size, 5% isopropanol in hexanes, 1 mL/minute), with 
samples prepared as 1 mg/mL solutions in 10% EtOH/hexanes:  
 
 (1R,3R)-39: tret = 21 min 
 (1S,3S)-39: tret = 27 min, >98% ee 
 
: –9.9° (c 1, CHCl3).  IR (ATR): 3374, 2984, 2938, 2245, 1689, 1466, 
1397, 1372, 1305, 1229, 1153, 1110, 1078, 1041, 1008, 911, 893, 837, 795, 
756, 732, 696, 648.  1H-NMR (500 MHz; CDCl3): δ 7.63 (d, J = 7.4 Hz, 1H), 
7.51-7.45 (m, 3H), 5.40 (td, J = 10.4, 6.4 Hz, 1H), 3.18 (s, 1H), 2.42 (dd, J = 
10.7, 2.5 Hz, 1H), 1.51 (s, 9H).  13C-NMR (126 MHz; CDCl3): δ 151.8, 139.0, 
137.6, 131.4, 130.2, 124.93, 124.73, 123.7, 84.6, 80.8, 77.9, 74.17, 74.05, 
28.0.  19F-NMR (471 MHz; CDCl3): δ -123.25 (d, J = 228.4 Hz, 1F), -125.63 (d, 
J = 229.1 Hz, 1F).  HRMS (ESI) m/z calcd for C16H16O4F2Na ([M+H]+) 
333.0914; found 333.0905. 
 
 
3-((1S,3S)-2,2-difluoro-1,3-dihydroxy-1-indanyl)propiolic acid ((1S,3S)-40).  
Ester (1S,3S)-39 (135 mg, 0.435 mmol, 1 equiv.) was dissolved in 5 mL 
CH2Cl2 and cooled to 0 ºC, then 5 mL TFA was added and the reaction 
mixture was stirred for 3 h.  Concentration by rotary evaporation at 0 ºC gave 
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crude acid (1S,3S)-40 (110 mg), which was used directly in the next step 
without further purification.  
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1S,3S)-2˝´,2˝´-difluoro-1˝´,3˝´-
dihydroxy-1˝´-indanyl)propioloyl]sulfamoyl)adenosine ((1S,3S)-41).  
Propiolic acid (1S,3S)-40  (assumed quantitative yield from previous step: 110 
mg, 0.433 mmol, 1 equiv), protected 5´-O-sulfamoyladenosine 34 (373 mg, 
0.541 mmol, 1.25 equiv) prepared as previously described,3  and DMAP (53 
mg, 0.433 mmol, 1.0 equiv.) was dissolved in CH2Cl2:MeCN (5 mL, 2:1) and 
EDCI (332 mg, 1.730 mmol, 4.0 equiv) was added.  The reaction was stirred 
for 12 h, then quenched with 15 mL 1 M KHSO4, and extracted with EtOAc (5 
x 15 mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  The reside was reconstituted in CH2Cl2, 
loaded into a pad of silica and washed with 100 mL CH2Cl2, then eluted with 
15% MeOH/ CH2Cl2 (150 mL) to afford the crude propiolyl-sulfamate 
(1S,3S)-41 (128 mg), which was used directly in the next step without further 
purification. 
 
 
2´,3´-O-(t-Butyldimethylsilyl)-5´-O-(N-[3˝-((1S,3S)-2˝´,2˝´-difluoro-1˝´,3˝´-
dihydroxy-1˝´-indanyl)propanoyl]sulfamoyl)adenosine ((1S,3S)-42).  
Crude propiolyl-sulfamate (1S,3S)-41 (128 mg, 0.158 mmol, 1 equiv.) from 
previous step and 10% Pd/C (168 mg, 0.158 mmol, 1 equiv) were suspended 
in solution of MeOH/NEt3 (15 mL, 9:1).  The reaction was then stirred 
vigorously under H2 balloon for 2 h, then diluted with EtOAc (15 mL), filtered 
through a celite pad, and concentrated by rotary evaporation to afford the 
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crude propanoyl-sulfamate (1S,3S)-42 (118 mg), which was used directly in 
the next step without further purification. 
 
 
(–)-5´-O-(N-[3˝-((1S,3S)-2˝´,2˝´-difluoro-1˝´,3˝´-dihydroxy-1˝´-
indanyl)propanoyl]sulfamoyl)adenosine ((1S,3S)-2).  Crude propanoyl-
sulfamate (1S,3S)-42  (118 mg, 0.145 mmol, 1 equiv.) was suspended in DMF 
(1.5 mL), then TASF (120 mg, 0.434 mmol, 3.0 equiv.) was added and the 
reaction mixture was stirred for 12 h at 50 ºC.  Concentration by rotary 
evaporation, purification by preparative HPLC (5% → 30% MeCN in H2O with 
0.1% TFA), and lyophilization yielded the anti-difluoroindanediol (1S,3S)-2 as 
a fluffy white solid (53 mg, 21% over 4 steps).  N.B.: HPLC fractions were 
stored at 0 °C until just prior to pooling and freezing (dry-ice bath) for 
lyophilization. 
: –6.5° (c 0.5, MeOH). IR (ATR): 3367, 2502, 2239, 2072, 1693, 1471, 
1429, 1380, 1202, 1139, 980, 787, 801, 769, 724, 642.  1H-NMR (500 MHz; 
CD3OD): δ 8.46 (s, 1H), 8.32 (s, 1H), 7.45-7.39 (m, 4H), 6.08 (d, J = 4.8 Hz, 
1H), 5.11 (dd, J = 9.7, 5.8 Hz, 1H), 4.63 (t, J = 5.0 Hz, 1H), 4.57-4.50 (m, 2H), 
4.40 (t, J = 4.9 Hz, 1H), 4.30 (q, J = 3.9 Hz, 1H), 2.84 (d, J = 8.7 Hz, 1H), 2.63 
(ddd, J = 9.3, 6.4, 4.7 Hz, 2H), 2.28-2.23 (m, 1H), 2.21-2.15 (m, 1H).  13C-NMR 
(126 MHz; CD3OD): δ 173.5, 150.2, 147.43, 147.40, 143.8, 143.3, 140.0, 
130.69, 130.63, 126.5, 125.0, 120.5, 90.3, 83.6, 79.6, 75.8, 74.9, 72.3, 71.6, 
49.3, 31.3, 31.1.  19F-NMR (471 MHz; CD3OD): δ -120.33 (d, J = 233.1 Hz, 
1F), -130.94 (d, J = 232.3 Hz, 1F).  HRMS (ESI) m/z calcd for C22H25N6O9F2S 
([M+H]+) 587.1372; found 587.1366. 
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G. X-Ray Crystallographic Analysis of syn-Diol (1S,3R)-40 
 
 
Figure 3.14. X-ray crystal structure of syn-diol (1S,3R)-15 (left) with (R)-a-methyl-4-
nitrobenzylamine (right, two NO2 rotamers) and MeOH (lower left).  
 
syn-Diol acid (1S,3R)-40 (10 mg, 0.0393 mmol, 1 equiv.) and (R)-α-methyl-4-
nitrobenzylamine (6.9 mg, 0.0413 mmol, 1.05 equiv., Sigma Aldrich) were 
placed in a 4 mL glass sample vial and dissolved in 400 μL MeOH.  The vial 
was placed in a 20 mL glass sample vial containing diethyl ether and the 20 
mL vial sealed tightly.  After 3 days at rt, clear needle shaped crystals were 
obtained.   
 
A specimen of [C8H11N2O2][C12H7F2O4]*CH3OH was used for X-ray 
crystallographic analysis at the University of Toledo Instrumentation Center at 
120 K on a Bruker APEX Duo diffractometer using CuKa radiation (1.54178 Å) 
for absolute stereochemistry determination.  The X-ray intensity data were 
measured.  The integration of the data using a monoclinic unit cell yielded a 
total of 14285 reflections to a maximum θ angle of 70.88° (0.82 Å resolution), 
of which 3562 were independent (average redundancy 4.010, completeness = 
95.5%, Rint = 2.21%, Rsig = 2.00%) and 3536 (99.27%) were greater than 
2σ(F2).  The final cell constants of a = 13.014(4) Å, b = 9.450(3) Å, c = 
18.211(5) Å, β = 98.828(8)°, volume = 2213.1(11) Å3, are based upon the 
refinement of the XYZ-centroids of reflections above 20 σ(I).   
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The structure was solved and refined using the Bruker SHELXTL Software 
Package, using the space group C 1 2 1, with Z = 4 for the formula unit, 
C21H22F2N2O7.  The final anisotropic full-matrix least-squares refinement on F2 
with 377 variables converged at R1 = 3.05%, for the observed data and wR2 = 
8.16% for all data.  The goodness-of-fit was 1.338.  The NO2 group is 
disordered over two equally occupied positions (both shown in Figure S8).  
The largest peak in the final difference electron density synthesis was 0.309 e-
/Å3 and the largest hole was -0.335 e-/Å3 with an RMS deviation of 0.040 e-/Å3.  
On the basis of the final model, the calculated density was 1.358 g/cm3 and 
F(000), 944 e-.  
 
The Flack parameter was determined from Parsons’ quotients to be –0.03(5), 
indicating the correct absolute configuration.  This parameter was determined 
based on 1377 Parsons’ quotients, [(I+)-(I-)]/[(I+)+(I-)].29  Further analysis 
based on Bayesian Statistics reveal a probability of 1 that the proposed 
structure is the correct one (P2 and P3 determined by PLATON).30 
 
CCDC 1512976 contains the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif 
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H. Docking of Inhibitors to MenE 
 
Protein Preparation.  The OSB-AMS•MenE co-crystal structure (PDB: 5C5H) 
was processed using the Protein Preparation Wizard in the Schrödinger suite 
(v2015.3).  Bond orders were assigned, hydrogen’s added, and waters beyond 
5 Å were deleted.  The protonation and tautomeric states of the protein-ligand 
complex were generated using EPIK at pH 7.4.  Hydrogen bond assignment 
and optimization was performed with PROPKA to sample hydrogen bonding 
and orientation of water molecules.  Non-bridging waters (< 2 hydrogen bonds) 
were removed.  Geometric refinement was performed using OPLS_2005 force 
field restrained minimization to a heavy atom convergence of 0.3 Å 
 
Ligand Preparation.  Ligand preparation was performed using Ligprep in the 
Schrödinger suite (v2015.3).  Lowest energy conformers were obtained using 
OPLS_2005 force field optimization.  Ionization and tautomeric states were 
generated using EPIK at pH 7.4.  
 
Grid Generation.  Using the Schrödinger suite (v2015.3) receptor grid 
generator, the receptor-binding site was defined as the area around the co-
crystalized ligand with a cube grid of 10 Å side length.  Nonpolar parts of the 
receptor were softened using Van der Waals radius scaling (factor 1.0 with 
partial cutoff of 0.25).  No constraints were defined and rotations allowed for all 
hydroxyl groups in the defined binding pocket.  
 
Docking Using Soft Receptor.  Using Glide (v5.3), ligands were docked to 
MenE using Glide XP docking precision.  Flexible ligand sampling was used 
and EPIK state penalties applied to docking scores.  Post-docking 
minimization was performed for all poses.  See also Figure S1. 
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I. MenE Biochemical Assay 
 
Enzyme inhibition studies were performed in 20 mM NaHPO4 buffer (pH 7.4) 
containing 150 mM NaCl and 1 mM MgCl2 using a MenE-MenB coupled assay 
in which MenE is rate-limiting. IC50 values were determined in reaction 
mixtures containing OSB (60 μM), ATP (240 μM), CoA (240 μM), mtMenB (2.5 
μM), and varying inhibitor concentrations (5 − 250 μM). Reactions were 
initiated by addition of ecMenE  (50 nM), and the production of DHNA-CoA 
was monitored at 392 nm (ε392  = 4000 M−1 cm−1).  
 
 
 
J. Antimicrobial Assays 
 
Minimum inhibitory concentrations (MICs) were determined using visual 
growth inspection of cells grown in transparent 96-well plates. E. coli , B. 
subtilis  (ATCC 6051), MRSA (ATCC BAA-1762), and M. tuberculosis (H37Rv) 
were grown to mid-log phase (OD600  of 0.6 − 0.8) in  synthetic broth, or 7H9 
with 0.5% glycerol, 0.05% Tween, and 10% OADC medium at 37 ° C in an 
orbital shaker. A final inoculum concentration of 1− 2 x 106 cells per well was 
treated with inhibitor at final concentrations ranging from 0.5 to 500 μg/mL. 
The MIC was defined as the minimum concentration at which a well showed 
no obvious growth by visual inspection (MIC-99). Growth rescue studies were 
performed by supplementing minimal medium (synthetic broth) with 10 μM 
menaquinone-4 (MK4) and following the same procedure in a 96-well plates. 
To determine the MK4-rescue MIC, 10% of the solution in each well was 
plated on synthetic agar plate and allowed to grow for 48 hours in 37 oC. 
Colony forming units (CFUs) were counted and compared to plates with 
untreated wells. Rescue MICs were defined as the minimum inhibitor 
concentration at which a plate showed ~90% growth after supplementation 
with MK4.      
 
 
 
K. Menaquinone Biosynthesis Assay 
 
The effect of MenE inhibitors on menaquinone levels in S. aureus was 
determined as follows. Cultures of S. aureus ATCC BAA-1762 (5 mL of 
synthetic broth medium with 10% glucose) were incubated overnight in a 37 
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°C shaker in the presence or absence of OSB-AMS (1) or Difluoroindanediol 
(2) below their MICs. The Blight and Dyer (1959) lipid extraction protocol was 
used to isolate the menaquinone-containing fraction from the cells.  Briefly, 
0.75 mL of a 1:2 (v/v) CHCl3 /MeOH solvent was added to 0.2 mL of culture. 
The mixture was vortexed thoroughly, and 0.25 mL of CHCl3 was added 
followed by further vortexing, after which 0.25 mL of H2O was added. The 
mixture was then vortexed and centrifuged at 500g for 5 min at room 
temperature. The bottom phase was recovered and transferred to a glass vial, 
and 200 μL was analyzed by APCI LC-MS/MS in positive ion mode using a 
Thermo TSQ Quantum Access (Thermo-Fisher) triple-quadrupole mass 
spectrometer. Samples were introduced into the mass spectrometer by flow 
injection at a rate of 100 μL/min with 2:1 MeOH/CHCl3 solvent. 
Multiplereaction monitoring (MRM) was performed at 30 eV; and MK8 levels 
were quantified using a MK9 standard curve (Sigma). Ubiquinone-4 (CoQ4) 
was used as an internal standard, and experiments were performed in 
duplicate.  
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CHAPTER 4 
DOCKING GUIDED DESIGN OF OSB-AMS LINKER ANALOGUES 
 
4.1. Introduction 
The use of an acyl-5´-O-sulfamoyladenosine (acyl-AMS) motif to mimic 
the cognate acyl-adenosine monophosphate (acyl-AMP) of adenylate-forming 
enzymes (Figure 4.1A) has been the primary means by which researchers1-11 
and nature12-16 have successfully inhibited a variety of targets in the adenylate-
forming enzyme superfamily.17   As was discussed in Chapter 1, although this 
approach provides excellent biochemical inhibitors of the cognate enzyme, 
acyl-AMS based inhibitors have several issues associated with the acyl-
sulfamate motif that can impede their usefulness as therapeutic lead 
compounds.  The primary problems associated with the acyl-sulfamate are 
unfavorable physicochemical and pharmacological properties, as well as 
instability of the acyl-sulfamate itself, which can undergo hydrolysis to release 
the highly cytotoxic compound, adenosine monosulfamate (AMS).   
The acyl-sulfamate of the acyl-AMS scaffold has a pKa ~1-2, and is 
therefore in a deprotonated anionic state at physiological pH.  This 
deprotonation confers increased polarity onto what is already a relatively polar 
and heteroatom rich area of the scaffold.  This significant increase in polarity 
has serious implications for the ADME (absorption, distribution, metabolism, 
and excretion) of acyl-AMS type inhibitors.  High polarity and negative charges 
have been implicated in poor compound accumulation in bacteria, high levels 
of non-specific protein binding, and high rates of in vivo clearance. 18-22      
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Figure 4.1.  Acyl-AMS inhibitors of adenylate-forming enzymes.  A) Examples of reported 
acyl-AMS inhibitors for adenylate-forming enzmes B) Common decomposition pathway of 
OSB-AMS.  
A potentially far more problematic issue with the acyl-sulfamate is 
overall stability.  In some scaffolds the acyl-sulfamate group is relatively 
stable, but in other derivatives, particularly in the OSB-AMS series of acyl-
sulfamate based inhibitors, this group is highly prone to hydrolysis.  This 
lability is largely due to highly favorable cyclization and spirocyclization events 
that OSB type scaffolds can undergo (Figure 4.1B), cleaving the acyl-
sulfamate and releasing free AMS.  AMS is a highly cytotoxic compound, 
typically inducing mammalian cell death in low to sub-nM concentrations.23  
Thus, to move our current line of MenE inhibitors into more favorable drug-like 
space and decrease the chemical and toxicological liability inherent in the 
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acyl-AMS motif, an acyl-phosphate bioisostere other than the traditional acyl-
sulfamate is needed.   However, finding a suitable bioisostere of the OSB-
AMP acyl-phosphate is non-trivial.  Since the acyl-phosphate is the location at 
which MenE performs its catalytic activity on the native OSB-AMP scaffold, 
there are many key interactions in the biding pocket between the scaffold and 
the enzyme, making this area of the scaffold canonically intolerant to 
modifications. Aldrich and coworkers describe the most relevant targeted 
studies to modify the acyl-sulfamate region of an acyl-AMS inhibitor in an 
attempt to inhibit MbtA, an adenylate-forming enzyme that belongs to the ANL 
family (Figure 4.2). 2,7,24-30     
 
Figure 4.2.  Reported linker analogues of salicyl-AMS and corresponding activity in 
antimicrobial assays. 
2,7,24-30
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Their efforts in this area focused on the rational design and synthesis of 
linker analogues of salicyl-AMS, a compound originally reported by our lab that 
has potent antimicrobial activity.2,7,24-30    The Aldrich group reported a number 
of salicyl-AMS linker analogues, some of which used relatively minor 
modifications to the acyl-sulfamate group.  However, they only report one 
analogue that retained activity (6), albeit at a ~2-log loss in potency verses 
that of the parent salicyl-AMS compound.  
It was clear that an alternative bioisostere of the acyl-phosphate was 
needed to advance the MenE inhibitor series.  However, previously reported 
efforts in this area suggested that the traditional rational design approach was 
not an effective strategy to probe the structure–activity relationships (SAR) 
around this area of the scaffold.  
 
4.2. Docking Guided Design of OSB-AMS Linker Analogues  
To find a more effective approach to probing the SAR in the linker 
region of the MenE binding pocket, we proposed to create a virtual library of 
rationally designed OSB-AMS linker analogues.  We would then dock the 
analogues into our previously reported OSB-AMS liganded MenE crystal 
structure,31 and use the results from the docking study to help prioritize the 
synthetic targets. This approach would allow us to probe a larger area of 
chemical space around that region than could quickly be performed by 
traditional rational design, and if properly executed should increase the relative 
rate at which we discover active inhibitors of MenE.  
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Figure 4.3.  Examples of OSB-AMS linker analogues in first-generation virtual library. 
We began by first creating a ~70-membered first-generation virtual 
library of OSB-AMS linker analogues (Figure 4.3).  The library was composed 
of different bioisosteres that ranged greatly in fidelity to the native acyl-
phosphate scaffold.   While some analogues attempted to retain as many key 
interactions in the binding pocket as possible (squaramide 13, sulfamide 14, 
acyl-tetrazole 15), others were envisioned to keep only one or two interactions 
with MenE but significantly decrease the desolvation-penalty relative to the 
acyl-sulfamate motif (m-phenol 16, hydroxy-serine 23, keto-oxymethyl 24).   
Critically, Mescar and coworkers had shown through kinetic studies that 
extension or shortening of the OSB succinyl chain was not well tolerated,32 so 
these analogues aimed to keep a nearly identical distance from the 5’-ribose 
heteroatom of adenosine (oxygen or nitrogen depending on analogue) to the 
ketone of OSB.  
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The analogues were docked to the MenE crystal structure (PDB: 5C5H) 
using Glide (Schrodinger Software Suite, Table 4.1, see experimental section 
4.4 for details), ranked by their Glide docking score, and analogues with a 
docking score of > –10 kcal/mol removed.    
Table 4.1.  Docking scores of example OSB-AMS linker analogues. 
 
Entry Analogue 
Docking 
Score 
(kcal/mol) 
Entry Analogue 
Docking 
Score 
(kcal/mol) 
13 
 
–13.76 19 
 
–13.69 
14 
 
–14.2 20 
 
–13.32 
15 
 
–13.98 21 
 
–13.69 
16 
 
–14.03 22 
 
–13.27 
17 
 
–14.63 23 
 
–14.70 
18 
 
–13.61 24 
 
–13.62 
OSB-AMS (1) docking score = –13.78 kcal/mol.  
The list was then inspected to insure that analogues were docking in 
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reasonable poses with retention of key interactions in the OSB and adenosine 
binding pockets, and importantly interaction with two key residues (Lys-347, 
Thr-272) in the linker region of the MenE binding pocket (Figure 4.4). 
 
Figure 4.4. Sample of poses from docking study. A) Docking pose of squaramide linker 
analogue 13. B) Docking pose of flip-Serine linker analogue 17. C) Docking pose of alkyl-
sulfamide linker analogue 14. D) Docking pose of acyl-tetrazole linker analogue 15. 
The list was then prioritized based on a combination of docking score, 
docking pose, ease of functionalization and diversification, likelihood of 
A) B) 
C) D) 
Thr272 
Lys347 
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increasing favorable physicochemical and pharmacological properties of the 
platform, and synthetic accessibility.  This curated list was used as the starting 
point for synthesis of linker analogues of OSB-AMS and investigating the 
linker region of the MenE binding pocket.   
 
4.3. Synthesis of OSB-AMS Linker Analogues   
 The first analogue to be made was the acyl-squaramide linker 
analogue.  Synthesis of this analogue proceeded by first obtaining the 
necessary OSB scaffold 28 with an alternate protecting group strategy to that 
we have reported previosly (Figure 4.5A).33-34  In parallel, condensation of 
dimethyl squarate with the protected AMSN scaffold 29, followed by treatment 
 
Figure 4.5. Synthesis of squamide linker analogue 13. DMAP = N,N-
dimethylaminopyridine, EDCI = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, TFA = 
trifluoroacetic acid, THF = tetrahydrofuran. 
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with anhydrous ammonia provided the desired squaramide 30.  Coupling of 
the squaramide 30 to the prepared OSB scaffold 28, followed by two-step 
deprotection provided the desired acyl-squaramide analogue 13. 
Synthesis of the alkyl-sulfamide analogue 14 (Figure 4.6) proceeded by 
first generating a reduced OSB intermediate 33 and appending it to the       
Cbz-protected AMSN analogue 34 using Mitsunobu conditions to provide 
intermediate 35.  This was then deprotected over two steps to generate the 
desired alkyl-sulfamide analogue 14. 
 
Figure 4.6. Synthesis of alkyl-sulfamide linker analogue 14.  DIAD = diisopropyl 
azodicarboxylate, TFA = trifluoroacetic acid, THF = tetrahydrofuran. 
The route to the acyl-tetrazole analogue 44 began by executing a 
lithium–halogen exchange with the aryl bromide 3635 to form the 
corresponding lithiated species (Figure 4.7).  This was then quenched with 
dimethyl carbonate to form the desired methyl ester, followed by acid 
catalyzed opening of the tetrahydrofuranyl ring to reveal the keto-alcohol 37.  
Intermediate 37 was oxidized to the aldehyde then converted to the 
cyanohydrin intermediate 38.  To protect both the alcohol and ketone of the 
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succinyl chain, which was found to be necessary during initial exploration of 
this route, the tetrahydrofuranyl ring was reformed to give the cyclic 
intermediate 39.  This intermediate was then converted to the desired 
tetrazole, the tetrahydrofuranyl ring was reopened, and the alcohol oxidized to 
give the desired acyl-tetrazole fragment 41.  Fragment 41 was appended onto 
the protected adenosine scaffold 42 using Mitsunobu conditions to give the 
fully formed, protected acyl-tetrazole analogue 43.  Upon attempting to 
 
Figure 4.7. Synthetic approach to the acyl-tetrazole linker analogue 42. DIAD = 
diisopropyl azodicarboxylate, THF = tetrahydrofuran. 
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deprotect the carboxylate to form the desired free acid intermediate 44, it was 
observed that the carbon–carbon bond between the carbonyl and tetrazole 
was highly labile and prone to addition–elimination reactions with a variety of 
nucleophiles.  We proposed that the reduced form of the analogue, the 
hydroxy-tetrazole linker analogue 45, should be hydrolytically stable, as it 
cannot undergo addition-elimination reactions.  The proposed hydroxy-
tetrazole analogue was docked into the MenE crystal structure and was found 
to dock within the parameters previously described in section 4.2 (S-hydroxy-
tetrazole 45 = –13.81 kcal/mol, R-hydroxy-tetrazole 45 = –12.79 kcal/mol). 
To achieve the hydroxy-tetrazole analogue, we modified our original 
route (Figure 4.8) by taking the formed tetrazole fragment 46, and directly 
appended the fragment to the adenosine scaffold 42 using Mitsunobu 
conditions.  Acid-catalyzed deprotection removed the isopropylidene and Boc 
 
Figure 4.8. Synthesis of hydroxy-tetrazole linker analogue.  DIAD = diisopropyl 
azodicarboxylate, TFA = trifluoroacetic acid, THF = tetrahydrofuran. 
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protecting groups as expected, but unexpectedly removed the methyl ester of 
OSB and cyclized to form the spirocycle intermediate 48.  The spirocycle was 
then opened using lithium hydroxide to provide the desired hydroxy-tetrazole 
analogue 45.   
 
Figure 4.9.  Synthesis of phenol linker analogue 16.  DIAD = diisopropyl azodicarboxylate, 
DMA = dimethylacetamide, dtbpf = 1,1'-bis(di-t-butylphosphino)ferrocene, NMO = N-
methylmorpholine N-oxide, TFA = trifluoroacetic acid, THF = tetrahydrofuran. 
Synthesis of the phenol linker analogue began by forming the key vinyl 
ketone fragment 52 over five highly scalable steps from dimethyl phthalate 
(Figure 4.9).  The vinyl ketone 52 efficiently underwent Heck coupling with     
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m-bromophenol (53), followed by a Mitsunobu reaction to append the 
adenosine scaffold 42 to the free phenol 54.  The olefin was reduced using 
Stryker’s reagent, followed by deprotection of the TBS ether to provide the free 
alcohol intermediate 56.  This was then oxidized to the desired carboxylate 
using TPAP and NMO, and finally deprotected to form the desired phenol 
linker analogue 16.  
 
 4.3. Biochemical Validation of Docking Guided Targeting   
Although the synthesis of additional linker analogues from the first-
generation library is ongoing, we wanted to gain preliminary validation of our 
original proposal.  Our analogues were tested by our collaborators in the 
laboratory of Professor Peter Tonge for biochemical inhibition of E. coli MenE 
as previously described (Figure 4.10, see experimental section 4.4 for 
details).31,36   Interestingly, while all of the analogues tested showed a 
significant drop in potency when compared to OSB-AMS, three of the four 
analogues were active, which is in stark contrast to previous reported efforts in 
this arena.  Perhaps the most unexpected result is that of the phenol linker 
analogue 16, which only lost ~2-log potency compared to OSB-AMS, while the 
more modest modification seen with the acyl-sulfamide analogue 14 resulted 
in a ~3-log loss of potency versus OSB-AMS.  Although use of the MenE 
docking construct did improve the rate of biochemically active compounds 
generated, the docking model itself is not perfect.  The squaramide linker 
analogue 13, which docked with a reasonable score and pose in the MenE 
binding pocket, had no activity against MenE in biochemical assays.   
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Figure 4.10. Biochemical activity of selected OSB-AMS linker analogues.  
The activity of the phenolic linker analogue can be rationalized through 
examination of the docking structure to MenE and consideration of the 
entropic costs associated with its binding to MenE.  The linker region only has 
one hydrogen-bond acceptor and no traditional hydrogen-bond donor.  
However, examination of the docking model of the phenolic linker analogue 16 
(Figure 4.11) shows that the aromatic ring is in close proximity to a highly 
conserved residue (Lys-437) and could possibly engage in a cation-π 
interaction with the lysine sidechain.   Additionally, the aromatic linker region, 
being uncharged and relatively nonpolar, will have a far lower desolvation 
penalty compared to the more polar and heteroatom rich structures seen in the 
other analogues. 
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Figure 4.11.  Phenolic linker analogue docking pose. 
 
4.3. Exploring the SAR of the Aromatic Linker Analogues of OSB-AMS   
Perhaps the most important and promising finding from the preliminary 
biochemical results is the phenolic linker analogue 16.  This analogue is 
significantly less polar than that of OSB-AMS at physiological pH and 
significantly more stable.  Given the promise of this analogue in regards to 
increasing favorable ADME and toxicological liability versus that of OSB-AMS, 
we decided to investigate the SAR of this analogue further.   We proposed a 
library of analogues that would both alter the electronics of the ring, as well as 
explore the surrounding space in this region.  Furthermore, we hypothesized 
that the proposed aromatic and heteroaromatic linker analogues could be 
rapidly generated with the general synthetic route used to achieve the 
phenolic linker analogue 16 (Figure 4.12).  
 
Lys347 
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Figure 4.12.  Original route to proposed aromatic and heteroaromatic linker analogues 
DIAD = diisopropyl azodicarboxylate, DMA = dimethylacetamide, dtbpf = 1,1'-bis(di-t-
butylphosphino)ferrocene, NMO = N-methylmorpholine N-oxide, TFA = 2,2,2-trifluoroacetic 
acid, THF = tetrahydrofuran. 
Although the p-phenolic linker analogue 62 and 3-(trifluoromethyl)-
phenolic linker analogue 63 (Figure 4.13) were synthesized using this 
approach; electron rich aromatic linker analogues or those functionalized with 
more sensitive functional groups suffered from very poor yields upon 
deprotection of the benzyl alcohol and oxidation to the carboxylic acid.  To 
 
Figure 4.13. Analogues synthesized using the originally proposed synthetic route.   
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circumvent this issue, our choice of initial Heck coupling partner (52) needed 
to be altered to avoid the late stage desilylation and oxidation steps. 
We proposed to use a fully oxidized and protected form of the left-hand 
fragment (67, Figure 4.14), which can be achieved in three steps from a 
commercially available boronic acid.33,37-38  This intermediate will allow for the 
rapid generation of a variety of aromatic and heteroaromatic linker analogues, 
 
Figure 4.14. Optimized route to proposed aromatic and heteraromatic linker analogues. 
DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene, DDQ = 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone, DIAD = diisopropyl azodicarboxylate, DMA = dimethylacetamide, dtbpf = 1,1'-
bis(di-t-butylphosphino)ferrocene, TFA = 2,2,2-trifluoroacetic acid, THF = tetrahydrofuran. 
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with a larger functional group tolerance than the original route. 
To date, the p-phenolic linker analogue 62 and 3-(trifluoromethyl)-
phenolic linker analogue 63 were tested in biochemical inhibition assays 
against E. coli MenE by our collaborators in the laboratory of Professor Peter 
Tonge.   The p-phenolic linker analogue 62 did not show activity against MenE 
(Figure 4.15), but the 3-(trifluoromethyl)-phenolic linker analogue 63 showed a 
modest IC50 of 26 µM.  Although the docking model of the phenolic liker 
analogue suggest there is sufficient room at the C3 position of the aromatic 
linker to accommodate the trifluoromethyl substituent, at this time we are 
unable to determine if the drop in potency with analogue 63 is due to 
increased steric hindrance from the trifluoromethyl substituent in the binding 
pocket, or a decreased ability to engage in a cation-π interaction with the 
conserved Lys-437.  
 
Figure 4.15. Biochemical activity of aromatic linker analogues.  Biochemical assays 
performed using MenE from E. coli.  
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4.3. Conclusions and Discussion 
 Acyl-AMS based inhibitors, although canonically excellent inhibitors of 
their cognate adenylate-forming enzymes, have a number of liabilities 
associated with them that limit their progression as drug candidates.  The 
negatively charged acyl-sulfamate has been implicated in a number of 
unfavorable physiochemical and ADME properties.  Additionally, when the 
acyl-sulfamate bond is cleaved, highly cytotoxic AMS is released. This 
cleavage is particularly common in the OSB-AMS class of acyl-sulfamate 
inhibitors, representing a significant toxicological liability to the progression of 
these inhibitors beyond use as a tool compounds.    
 To improve the drug-like properties of our MenE inhibitors and reduce 
or eliminate the toxicological liability associated with the acyl-AMS motif, we 
sought to design and synthesize a series of OSB-AMS linker analogues.  
However, previous work in this area by other groups using a traditional rational 
design approach, had shown the linker region of acyl-AMS inhibitors to be 
highly intolerant of modification.  To take a different approach, we used the 
MenE docking construct originally discussed in Chapter 3, to dock a virtual 
library of OSB-AMS linker analogues.   This approach allowed us to probe a 
far larger area of chemical space in the linker region, and discover a number 
of analogues that showed inhibitory activity against MenE.  The most 
promising analogue to come from the initial screen was the phenolic linker 
analogue 16.  Although the analogue had a ~2-log loss in potency versus 
OSB-AMS, it exhibited greatly increased stability and hydrophobicity, which 
represents a possible vector for the MenE inhibitors into more favorable drug-
like space.   Using the newly optimized synthetic route, a large variety of 
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different aromatic and heteroaromatic linker analogues can be rapidly 
synthesized, and the SAR around the linker region ascertained with the 
overarching goal increasing the potency of the inhibitors and achieving a low-
nM inhibitor of MenE.  
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4.4.  Experimental Section 
 
A. Materials and Methods 
 Reagents were obtained from Aldrich Chemical (www.sigma-
aldrich.com) or Acros Organics (www.fishersci.com) and used without further 
purification. Optima or HPLC grade solvents were obtained from Fisher 
Scientific (www.fishersci.com), degassed with Ar, and purified on a solvent 
drying system. Reactions were performed in flame-dried glassware under 
positive Ar pressure with magnetic stirring.  
 
TLC was performed on 0.25 mm E. Merck silica gel 60 F254 plates and 
visualized under UV light (254 nm) or by staining with potassium 
permanganate (KMnO4), cerium ammonium molybdenate (CAM), or iodine (I2). 
Silica flash chromatography was performed on E. Merck 230–400 mesh silica 
gel 60. Preparative scale HPLC purification was carried out on a Waters 2545 
HPLC with 2996 diode array detector using a Sunfire Prep C18 reverse phase 
column (10 Å~ 150 mm, 5 μm) with UV detection at 254 nm. Samples were 
lyophilized using a Labconco Freezone 2.5 instrument. 
 
IR spectra were recorded on a Bruker Optics Tensor 27 FTIR spectrometer 
with Pike technologies MIRacle ATR (attenuated total reflectance, ZnSe 
crystal) accessory and peaks reported in cm–1. NMR spectra were recorded on 
a Bruker Avance III 500 instrument or Bruker Avance III 600 instrument at 24 
°C in CDCl3 unless otherwise indicated. Spectra were processed using Bruker 
TopSpin or nucleomatica iNMR (www.inmr.net) software, and chemical shifts 
are expressed in ppm relative to TMS (1H, 0 ppm) or residual solvent signals: 
CDCl3 (1H, 7.24 ppm; 13C, 77.23 ppm), CD3OD (1H, 3.31 ppm; 13C, 49.15 ppm), 
D2O (1H, 4.80 ppm); coupling constants are expressed in Hz. Mass spectra 
were obtained at the MSKCC Analytical Core Facility on a Waters Acuity SQD 
LC-MS by electrospray (ESI) ionization or atmospheric pressure chemical 
ionization (AP-CI). 
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B. Synthesis of squaramide linker analogue.  
 
 
 
 
Benzyl 2-(4´-tert-butoxy-4´-oxobutanoyl)benzoate (27).  Keto diester 26 
(1.64 g, 5.610 mmol, 1 equiv.) prepared as previously described,33 was 
dissolved in 5 mL MeOH and 0.5 mL water before LiOH (136 mg, 5.66 mmol, 
1.01 equiv.) was added and the reaction stirred for 5 hours.  The reaction was 
concentrated by rotary evaporation and dried under high vacuum before being 
suspended in 10 mL acetonitrile.  K2CO3  (1.162 g, 8.413 mmol, 1.5 equiv.) 
and benzyl bromide (1.438 g, 8.413 mmol, 1.5 equiv.) added and the reaction 
stirred for 12 hours at room temperature before the reaction was quenched 
with 50 mL water, extracted with EtOAc (4 x 50 mL).  The combined organic 
extracts were dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (10%  25% EtOAc in hexanes) 
yielded the product (27) as a clear oil (1.9 g, 92%). 
IR (ATR): 2979, 1719, 1575, 1456, 1367, 1270, 1151, 1092, 991, 949, 912, 
848, 732, 698, 648.  1H-NMR (600 MHz; CDCl3): δ 7.92 (dd, J = 7.8, 1.1 Hz, 
1H), 7.55 (td, J = 7.5, 1.2 Hz, 1H), 7.46 (td, J = 7.6, 1.2 Hz, 1H), 7.43 (dd, J = 
7.6, 0.9 Hz, 1H), 7.41-7.39 (m, 2H), 7.38-7.36 (m, 2H), 7.35-7.32 (m, 1H), 5.29 
(s, 2H), 3.03 (t, J = 6.8 Hz, 2H), 2.57 (t, J = 6.8 Hz, 2H), 1.45 (s, 9H).  
13C-NMR (151 MHz; CDCl3): δ 203.9, 172.0, 166.4, 143.2, 135.3, 132.3, 
130.0, 129.7, 128.63, 128.54, 128.48, 128.1, 126.4, 80.5, 67.5, 37.7, 29.4, 
28.1 HRMS (ESI) m/z calcd for C22H24O5 ([M+H]
+) 369.1702; found 369.1711. 
 
 
 
 
4-(2´-[Benzyloxycarbonyl]phenyl)-4-oxobutanoic acid (28).  Keto diester 
27 (1.9 g, 5.157 mmol, 1 equiv.) was dissolved in 5 mL CH2Cl2 and cooled to 
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0 ºC before 0.5 mL water and 5 mL TFA was added and the reaction stirred for 
3 hours.  Concentration by rotary evaporation and purification by silica flash 
chromatography (40%  60% EtOAc in hexanes) yielded the product (28) as 
a white solid (1.4 g, 87%). 
 
IR (ATR): 3035, 1706, 1597, 1575, 1498, 1400, 1377, 1272, 1136, 1094, 
1041, 991, 956, 912, 735, 698, 648.  1H-NMR (500 MHz; CDCl3): δ 7.96-7.94 
(m, 1H), 7.57 (td, J = 7.5, 1.2 Hz, 1H), 7.49 (td, J = 7.7, 1.2 Hz, 1H), 7.41-7.37 
(m, 5H), 7.36-7.33 (m, 1H), 5.30 (s, 2H), 3.06 (t, J = 6.7 Hz, 2H), 2.70 (t, J = 
6.7 Hz, 2H).  13C-NMR (126 MHz; CDCl3): δ 203.6, 178.8, 166.3, 142.9, 135.2, 
132.5, 130.1, 129.9, 128.69, 128.63, 128.59, 128.0, 126.3, 67.6, 37.4, 28.0.  
HRMS (ESI) m/z calcd for C18H16O5 ([M+H]
+) 312.0998; found 312.1005. 
 
 
 
2´,3´-O-t-Butyldimethylsilyl-5´-N-(3-amino-cyclobut-3-ene-1,2-dione) 
aminodeoxyadenosine (30).  Protected adenosine analogue 29 (180 mg, 
0.364 mmol, 1 equiv.) prepared as previously described,36,39 was suspended 
in 5 mL MeOH before dimethoxysquarate (103 mg, 0.727 mmol, 2.0 equiv.) 
was added.  The reaction was stirred for 4 hours before the reaction was 
cooled to 0 ºC and anhydrous ammonia slowly bubbled into the solution for 15 
min.  The reaction was stirred for 1 hour while returning to room temperature 
before being filtered through a pad of celite and solvent removed by rotary 
evaporation.  The residue was reconstituted in 15% MeOH in EtOAc, filtered 
though a pad of silica, and the pad washed with 100 mL 15% MeOH in EtOAc.  
The eluent was concentrated by rotary evaporation to give the crude product 
(30) as a yellow tinged solid (172 mg), which was used without further 
purification.  
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2´,3´-O-t-Butyldimethylsilyl-5´-N-(N-[4´´-(2´´-[benzyloxycarbonyl]phenyl)-
4-oxobutanoyl]-(3-amino-cyclobut-3-ene-1,2-dione))aminodeoxy 
adenosine (31).  Carboxylic acid 28 (87 mg, 0.280 mmol, 1.1 equiv.), 
protected AMSq 30 (165 mg, 0.280 mmol, 1 equiv) and DMAP (34 mg, 0.280 
mmol, 1.0 equiv.) were dissolved in CH2Cl2:MeCN (5 mL, 50:50) before EDCI 
(214 mg, 1.118 mmol, 4.0 equiv) was added.  The reaction was stirred for 
12 h, then quenched with 20 mL 1M KHSO4, and extracted with CH2Cl2 (5 x 20 
mL).  The combined organic extracts were dried (Na2SO4), filtered, and 
concentrated by rotary evaporation.  The reside was reconstituted in 5% 
MeOH in EtOAc (~20 mL), filtered though a pad of silica and the pad washed 
with 100 mL 5% MeOH in EtOAc.  Eluent was then concentrated by rotary 
evaporation to afford the crude product 31 (125 mg), which was used without 
further purification. 
 
 
 
5´-N-(N-[4´´-(2´´(carboxyl)phenyl)-4´´-oxobutanoyl]-(3-amino-cyclobut-3-
ene-1,2-dione))aminodeoxyadenosine (13).  Crude protected OSB-AMSq 31 
(125 mg, 0.538 mmol, 1 equiv.) and 10% Pd/C (15 mg, 0.014 mmol, 0.1 
equiv.) were suspended in MeOH (14 mL) before being stirred under H2 
balloon for 4h.  The reaction was then filtered through a celite pad and 
concentrated by rotary evaporation before being dried under high vacuum.  
The residue was suspended in DMF (3 mL) and TASF (108 mg, 0.394 mmol, 
2.5 equiv.) added before being stirred for 12 h at 50 ºC. Concentration by 
rotary evaporation, purification by preparative HPLC (5%  95% MeCN in 
H2O with 0.01% TFA), and lyophilization yielded the product (13) as a fluffy 
white solid (52 mg, 23% over 4 steps). 
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IR (ATR): 3364, 2487, 1803, 1698, 1601, 1537, 1447, 1204, 1143, 1124, 980, 
895, 801, 768, 724, 702, 638.  1H-NMR (600 MHz; MeOD): δ 8.45 (s, 1H), 
8.33 (s, 1H), 7.85-7.84 (m, 1H), 7.74-7.71 (m, 1H), 7.61-7.57 (m, 2H), 6.06 (d, 
J = 4.7 Hz, 1H), 4.72 (t, J = 5.0 Hz, 1H), 4.41 (t, J = 5.1 Hz, 1H), 4.24 (q, J = 
4.7 Hz, 1H), 4.07 (ddd, J = 46.9, 14.3, 4.9 Hz, 2H), 2.99-2.86 (m, 2H), 2.66-
2.63 (m, 2H).  13C-NMR (151 MHz; MeOD): δ 189.6, 183.8, 174.5, 173.6, 
170.1, 160.9, 153.32, 153.31, 150.2, 147.79, 147.78, 147.78, 147.76, 147.74, 
147.73, 143.6, 120.7, 90.5, 85.0, 75.4, 72.2, 49.6, 46.0, 38.7, 30.9.  HRMS 
(ESI) m/z calcd for C25H24N7O9 ([M+H]
+) 566.1636; found 566.1627. 
 
 
C. Synthesis of sulfamide linker analogue.  
 
 
Benzyl 2-(4-hydroxybutanoyl)benzoate (33).  Aryl bromide 32 (1 g, 3.889 
mmol, 1 equiv.) prepared as previously described,33 was suspended in 4 mL 
THF and cooled to -78 ºC before n-BuLi (3.038 mL, 4.861 mmol, 1.6 M in THF, 
1.25 equiv.) was added.  After 1 h, the reaction was transferred via cannula 
over 5 min to a stirring solution of benzyl chloroformate (1.326g, 7.778 mmol, 
2 equiv.) in 5 mL THF at -78 ºC before being stirred for 2 h while returning to 
room temperature.  The reaction was then quenched with HCl (20 mL, 1M) 
and stirred for 10 min before being extracted with EtOAc (4 x 25 mL), organics 
combined, dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (40%  60% EtOAc in hexanes) 
yielded the product (33) as a clear oil (950 mg, 82%). 
IR (ATR): 3393, 3068, 3036, 2954, 2886, 1716, 1599, 1577, 1500, 1457, 
1406, 1378, 1274, 1139, 1101, 1079, 1004, 961, 915, 755, 701, 649.  1H-NMR 
(600 MHz; CDCl3): δ 7.95-7.94 (m, 1H), 7.57 (td, J = 7.5, 1.1 Hz, 1H), 7.48 (td, 
J = 7.7, 1.0 Hz, 1H), 7.40 (dt, J = 13.8, 7.0 Hz, 4H), 7.36-7.33 (m, 2H), 5.32 (s, 
2H), 3.70 (t, J = 6.0 Hz, 2H), 2.88 (t, J = 6.8 Hz, 2H), 2.19 (s, 1H), 1.92 
(quintet, J = 6.4 Hz, 2H).  13C-NMR (151 MHz; CDCl3): δ 206.0, 166.6, 143.7, 
135.3, 132.5, 130.1, 129.7, 128.67, 128.55, 128.54, 128.0, 126.2, 67.6, 61.7, 
39.4, 26.6.  HRMS (ESI) m/z calcd for C18H18O4Na([M+H]
+) 321.1103; found 
321.1110. 
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6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-N-(N-[benzyloxycarbonyl] 
-[benzyl 2-(4-hydroxybutanoyl)]sulfamoyl)aminodeoxyadenosine (35).  
Triphenylphosphine (105 mg, 0.402 mmol, 1.5 equiv.) in 1 mL THF was added 
drop wise to a stirring solution of DIAD (81 mg, 0.402 mmol, 1.5 equiv.) in 5 
mL THF at 0 ºC.  After 10 min, alcohol 33 (80 mg, 0.268 mmol, 1 equiv.) in 1 
mL THF was added dropwise followed by protected adenosine analogue 34 
(266 mg, 0.364 mmol, 1 equiv.) prepared as previously described,33 in 1 mL 
THF.  The reaction was allowed to stir for 14 h while returning to rt before 1 
mL MeOH was added and the solvent was removed by rotary evaporation.   
The resulting residue was reconstituted in diethyl ether, filtered through a pad 
of silica, the pad washed with 100 mL diethyl ether, and the solvent removed 
by rotary evaporation to give the crude product 35 (350 mg, 145%), which was 
used without further purification.  
 
 
 
5´-N-(N-[4´´-(2´´´-[Carboxyl]phenyl)-4-oxobutane]sulfamoyl)amino 
deoxyadenosine (14). Crude intermediate 35 from the previous step 
(assumed quantitative yield) and 10% Pd/C (28 mg, 0.027 mmol, 0.1 equiv.) 
were suspended in MeOH (5 mL).  The reaction was stirred vigorously under 
H2 balloon for 12 h, then diluted with EtOAc (5 mL), filtered through a celite 
pad, and concentrated by rotary evaporation.  The crude material was then 
reconstituted in CH2Cl2 (15 mL) and cooled to 0 ºC before water (0.5 mL) and 
TFA (15 mL) added and the reaction stirred for 3 h.  Concentration by rotary 
evaporation, purification by preparative HPLC (5%  30% MeCN in H2O with 
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0.1% TFA), and lyophilization yielded the product 14 as a fluffy white solid (51 
mg, 38% over 3 steps). 
IR (ATR): 3393, 3068, 3036, 2954, 2886, 1716, 1599, 1577, 1500, 1457, 
1406, 1378, 1274, 1139, 1101, 1079, 1004, 961, 915, 755, 701, 649.  1H-NMR 
((600 MHz; D2O): δ 8.13 (s, 1H), 8.05 (s, 1H), 7.42 (dd, J = 7.7, 1.2 Hz, 1H), 
7.35 (td, J = 7.5, 1.2 Hz, 1H), 7.23 (td, J = 7.5, 1.1 Hz, 1H), 7.16 (dd, J = 7.5, 
0.9 Hz, 1H), 5.85 (d, J = 6.4 Hz, 1H), 4.68 (dd, J = 6.3, 5.5 Hz, 1H), 4.30 (dd, J 
= 5.4, 3.2 Hz, 1H), 4.25 (q, J = 3.4 Hz, 1H), 3.29-3.22 (m, 3H), 2.96-2.88 (m, 
2H), 2.73 (td, J = 7.3, 1.6 Hz, 2H), 1.72 (quintet, J = 7.2 Hz, 2H).  13C-NMR 
(151 MHz; D2O): δ 175.8, 155.6, 152.4, 148.3, 141.1, 138.6, 137.0, 131.0, 
129.5, 127.8, 126.4, 119.3, 117.3, 115.4, 88.8, 83.6, 72.8, 71.1, 48.9, 44.0, 
41.8, 39.0, 23.6.  HRMS (ESI) m/z calcd for C21H26N7O8S ([M+H]
+) 536.1564; 
found 536.1539. 
 
 
D. Synthesis of hydroxyl-tetrazole linker analogue.  
 
 
 
 
Methyl 2-(4-hydroxybutanoyl)benzoate (37).  Aryl bromide 36 (3 g, 11.66 
mmol, 1 equiv.) prepared as previously described,36 was suspended in 10 mL 
THF and cooled to -78 ºC before n-BuLi (5.127 mL, 12.82 mmol, 2.5 M in 
hexanes, 1.1 equiv.) was added.  After 1 h, the reaction was transferred via 
cannula over 5 min to a stirring solution of dimethyl carbonate (2.1, 23.32 
mmol, 2 equiv.) in 5 mL THF at -78 ºC, and stirred for 2 h while returning to 
room temperature.  The reaction was then quenched with HCl (20 mL, 1M) 
and stirred for 10 min before being extracted with EtOAc (4 x 25 mL), organics 
combined, dried (Na2SO4), filtered, and concentrated by rotary evaporation.  
Purification by silica flash chromatography (25%  100% EtOAc in hexanes) 
yielded the product (37) as a clear oil (1.95 g, 75%). 
IR (ATR): 3400, 2954, 2883, 1720, 1597, 1575, 1486, 1436, 1406, 1370, 
1285, 1195, 1136, 1098, 1054, 963, 914, 830, 764, 737, 709, 781, 647.  
1H-NMR (600 MHz; CDCl3): δ 7.92 (dt, J = 7.8, 0.5 Hz, 1H), 7.58 (td, J = 7.5, 
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0.9 Hz, 1H), 7.50 (td, J = 7.7, 1.0 Hz, 1H), 7.35 (dt, J = 7.6, 0.5 Hz, 1H), 3.90 
(s, 3H), 3.79 (t, J = 6.0 Hz, 2H), 2.94 (t, J = 6.7 Hz, 2H), 2.02 (quintet, J = 6.3 
Hz, 2H).  13C-NMR (151 MHz; CDCl3): δ 206.2, 167.2, 143.7, 132.5, 130.0, 
129.7, 128.0, 126.2, 61.8, 52.7, 39.4, 26.7.  HRMS (ESI) m/z calcd for 
C12H15O4 ([M+H]
+) 223.0970; found 223.0966. 
 
 
 
 
Methyl 2-(4-cyano-4-hydroxybutanoyl)benzoate (38).  Dess-Martin 
periodinane (2.146 g, 5.061 mmol, 1.25 equiv.) was added to a stirring solution 
of intermediate 37 (900 mg, 4.049 mmol, 1 equiv.) and sodium bicarbonate 
(1.36 g, 16.19 mmol, 4.0 equiv.) in CH2Cl2 (15 mL).  After 1 h, the reaction was 
poured into a solution of saturated sodium thiosulfate (50 mL) saturated 
sodium bicarbonate (25 mL), and stirred vigorously for 10 min before being 
extracted with CH2Cl2 (4 x 50 mL), organics combined, dried (Na2SO4), filtered, 
and concentrated by rotary evaporation.  TMSCN (421.6 mg, 4.250 mmol, 
1.05 equiv) and LiCl (17.16 µg, 0.405 µmol, 0.0001 equiv. 0.3 M in THF) were 
added to the crude aldehyde and the reaction stirred vigorously for 2h.   The 
reaction was then quenched by addition of 6 M HCl (20 mL) and stirred for 10 
min before being extracted with EtOAc (4 x 25 mL), organics combined, dried 
(Na2SO4), filtered, and concentrated by rotary evaporation.   Purification by 
silica flash chromatography (30%  50% EtOAc in hexanes) yielded the 
product (38) as a clear oil (790 mg, 79%). 
IR (ATR): 3434, 3070, 3002, 2954, 2848, 2253, 1793, 1711, 1597, 1576, 
1487, 1436, 1409, 1371, 1285, 1203, 1165, 1138, 1093, 994, 960, 913, 830, 
802, 761, 736, 708, 681, 648.  1H-NMR (600 MHz; CDCl3): δ 7.97 (dd, J = 7.8, 
0.7 Hz, 1H), 7.62 (td, J = 7.5, 1.2 Hz, 1H), 7.53 (td, J = 7.7, 1.1 Hz, 1H), 7.33 
(dd, J = 7.6, 0.7 Hz, 1H), 4.81 (s, 1H), 4.03 (s, 1H), 3.92 (s, 3H), 3.14 (ddd, J = 
18.8, 8.9, 4.9 Hz, 1H), 2.98 (ddd, J = 18.8, 6.3, 5.0 Hz, 1H), 2.43 (ddt, J = 
14.2, 9.3, 4.8 Hz, 1H), 2.25 (dddd, J = 14.4, 7.8, 6.5, 5.0 Hz, 1H).   13C-NMR 
(151 MHz; CDCl3): δ 205.9, 167.1, 143.3, 133.0, 130.21, 130.03, 127.5, 125.9, 
119.8, 60.2, 53.0, 38.3, 29.4. HRMS (ESI) m/z calcd for C19H17O4Na 
([M+Na]+) 346.1055; found 346.1041. 
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Methyl 2-(5-cyano-2-methoxytetrahydrofuran-2-yl)benzoate (39).  
Trimethyl orthoformate (858 mg, 8.088 mmol, 4.0 equiv.) and concentrated 
sulfuric acid (19.8 mg, 0.202 mmol, 0.1 equiv.) were added to a stirring 
solution of cyanohydrin intermediate 38 (500 mg, 2.022 mmol, 1 equiv.)  in 
MeOH (20 mL) before being heated reflux.  After 12 h, the reaction was cooled 
to room temperature, poured into saturated sodium bicarbonate (50 mL), 
extracted with EtOAc (4 x 50 mL), organics combined, dried (Na2SO4), filtered, 
and concentrated by rotary evaporation.  Purification by silica flash 
chromatography (10%  30% EtOAc in hexanes containing 1% NEt3) yielded 
the product (39) as a clear oil (425 mg, 80%). 
IR (ATR): 2999, 2948, 2837, 1729, 1434, 1295, 1268, 1191, 1131, 1099, 
1076, 1031, 960, 928, 874, 827, 784, 762, 738, 703, 651.  1H-NMR (600 MHz; 
CDCl3): δ 7.54 (dt, J = 7.9, 0.6 Hz, 1H), 7.48-7.43 (m, 1H), 7.42-7.36 (m, 2H), 
4.89-4.86 (m, 1H), 3.88 (d, J = 11.6 Hz, 3H), 3.15 (s, 3H), 2.63-2.49 (m, 3H), 
2.38-2.20 (m, 1H).   13C-NMR (151 MHz; CDCl3): δ 170.5, 136.4, 132.4, 130.1, 
128.5, 128.1, 127.2, 119.3, 110.9, 66.0, 52.4, 50.7, 40.1, 30.8.   HRMS (ESI) 
m/z calcd for C14H15O4NNa ([M+Na]
+) 284.0899; found 284.0903. 
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-N-(N-2´´-[methyloxy 
carbonyl] - [benzyl-(2-methoxy-5-[2H-tetrazol-5-yl] tetrahydrofuran-2-yl)]) 
aminodeoxyadenosine (47).  Intermediate 39 (206 mg, 0.788 mmol, 1 
equiv.), sodium azide (153.7 mg, 2.365 mmol, 3.0 equiv.), and 
triethylammonium hydrochloride (325.5 mg, 2.365 mmol, 3.0 equiv.) were 
suspended in toluene (15 mL) and stirred at 100 ºC for 4 h.  The reaction was 
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then cooled to room temperature, diluted with 30 mL acetone, filtered through 
a pad of celite and the filtrate concentrated by rotary evaporation.  The residue 
was dissolved in EtOAc (50 mL) and washed with saturated ammonium 
chloride (2 x 25 mL), dried (Na2SO4), filtered, and concentrated by rotary 
evaporation to give the crude tetrazole intermediate 46.  The crude tetrazole 
46 was then suspended in THF (15 mL) with protected adenosine 42 (321 mg, 
0.789 mmol, 1 equiv.) prepared as previously described,33 and resin bound 
PPh3 (969 mg, 1.182 mmol, 1.5 equiv. 32% w/w) before being cooled to 0 ºC 
and diisopropyl azodicarboxylate (239 mg, 1.182 mmol, 1.5 equiv) added.  The 
reaction was allowed to stir for 14 h while returning to room temperature 
before being quenched with water (1 mL), filtered through a pad of celite and 
the filtrate concentrated by rotary evaporation to yield the crude product 47 as 
a yellow solid (680 mg). 
 
 
 
 
5´-N-(N-[4´´-([2´´´-(Carboxyl)phenyl]4-hydroxy)2H-tetrazol-5-yl]butanoyl) 
aminodeoxyadenosine  (45).  Intermediate 47 was reconstituted in CH2Cl2 
(20 mL) and cooled to 0 ºC before TFA (20 mL) and water (1 mL) added and 
the reaction stirred for 4 h while returning to room temperature before being 
concentrated by rotary evaporation and dried under high vacuum for 4h to give 
the crude spirocycle product 48.  The residue was then dissolved in MeOH (25 
mL) and water (3 mL) before LiOH (75 mg, 3.152 mmol, 4.0 equiv.) added and 
the reaction stirred at room temperature for 12 h.  Concentration by rotary 
evaporation, purification by preparative HPLC (5%  45% MeCN in H2O with 
0.1% TFA), and lyophilization yielded the product 45 as a fluffy white solid 
(145 mg, 35% over 4 steps). 
IR (ATR): 3350, 1751, 1694, 1509, 1468, 1428, 1324, 1289, 1202, 1138, 
1062, 1033, 898, 831, 801, 767, 723, 700, 643.  1H-NMR (600 MHz; D2O): δ 
8.00 (d, J = 4.9 Hz, 1H), 7.84 (s, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.39 (q, J = 7.8 
Hz, 1H), 7.30-7.25 (m, 1H), 7.19 (dd, J = 23.4, 7.7 Hz, 1H), 5.92 (t, J = 3.0 Hz, 
1H), 5.11 (dtd, J = 29.2, 12.4, 4.7 Hz, 2H), 5.01 (dt, J = 15.2, 6.6 Hz, 1H), 
4.59-4.56 (m, 1H), 4.50 (dq, J = 9.7, 4.8 Hz, 2H), 2.79-2.72 (m, 2H), 2.19-2.09 
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(m, 2H).   13C-NMR (151 MHz; D2O): δ 208.3, 175.96, 175.80, 167.51, 167.48, 
163.1, 162.9, 160.2, 155.29, 155.29, 152.6, 148.4, 139.5, 138.34, 138.30, 
138.15, 138.13, 137.18, 137.17, 137.16, 137.01, 136.98, 131.09, 131.08, 
131.01, 131.00, 130.99, 129.35, 129.31, 127.80, 127.76, 126.51, 126.49, 
126.36, 126.34, 126.34, 119.2, 118.60, 118.57, 117.3, 115.3, 113.4, 88.30, 
88.24, 80.63, 80.55, 73.07, 73.02, 70.05, 69.98, 64.5, 53.25, 53.12, 29.82, 
29.76.   HRMS (ESI) m/z calcd for C22H22O7N9 ([M+H]
+) 524.1642; found 
524.1630. 
 
 
 
E. Synthesis of m-phenolic linker analogue.  
 
 
 
 
(2-((tert-Butyldimethylsilyloxy)methyl)phenyl)methanol (50). Dimethyl 
phthalate (20 g, 102.9 mmol, 1 equiv.) in THF (50 mL) was added dropwise to 
a stirring solution of lithium aluminum hydride (4.880 g, 128.6 mmol, 1.25 
equiv.) in ether (200 mL) at 0 ºC before being allowed to return to room 
temperature.  After 36 h the reaction was cooled to 0 ºC before water (5 mL), 
aqueous NaOH (5 mL, 3.75 M), and water (15 mL) were added sequentially 
and the reaction stirred for 15 min.  MgSO4 (5 g) was then added and the 
reaction stirred for 15 min while returning to room temperature before being 
filtered through a pad of celite and the solvent removed by rotary evaporation. 
The crude diol (11.3 g, 81.78 mmol, 1 equiv.) and TBSCl (12.94 g, 85.86 
mmol, 1.05 equiv) were dissolved in dichloromethane (150 mL) and cooled to 
0 ºC before triethylamine (45.64 mL, 327.1 mmol, 4 equiv) was added and the 
reaction returned to room temperature.  After 14 h the reaction was quenched 
with 150 mL saturated ammonium chloride, the organic layer removed, the 
aqueous layer extracted with dichloromethane (3 x 150 mL), organics 
combined, dried (Na2SO4), filtered, and concentrated by rotary evaporation to 
give the crude alcohol 50 (17.6 g) which was used without further purification.   
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1-(2-((tert-Butyldimethylsilyloxy)methyl)phenyl)prop-2-en-1-one (52).  
Crude alcohol 50 (17.6 g, 69.72 mmol, 1 equiv) was suspended in hexanes 
(500 mL) before MnO2 (90 g, 1.045 mol, 15 equiv.) was added and the 
reaction stirred for 14 h.  The reaction was then filtered through a pad of celite 
and the solvent removed by rotary evaporation.  The crude aldehyde (15.3 g, 
61.10 mmol, 1 equiv.) was dissolved in THF (60 mL) and cooled to 0 ºC before 
vinylmagnesium bromide (91.65 mL, 91.65 mmol, 1 M in THF, 1.5 equiv) was 
added dropwise over 30 min.  After 1 h, the reaction was quenched with 
saturated ammonium chloride (200 mL), extracted with EtOAc (3 x 200 mL), 
organics combined, dried (Na2SO4), filtered, and concentrated by rotary 
evaporation.  The crude alcohol was suspended in hexanes (500 mL) before 
MnO2 (53 g, 610.4 mmol, 10 equiv.) was added and the reaction stirred for 8 
h.  The reaction was then filtered through a pad of celite and the solvent 
removed by rotary evaporation.  Purification by silica flash chromatography 
(0%  20% EtOAc in hexanes) yielded the product (52) as a clear oil (16.2 g, 
58% over 5 steps). 
IR (ATR): 2957, 2932, 2888, 2859, 1674, 1609, 1575, 1474, 1404, 1364, 
1298, 1258, 1230, 197, 1130, 1081, 994, 966, 840, 817, 779, 755, 671.  
1H-NMR (600 MHz; CDCl3): δ 7.74 (dd, J = 7.8, 0.7 Hz, 1H), 7.56 (dd, J = 7.7, 
1.2 Hz, 1H), 7.51 (td, J = 7.6, 1.3 Hz, 1H), 7.33-7.31 (m, 1H), 6.87 (dd, J = 
17.4, 10.6 Hz, 1H), 6.20 (dd, J = 17.4, 1.4 Hz, 1H), 5.96 (dd, J = 10.6, 1.4 Hz, 
1H), 4.95 (s, 2H), 0.94 (s, 9H), 0.10 (s, 6H). 13C-NMR (151 MHz; CDCl3): δ 
195.2, 142.4, 135.7, 135.2, 131.5, 130.8, 128.8, 127.1, 126.3, 63.0, 26.0, 18.4, 
-5.4.  HRMS (ESI) m/z calcd for C16H25O2Si ([M+H]
+) 277.1624; found 
277.1631. 
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(E)-1-(2-((tert-Butyldimethylsilyloxy)methyl)phenyl)-3-(3-hydroxyphenyl) 
prop-2-en-1-one (54).  Vinyl ketone 52 (300 mg, 1.085 mmol, 1.2 equiv.), 3-
bromophenol (53) (156 mg, 0.904 mmol, 1 equiv.), NBu4Cl (25 mg, 0.0904 
mmol, 0.1 equiv.), and PdCl2(dtbpf) (59 mg, 0.0904 mmol, 0.1 equiv) were 
suspended in DMA (2.7mL) before NCy2Me (265 mg, 1.356 mmol, 1.5 equiv.) 
was added and the reaction stirred vigorously at 85 ºC in a sealed tube for 16 
h.  The reaction was cooled to room temperature before being diluted with 8 
mL water and extracted with Et2O (4 x 8 mL), organics combined, dried 
(Na2SO4), filtered, and concentrated by rotary evaporation.  Purification by 
silica flash chromatography (10%  30% EtOAc in hexanes) yielded the 
product (54) as a white solid (274 mg, 82%). 
IR (ATR): 3354, 2955, 2929, 2892, 2857, 1625, 1600, 1472, 1452, 1361, 
1257, 1160, 112, 1084, 1022, 997, 983, 839, 816, 778, 740, 677, 610.  
1H-NMR (600 MHz; CDCl3): δ 7.75-7.74 (m, 1H), 7.60 (dd, J = 7.6, 1.1 Hz, 
1H), 7.53 (td, J = 7.6, 1.2 Hz, 1H), 7.46 (d, J = 16.0 Hz, 1H), 7.35 (t, J = 7.3 
Hz, 1H), 7.28-7.25 (m, 1H), 7.18 (d, J = 16.0 Hz, 1H), 7.13 (d, J = 7.7 Hz, 1H), 
7.05 (t, J = 2.0 Hz, 1H), 6.89 (ddd, J = 8.1, 2.5, 0.7 Hz, 1H), 5.41 (s, 1H), 4.96 
(s, 2H), 0.92 (s, 9H), 0.09 (s, 6H).  13C-NMR (151 MHz; CDCl3): δ 195.4, 
156.1, 145.6, 142.0, 136.30, 136.20, 131.3, 130.2, 128.4, 127.2, 126.4, 126.2, 
121.3, 117.9, 114.7, 63.0, 26.0, 18.4, -5.3.  HRMS (ESI) m/z calcd for 
C22H27O3Si ([M+H]
+) 367.1729; found 367.1743. 
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-([E]-1-[2-([tert-
butyldimethylsilyloxy]methyl)phenyl]-3-(3-hydroxyphenyl) prop-2-en-1-
one)adenosine (55).  DIAD (103 mg, 0.509 mmol, 1.5 equiv.) was added 
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dropwise to a stirring solution of phenol 54 (125 mg, 0.339 mmol, 1 equiv.), 
protected adenosine 42 (138 mg, 0.339 mmol, 1 equiv.), and resin bound 
PPh3 (417 mg, 0.509 mmol, 32 % by weight, 1.5 equiv.) in THF (4 mL) at 0 ºC 
before being allowed to return to room temperature.  After 14 h, the reaction 
was quenched with water (0.2 mL) and filtered through a pad of celite, the pad 
washed with EtOAc, and solvent removed by rotary evaporation.  Purification 
by silica flash chromatography (40%  60% EtOAc in hexanes) yielded the 
product (55) as a white solid (205 mg, 80%). 
IR (ATR): 2932, 2858, 1752, 1700, 1620, 1586, 1528, 1464, 1370, 1326, 
1303, 1232, 1213, 1146, 1083, 1012, 945, 911, 840, 776, 734, 670, 646.  
1H-NMR (600 MHz; CDCl3): δ 8.78 (s, 1H), 8.09 (s, 1H), 7.92 (s, 1H), 7.75 (d, 
J = 7.8 Hz, 1H), 7.61 (dd, J = 7.6, 1.1 Hz, 1H), 7.53 (td, J = 7.6, 1.2 Hz, 1H), 
7.46 (t, J = 13.3 Hz, 1H), 7.36 (td, J = 7.5, 0.6 Hz, 1H), 7.27 (t, J = 4.0 Hz, 2H), 
7.19-7.15 (m, 2H), 7.01 (t, J = 1.8 Hz, 1H), 6.79 (dd, J = 8.1, 2.4 Hz, 1H), 6.26 
(d, J = 2.3 Hz, 1H), 5.48 (dd, J = 6.2, 2.3 Hz, 1H), 5.18 (dd, J = 6.2, 3.0 Hz, 
1H), 4.96 (s, 2H), 4.75-4.66 (m, 2H), 4.29 (dd, J = 10.2, 4.0 Hz, 1H), 4.18 (dd, 
J = 10.1, 4.9 Hz, 1H), 1.67 (s, 3H), 1.55 (s, 9H), 1.49 (s, 3H), 1.43 (s, 3H), 
0.93 (s, 9H), 0.09 (s, 6H).  13C-NMR (151 MHz; CDCl3): δ 194.8, 158.4, 153.2, 
150.4, 150.0, 149.5, 145.0, 142.1, 141.2, 136.3, 131.3, 130.2, 128.4, 127.2, 
126.51, 126.40, 122.3, 122.0, 116.7, 114.7, 113.8, 113.3, 91.6, 85.5, 84.7, 
82.4, 81.8, 68.1, 63.0, 28.21, 28.16, 27.3, 26.0, 25.4, 18.4, -5.3.  HRMS (ESI) 
m/z calcd for C40H52N5O8Si ([M+H]
+) 758.3585; found 758.3561. 
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(1-[2-(hydroxymethyl) 
phenyl]-3-(3-hydroxyphenyl) prop-2-en-1-one)adenosine (56).  
Phenylsilane (28.5 mg, 263.8 μmol, 2 equiv.) was added to a stirring solution 
of intermediate 55 (100 mg, 131.9 μmol, 1 equiv.) and Strykers catalyst (23 
mg, 11.9 μmol, 0.09 equiv.) in toluene (2 mL).  After 16 h, the reaction was 
quenched with saturated ammonium chloride (5 mL) and stirred for 5 min 
before 10% ammonium hydroxide (5 mL) was added and the reaction stirred 
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for an additional 5 min.  The reaction was then extracted with Et2O (4 x 10 
mL), organics combined, dried (Na2SO4), filtered, concentrated by rotary 
evaporation, and dried under high vacuum for 1 h.  The reside was 
reconstituted in THF (3 mL) and cooled to 0 ºC before TBAF (264 μL, 264 
μmol, 1M in THF, 2 equiv.) was added and the reaction stirred for 1 h.  CaCO3 
(132 mg, 1.315 mmol, 10 equiv.) and MeOH (3 mL) was added and the 
reaction stirred for 15 min before sulfonic acid resin (Dowex 50WX8, 200 mg) 
was added and the reaction stirred for an additional 10 min.  The reaction was 
then filtered through a pad of celite and concentrated by rotary evaporation to 
give the crude product 56 (86 mg, 101% yield). 
 
 
 
 
5´-O-([2-(Carboxyl)phenyl]3-(3-hydroxyphenyl)propanoyl)adenosine 
 (16).  Water (24 mg, 1.33 mmol, 10 equiv.), NMO (156 mg, 1.33 mmol, 10 
equiv.) and TPAP (4.8 mg, 13 μmol, 0.1 equiv.) were added to a stirring 
solution of crude intermediate 56 (86 mg, 133.1 μmol, 1 equiv.) in MeCN (2 
mL) before being stirred at room temperature for 14 h.  The reaction was then 
quenched with isopropanol and 1 M KHSO4 (1 mL) was added before the 
reaction was diluted with water (10 mL), extracted with EtOAc (4 x 10 mL), 
organics combined, dried (Na2SO4), filtered, concentrated by rotary 
evaporation.  The residue was reconstituted in CH2Cl2 (5 mL) and cooled to 0 
ºC before TFA (5 mL) and water (0.1 mL) added and the reaction stirred for 4 
h while returning to room temperature.  Concentration by rotary evaporation, 
purification by preparative HPLC (5%  45% MeCN in H2O with 0.1% TFA), 
and lyophilization yielded the product 16 as a fluffy white solid (30 mg, 44% 
over 4 steps). 
IR (ATR): 3320, 2946, 2837, 1757, 1697, 1607, 1492, 1447, 1424, 1290, 
1262, 1204, 1141, 1103, 1030, 900, 842, 802, 771, 726, 701, 644.  1H-NMR 
(600 MHz; MeOD): δ 8.40 (s, 1H), 8.29 (s, 1H), 7.80-7.77 (m, 1H), 7.70-7.69 
(m, 1H), 7.58-7.55 (m, 2H), 7.12-7.09 (m, 1H), 6.73-6.69 (m, 2H), 6.10 (d, J = 
4.5 Hz, 1H), 4.67 (t, J = 4.7 Hz, 1H), 4.44 (dd, J = 5.9, 3.7 Hz, 1H), 4.35 (dt, J 
= 4.7, 3.0 Hz, 1H), 4.28-4.26 (m, 1H), 4.17-4.14 (m, 1H), 2.69-2.28 (m, 4H).  
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13C-NMR (151 MHz; CDCl3): δ 160.1, 153.1, 150.2, 147.36, 147.33, 144.27, 
144.25, 144.25, 143.0, 130.74, 130.72, 122.45, 122.42, 122.37, 120.4, 115.66, 
115.63, 113.2, 90.5, 85.1, 76.4, 71.9, 68.3, 49.9, 49.6, 31.1.  HRMS (ESI) m/z 
calcd for C26H26N5O7 ([M+H]
+) 520.1832; found 520.1824. 
 
 
E. Synthesis of p-phenolic linker analogue. 
 
 
 
 
(E)-1-(2-((tert-butyldimethylsilyloxy)methyl)phenyl)-3-(4-hydroxyphenyl) 
prop-2-en-1-one (S1).  Vinyl ketone 52 (300 mg, 1.085 mmol, 1.2 equiv.), 4-
bromophenol (156 mg, 0.904 mmol, 1 equiv.), NBu4Cl (25 mg, 0.0904 mmol, 
0.1 equiv.), and PdCl2(dtbpf) (59 mg, 0.0904 mmol, 0.1 equiv) were 
suspended in DMA (2.7mL) before NCy2Me (265 mg, 1.356 mmol, 1.5 equiv.) 
was added and the reaction stirred vigorously at 85 ºC in a sealed tube for 16 
h.  The reaction was cooled to room temperature before being diluted with 8 
mL water and extracted with Et2O (4 x 8 mL), organics combined, dried 
(Na2SO4), filtered, and concentrated by rotary evaporation.  Purification by 
silica flash chromatography (10%  30% EtOAc in hexanes) yielded the 
product (S1) as a white solid (270 mg, 81%). 
 
IR (ATR): 3332, 2957, 2931, 2887, 2858, 1626, 1580, 1514, 1473, 1443, 1364, 
1336, 1282, 1258, 1215, 1171, 1128, 1085, 1025, 985, 941, 911, 834, 777, 
734, 671, 631.  1H-NMR ((600 MHz; CDCl3): δ 7.72 (d, J = 7.8 Hz, 1H), 7.56 
(dd, J = 7.6, 0.9 Hz, 1H), 7.52 (td, J = 7.6, 1.0 Hz, 1H), 7.47-7.43 (m, 3H), 7.35 
(td, J = 7.5, 0.4 Hz, 1H), 7.05 (d, J = 15.9 Hz, 1H), 6.87-6.84 (m, 2H), 6.59 (s, 
1H), 4.94 (s, 2H), 0.91 (s, 9H), 0.08 (s, 6H).  13C-NMR (151 MHz; CDCl3): δ 
196.5, 158.7, 146.7, 141.4, 136.7, 131.0, 130.6, 128.2, 127.3, 127.0, 126.5, 
123.6, 116.1, 62.9, 26.0, 18.4, -5.4.  HRMS (ESI) m/z calcd for C22H27O3Si 
([M+H]+) 367.1729; found 367.1727. 
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6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-([E]-1-[2-([tert-
butyldimethylsilyloxy]methyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-
one)adenosine (S2).  DIAD (189 mg, 0.936 mmol, 1.5 equiv.) was added 
dropwise to a stirring solution of phenol S1 (230 mg, 0.624 mmol, 1 equiv.), 
protected adenosine 42 (254 mg, 0.624 mmol, 1 equiv.), and resin bound 
PPh3 (767 mg, 0.936 mmol, 32 % by weigh, 1.5 equiv.) in THF (6 mL) at 0 ºC 
before being allowed to return to room temperature.  After 14 h, the reaction 
was quenched with water (0.2 mL) and filtered through a pad of celite, the pad 
washed with EtOAc, and solvent removed by rotary evaporation.  Purification 
by silica flash chromatography (40%  60% EtOAc in hexanes) yielded the 
product (S2) as a white solid (310 mg, 66%). 
IR (ATR): 2989, 2954, 2931, 2857, 2247, 1751, 1705, 1658, 1609, 1511, 
1463, 1423, 1384, 1369, 1327, 1304, 1251, 1213, 1174, 1144, 1081, 1017, 
982, 909, 836, 776, 729, 668, 645.  1H-NMR ((600 MHz; CDCl3): δ 8.79 (s, 
1H), 8.09 (s, 1H), 8.05 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.60 (dd, J = 7.6, 1.1 
Hz, 1H), 7.52 (td, J = 7.6, 1.2 Hz, 1H), 7.49-7.44 (m, 3H), 7.35 (t, J = 7.5 Hz, 
1H), 7.09 (d, J = 15.9 Hz, 1H), 6.79-6.76 (m, 2H), 6.25 (d, J = 2.2 Hz, 1H), 
5.52 (dd, J = 6.2, 2.2 Hz, 1H), 5.19 (dd, J = 6.2, 2.9 Hz, 1H), 4.95 (s, 2H), 4.72 
(dd, J = 7.4, 4.3 Hz, 1H), 4.30 (dd, J = 10.2, 4.1 Hz, 1H), 4.18 (dd, J = 10.2, 
4.9 Hz, 1H), 1.67 (s, 3H), 1.56 (s, 9H), 1.43 (s, 3H), 0.92 (s, 9H), 0.09 (s, 6H).  
13C-NMR (151 MHz; CDCl3): δ 195.1, 159.9, 153.2, 150.26, 150.06, 149.6, 
145.1, 141.8, 141.3, 136.6, 131.0, 130.2, 128.25, 128.23, 127.1, 126.3, 124.2, 
122.2, 114.74, 114.66, 91.7, 85.5, 84.6, 82.4, 81.8, 68.0, 62.9, 28.1, 27.2, 
26.0, 25.4, 18.4, -5.3.  HRMS (ESI) m/z calcd for C40H52N5O8Si ([M+H]
+) 
758.3585; found 758.3576. 
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6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(1-[2-(hydroxymethyl) 
phenyl]-3-(3-hydroxyphenyl) prop-2-en-1-one)adenosine (S3).      
Phenylsilane (96 mg, 699.2 μmol, 2 equiv.) was added to a stirring solution of 
intermediate S2 (265 mg, 349.6 μmol, 1 equiv.) and Strykers catalyst (62 mg, 
31.5 μmol, 0.09 equiv.) in toluene (5 mL) and room temperature.  After 16 h, 
the reaction was quenched with saturated ammonium chloride (10 mL) and 
stirred for 5 min before 10% ammonium hydroxide (10 mL) was added and the 
reaction stirred for an additional 5 min.  The reaction was then extracted with 
Et2O (4 x 20 mL), organics combined, dried (Na2SO4), filtered, concentrated by 
rotary evaporation, and dried under high vacuum for 1 h.  The reside was 
reconstituted in THF (5 mL) and cooled to 0 ºC before TBAF (697 μM, 697 
μmol, 1M in THF, 2 equiv.) was added and the reaction stirred for 1 h.  CaCO3 
(349 mg, 3.486 mmol, 10 equiv.) and MeOH (3 mL) was added and the 
reaction stirred for 15 min before sulfonic acid resin (dowex 50WX8, 500 mg) 
was added and the reaction stirred for an additional 10 min.  The reaction was 
then filtered through a pad of celite and concentrated by rotary evaporation to 
give the crude product S3 (202 mg, 90% yield). 
 
 
 
 
5´-O-([2-(Carboxyl)phenyl]3-(3-hydroxyphenyl)propanoyl)adenosine 
(62).  Water (56 mg, 3.128 mmol, 10 equiv.), NMO (366 mg, 3.128 mmol, 10 
equiv.) and TPAP (11 mg, 31 μmol, 0.1 equiv.) were added to a stirring 
solution of crude intermediate S3 (202 mg, 312.8 μmol, 1 equiv.) in MeCN (5 
mL) before being stirred at room temperature for 14 h.  The reaction was then 
quenched with isopropanol and 1 M KHSO4 (1 mL) was added before the 
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reaction was diluted with water (20 mL), extracted with EtOAc (4 x 20 mL), 
organics combined, dried (Na2SO4), filtered, concentrated by rotary 
evaporation, and dried under high vacuum 1 h.  The residue was reconstituted 
in CH2Cl2 (8 mL) and cooled to 0 ºC before TFA (8 mL) and water (0.8 mL) 
added and the reaction stirred for 4 h while returning to room temperature.  
Concentration by rotary evaporation, purification by preparative HPLC (5%  
45% MeCN in H2O with 0.1% TFA), and lyophilization yielded the product 62 
as a fluffy white solid (65 mg, 36% over 4 steps). 
IR (ATR): 3323, 2921, 2869, 1750, 1690, 1614, 1512, 1424, 1292, 1242, 
1203, 1140, 1050, 980, 898, 827, 801, 769, 724, 699, 642.  1H-NMR (600 
MHz; MeOD): δ 8.45 (s, 1H), 8.33 (s, 1H), 7.84-7.83 (m, 1H), 7.77-7.76 (m, 
1H), 7.64-7.63 (m, 2H), 7.04-7.03 (m, 2H), 6.87-6.85 (m, 2H), 6.14 (d, J = 4.6 
Hz, 1H), 4.72 (t, J = 4.8 Hz, 1H), 4.49 (t, J = 4.8 Hz, 1H), 4.40 (q, J = 3.9 Hz, 
1H), 4.32-4.30 (m, 1H), 4.20 (dd, J = 10.9, 3.3 Hz, 1H), 2.72-2.65 (m, 1H), 
2.48-2.29 (m, 3H).  13C-NMR (151 MHz; CDCl3): δ 158.3, 153.38, 153.37, 
150.2, 147.71, 147.70, 142.8, 136.7, 135.9, 135.20, 135.19, 135.19, 135.18, 
131.7, 130.5, 120.46, 120.45, 115.7, 90.5, 85.1, 76.4, 71.9, 68.5, 50.0, 49.6, 
30.2.  HRMS (ESI) m/z calcd for C26H26N5O7 ([M+H]
+) 520.1832; found 
520.1809. 
 
 
 
F. Synthesis of m-(3-trifluoromethyl)phenolic linker analogue. 
 
 
 
 
(E)-1-(2-((tert-butyldimethylsilyloxy)methyl)phenyl)-3-(3-hydroxy-5-
(trifluoromethyl) phenyl)prop-2-en-1-one (S4).  Vinyl ketone 52 (300 mg, 
1.085 mmol, 1.2 equiv.), 3-bromo-5-trifluoromethylphenol (218 mg, 0.904 
mmol, 1 equiv.), NBu4Cl (25 mg, 0.0904 mmol, 0.1 equiv.), and PdCl2(dtbpf) 
(59 mg, 0.0904 mmol, 0.1 equiv) were suspended in DMA (2.7 mL) before 
NCy2Me (265 mg, 1.356 mmol, 1.5 equiv.) was added and the reaction stirred 
vigorously at 85 ºC in a sealed tube for 16 h.  The reaction was cooled to room 
temperature before being diluted with 8 mL water and extracted with Et2O (4 x 
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8 mL), organics combined, dried (Na2SO4), filtered, and concentrated by rotary 
evaporation.  Purification by silica flash chromatography (10%  30% EtOAc 
in hexanes) yielded the product (S4) as a white solid (290 mg, 74%). 
IR (ATR): 3372, 2955, 291, 2885, 2858, 1601, 1449, 1369, 1310, 1258, 1219, 
1173, 1130, 1098, 1024, 981, 911, 839, 815, 778, 736, 690, 669, 620.  
1H-NMR ((500 MHz; CDCl3): δ 7.73 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 7.6 Hz, 
1H), 7.54 (t, J = 7.5 Hz, 1H), 7.46 (d, J = 16.0 Hz, 1H), 7.38-7.35 (m, 2H), 7.23 
(d, J = 16.0 Hz, 2H), 7.12 (s, 1H), 6.08 (s, 1H), 4.96 (s, 2H), 0.92 (s, 9H), 0.09 
(s, 6H).  13C-NMR (126 MHz; CDCl3): δ 195.1, 156.6, 143.8, 142.0, 137.0, 
136.0, 132.8, 131.7, 128.5, 127.60, 127.52, 126.6, 123.5, 118.1, 117.3, 114.4, 
63.1, 26.0, 18.4, -5.4.   19F-NMR (126 MHz; CDCl3): δ –63.0.  HRMS (ESI) m/z 
calcd for C23H28O3F3Si ([M+H]
+) 437.1760; found 437.1739. 
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-([E]-1-[2-([tert-
butyldimethylsilyloxy]methyl)phenyl]-3-(3-hydroxy-5-(trifluoromethyl) 
phenyl) prop-2-en-1-one)adenosine  (S5).  DIAD (125 mg, 0.619 mmol, 1.5 
equiv.) was added dropwise to a stirring solution of phenol S4 (270 mg, 0.619 
mmol, 1 equiv.), protected adenosine 42 (126 mg, 0.309 mmol, 1 equiv.), and 
resin bound PPh3 (507 mg, 0.619 mmol, 32 % by weigh, 1.5 equiv.) in THF (6 
mL) at 0 ºC before being allowed to return to room temperature.  After 14 h, 
the reaction was quenched with water (0.2 mL) and filtered through a pad of 
celite, the pad washed with EtOAc, and solvent removed by rotary 
evaporation.  Purification by silica flash chromatography (40%  60% EtOAc 
in hexanes) yielded the product (S5) as a white solid (215 mg, 84%). 
 
IR (ATR): 2982, 2955, 2934, 2857, 2244, 1753, 1717, 1666, 1610, 1521, 
1464, 1359, 1326, 1300, 1233, 1173, 1133, 1104, 1080, 1020, 977, 911, 587, 
839, 815, 778, 734, 689, 646.  1H-NMR ((600 MHz; CDCl3): δ 8.76 (s, 1H), 
8.04 (s, 1H), 7.92 (s, 1H), 7.76 (d, J = 7.7 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 
7.55 (td, J = 7.6, 0.9 Hz, 1H), 7.44 (d, J = 16.0 Hz, 1H), 7.39 (dd, J = 13.8, 5.5 
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Hz, 2H), 7.26 (s, 1H), 7.22 (d, J = 16.0 Hz, 1H), 7.15 (s, 1H), 7.03 (s, 1H), 6.22 
(d, J = 2.2 Hz, 1H), 5.52 (dd, J = 6.2, 2.2 Hz, 1H), 5.21 (dd, J = 6.2, 3.3 Hz, 
1H), 4.96 (s, 2H), 4.70-4.68 (m, 1H), 4.29 (ddd, J = 48.5, 10.0, 4.9 Hz, 2H), 
1.67 (s, 3H), 1.55 (s, 9H), 1.44 (s, 3H), 0.93 (s, 9H), 0.09 (s, 6H).  13C-NMR 
(126 MHz; CDCl3): δ 194.1, 158.7, 153.2, 150.27, 150.16, 149.5, 142.9, 142.3, 
141.4, 137.3, 135.9, 132.8, 131.6, 128.5, 127.9, 127.3, 126.5, 123.4, 122.4, 
118.0, 117.1, 114.9, 113.0, 91.4, 85.3, 84.4, 82.4, 81.7, 68.5, 63.0, 28.1, 27.2, 
26.0, 25.4, 18.4, -5.3.  19F-NMR (126 MHz; CDCl3): δ –63.0.  HRMS (ESI) m/z 
calcd for C41H51N5O8F3Si ([M+H]
+) 826.3459; found 826.3453. 
 
 
 
 
6-N-t-Butoxycarbonyl-2´,3´-O-isopropylidene-5´-O-(1-[2-(hydroxymethyl) 
phenyl]-3-(3-hydroxy-5-(trifluoromethyl)phenyl)prop-2-en-1-one) 
adenosine  (S6).  Phenylsilane (56 mg, 521 μmol, 2 equiv.) was added to a 
stirring solution of intermediate S5 (215 mg, 260.3 μmol, 1 equiv.) and 
Strykers catalyst (51 mg, 26.0 μmol, 0.09 equiv.) in toluene (5 mL) and room 
temperature.  After 16 h, the reaction was quenched with saturated ammonium 
chloride (10 mL) and stirred for 5 min before 10% ammonium hydroxide (10 
mL) was added and the reaction stirred for an additional 5 min.  The reaction 
was then extracted with Et2O (4 x 20 mL), organics combined, dried (Na2SO4), 
filtered, concentrated by rotary evaporation. Purification by silica flash 
chromatography (50%  100% EtOAc in hexanes) yielded the product (S6) as 
a white solid (207 mg, 96%). 
 
IR (ATR): 2982, 2956, 2933, 2902, 2858, 2245, 1753, 1681, 1610, 1587, 
1522, 1463, 1359, 1329, 1233, 1172, 1144, 1128, 1105, 1080, 1107, 972, 911, 
854, 839, 814, 777, 734, 702, 670, 646.  1H-NMR ((600 MHz; CDCl3): δ 8.78 
(s, 1H), 8.05 (s, 1H), 7.95 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.73-7.71 (m, 1H), 
7.55-7.52 (m, 1H), 7.34-7.31 (m, 1H), 7.10 (s, 1H), 6.84 (s, 2H), 6.23 (d, J = 
2.2 Hz, 1H), 5.50 (dd, J = 6.2, 2.3 Hz, 1H), 5.17 (dd, J = 6.2, 3.1 Hz, 1H), 5.00 
(s, 2H), 4.68 (q, J = 3.9 Hz, 1H), 4.23 (ddd, J = 55.1, 10.1, 4.6 Hz, 2H), 3.25 (t, 
J = 7.6 Hz, 2H), 3.02 (t, J = 7.5 Hz, 2H), 1.66 (s, 3H), 1.55 (s, 9H), 1.43 (s, 
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3H), 0.95 (s, 9H), 0.11 (s, 6H).  13C-NMR (126 MHz; CDCl3): δ 201.4, 158.3, 
153.2, 150.3, 150.1, 149.5, 144.2, 143.3, 141.3, 134.5, 132.3, 132.1, 128.7, 
126.9, 126.4, 123.8, 122.3, 118.4, 118.2, 114.8, 109.0, 91.6, 85.3, 84.5, 82.4, 
81.7, 68.2, 63.5, 41.8, 30.0, 28.1, 27.3, 26.0, 25.4, 18.4, -5.3.  19F-NMR (126 
MHz; CDCl3): δ –62.7. HRMS (ESI) m/z calcd for C41H53N5O8F3Si ([M+H]
+) 
828.3610; found 828.3616. 
 
 
 
 
5´-O-([2-(Carboxyl)phenyl]3-(3-hydroxy-5-(trifluoromethyl)phenyl) 
propanoyl)adenosine  (63).  TBAF (786 μL, 786.0 μmol, 1M in THF, 3 equiv.) 
was added to intermediate S6 (217 mg, 260.3 μmol, 1 equiv.) in THF (5 mL) at 
0 ºC before and stirred for 1 h.  CaCO3 (349 mg, 3.486 mmol, 10 equiv.) and 
MeOH (3 mL) was added and the reaction stirred for 15 min before sulfonic 
acid resin (Dowex 50WX8, 500 mg) was added and the reaction stirred for an 
additional 10 min.  The reaction was then filtered through a pad of celite and 
concentrated by rotary evaporation.  The residue was reconstituted in MeCN 
(5 mL) before water (45 mg, 2.5 mmol, 10 equiv.), NMO (295 mg, 2.521 mmol, 
10 equiv.), and TPAP (8.9 mg, 25 μmol, 0.1 equiv.) were added and stirred at 
room temperature for 14 h.  The reaction was then quenched with isopropanol 
and 1 M KHSO4 (1 mL) was added before the reaction was diluted with water 
(20 mL), extracted with EtOAc (4 x 20 mL), organics combined, dried 
(Na2SO4), filtered, concentrated by rotary evaporation, and dried under high 
vacuum 1 h.  The residue was reconstituted in CH2Cl2 (8 mL) and cooled to 0 
ºC before TFA (8 mL) and water (0.8 mL) added and the reaction stirred for 4 
h while returning to room temperature.  Concentration by rotary evaporation, 
purification by preparative HPLC (5%  45% MeCN in H2O with 0.1% TFA), 
and lyophilization yielded the product 63 as a fluffy white solid (46 mg, 31% 
over 4 steps). 
IR (ATR): 3346, 2509, 2247, 2076, 1756, 1693, 1608, 1455, 1353, 1320, 
1289, 1245, 1205, 1126, 1055, 982, 898, 842, 802, 767, 726, 703, 644.  
1H-NMR ((600 MHz; MeOD): δ 8.43 (s, 1H), 8.34 (s, 1H), 7.84-7.81 (m, 1H), 
7.72-7.68 (m, 1H), 7.60-7.57 (m, 2H), 7.05-6.96 (m, 3H), 6.14 (d, J = 4.4 Hz, 
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1H), 4.76 (t, J = 4.7 Hz, 1H), 4.53 (t, J = 5.0 Hz, 1H), 4.43-4.38 (m, 2H), 4.28 
(dd, J = 10.8, 3.5 Hz, 1H), 2.89-2.50 (m, 4H).  13C-NMR (126 MHz; MeOD): δ 
160.4, 153.13, 153.05, 153.03, 150.1, 147.1, 145.77, 145.71, 145.65, 143.22, 
143.18, 132.9, 131.58, 131.43, 125.4, 124.1, 120.5, 119.4, 118.9, 110.4, 90.7, 
84.8, 76.0, 71.8, 68.8, 49.3, 31.0.  19F-NMR (126 MHz; MeOD): δ –64.07.  
HRMS (ESI) m/z calcd for C27H25N5O7F3 ([M+H]
+) 588.1706; found 588.1681. 
 
 
 
G. MenE Biochemical Assay 
 
Enzyme inhibition studies were performed in 20 mM NaHPO4 buffer (pH 7.4) 
containing 150 mM NaCl and 1 mM MgCl2 using a MenE-MenB coupled assay 
in which MenE is rate-limiting. IC50 values were determined in reaction 
mixtures containing OSB (60 μM), ATP (240 μM), CoA (240 μM), mtMenB (2.5 
μM), and varying inhibitor concentrations (5 − 250 μM). Reactions were 
initiated by addition of ecMenE  (50 nM), and the production of DHNA-CoA 
was monitored at 392 nm (ε392  = 4000 M−1 cm−1).  
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H. Docking of Inhibitors to MenE 
 
Protein Preparation.  The OSB-AMS•MenE co-crystal structure (PDB: 5C5H) 
was processed using the Protein Preparation Wizard in the Schrödinger suite 
(v2017.2).  Bond orders were assigned, hydrogen’s added, and waters beyond 
5 Å were deleted.  The protonation and tautomeric states of the protein-ligand 
complex were generated using EPIK at pH 7.4.  Hydrogen bond assignment 
and optimization was performed with PROPKA to sample hydrogen bonding 
and orientation of water molecules.  Non-bridging waters (< 2 hydrogen 
bonds) were removed.  Geometric refinement was performed using OPLS_3 
force field restrained minimization to a heavy atom convergence of 0.3 Å 
 
Ligand Preparation.  Ligand preparation was performed using Ligprep in the 
Schrödinger suite (v2017.2).  Lowest energy conformers were obtained using 
OPLS_3 force field optimization.  Ionization and tautomeric states were 
generated using EPIK at pH 7.4.  
 
Grid Generation.  Using the Schrödinger suite (v2017.2) receptor grid 
generator, the receptor-binding site was defined as the area around the co-
crystalized ligand with a cube grid of 10 Å side length.  Nonpolar parts of the 
receptor were softened using Van der Waals radius scaling (factor 1.0 with 
partial cutoff of 0.25).  No constraints were defined and rotations allowed for all 
hydroxyl groups in the defined binding pocket.  
 
Docking Using Soft Receptor.  Using Glide (v7.2), ligands were docked to 
MenE using Glide XP docking precision.  Flexible ligand sampling was used 
and EPIK state penalties applied to docking scores.  Post-docking 
minimization was performed for all poses. 
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Table 4.2.1 Docking scores of OSB-AMS linker analogues. OSB-AMS (1) docking score = 
–13.78 kcal/mol.  
 
Entry Analogue 
Docking Score 
(kcal/mol) 
Entry Analogue 
Docking Score 
(kcal/mol) 
13 
 
–13.76 22 
 
–13.27 
14 
 
–14.2 23 
 
–14.70 
15 
 
–13.98 24 
 
–13.62 
16 
 
–14.03 S7 
 
–15.27 
17 
 
–14.63 S8 
 
–15.25 
18 
 
–13.61 S9 
 
–14.94 
19 
 
–13.69 S11 
 
–14.55 
20 
 
–13.32 S12 
 
–14.50 
21 
 
–13.69 S13 
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Table 4.2.2 Docking scores of OSB-AMS linker analogues. OSB-AMS (1) docking score = 
–13.78 kcal/mol.  
 
Entry Analogue 
Docking Score 
(kcal/mol) 
Entry Analogue 
Docking Score 
(kcal/mol) 
S14 
 
–14.48 S23 
 
–14.05 
S15 
 
–14.42 S24 
 
–14.05 
S16 
 
–14.32 S25 
 
–13.98 
S17 
 
–14.28 S26 
 
–13.95 
S18 
 
–14.22 S27 
 
–13.91 
S19 
 
–14.22 S28 
 
–13.85 
S20 
 
–14.09 S29 
 
–13.73 
S21 
 
–14.08 S30 
 
–13.71 
S22 
 
–14.08 S31 
 
–13.63 
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Table 4.2.3 Docking scores of OSB-AMS linker analogues. OSB-AMS (1) docking score = 
–13.78 kcal/mol.  
 
Entry Analogue 
Docking Score 
(kcal/mol) 
Entry Analogue 
Docking Score 
(kcal/mol) 
S32 
 
–13.62 S41 
 
–13.30 
S33 
 
–13.62 S42 
 
–13.30 
S34 
 
–13.60 S43 
 
–13.29 
S35 
 
–13.54 S44 
 
–13.27 
S36 
 
–13.53 S45 
 
–13.26 
S37 
 
–13.45 S46 
 
–13.19 
S38 
 
–13.38 S47 
 
–13.18 
S39 
 
–13.36 S48 
 
–13.17 
S40 
 
–13.31 S49 
 
–13.01 
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Table 4.2.4 Docking scores of OSB-AMS linker analogues. OSB-AMS (1) docking score = 
–13.78 kcal/mol. 
 
Entry Analogue 
Docking Score 
(kcal/mol) 
Entry Analogue 
Docking Score 
(kcal/mol) 
S50 
 
–12.98 S58 
 
–11.90 
S51 
 
–12.95 S59 
 
–10.76 
S52 
 
–12.91 S60 
 
> –10 
S53 
 
–12.84 S61 
 
> –10 
S54 
 
–12.83 S62 
 
> –10 
S55 
 
–12.79 S63 
 
> –10 
S56 
 
–12.55 S64 
 
> –10 
S57 
 
–12.42 S65  > –10 
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Table 4.2.5 Docking scores of OSB-AMS linker analogues. OSB-AMS (1) docking score = 
–13.78 kcal/mol.  
 
Entry Analogue 
Docking Score 
(kcal/mol) 
Entry Analogue 
Docking Score 
(kcal/mol) 
S66  > –10    
S67 
 
> –10    
S68 
 
> –10    
S69 
 
> –10    
S70 
 
> –10    
S71 
 
> –10    
S72 
 
> –10    
S73 
 
> –10    
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1. Conclusions 
A series of keto-acid and lactol analogues of OSB-AMS were designed 
and synthesized to determine the active pharmacophore for MenE and 
discover an analogue that exhibited increased antimicrobial activity 
(Figure 5.1A).1    
	
Figure 5.1.  Selected analogues of OSB-AMS A) Biochemically active keto-acid and lactol 
analogues of OSB-AMS, IC50s reported against E. coli MenE.  B) The four diastereomers of 
the difluoroindanediol analogue.  
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the relatively acidic acyl-sulfamate.  We modified the proposed structure by 
substituting fluorine at the α-keto position, which inductively stabilized the 
tertiary alcohol of the indanol motif and allowed for the synthesis of the 
difluoroindanediol analogue 5.  Ultimately, this analogue, although only a low-
µM inhibitor of MenE in biochemical assays, was the only analogue to have 
improved antimicrobial activity versus OSB-AMS.  While the initial rescue 
studies using exogenous menaquinone (MK-4) suggested that the mechanism 
of action of the difluoroindanediol analogue was inhibition of menaquinone, the 
high similarity between the active concentrations of drug in biochemical and 
antimicrobial assays suggested that the mechanism of action was not through 
inhibition of MenE.  To elucidate the mechanism of action of the 
difluoroindanediol analogue, we designed and executed a stereoselective 
synthesis of the four diastereomeric difluoroindanediol analogues (Figure 
5.1B) and tested their individual activities against MenE.2  In so doing, we 
discovered that only one of the four diastereomers was active against MenE in 
biochemical assays (Table 5.1).  Docking studies suggested that the active 
diastereomer is best suited to fill the OSB binding pocket, and retain key 
interactions in the binding pocket.  Interestingly, this docking is through direct 
interaction with a conserved threonine rather than the bridging waters with 
which the carboxylate of OSB interacts.   Upon testing the diastereomers in 
antimicrobial assays, we discovered that all four diastereomers are equipotent 
against a variety of bacteria and showed no inhibition of menaquinone 
biosynthesis in LC-MS/MS studies examining the levels of endogenous 
menaquinone in methicillin-resistant S. aureus (MRSA).  This indicated that, 
although the analogues have modest activity against bacteria, the primary 
mechanism of action is not inhibition of menaquinone biosynthesis and is 
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instead an unknown mechanism of action.  Future work with the 
difluoroindanediol scaffold should investigate the mechanism of action through 
generation and sequencing of resistant mutants and pull-down studies using 
functionalized difluoroindanediol derivatives.   
 Table 5.1.  Biochemical and antimicrobial activity of diastereomeric 
difluoroindanediols 2.   
entry inhibitor 
MenE IC50 
[µM]a 
B. subtilis 
MIC [µg/mL]b 
MRSA             
MIC [ug/mL]b,c 
M. tuberculosis  
MIC [µg/mL]b 
1 5d 18.3 ± 3.7e 15.6 (62.5) 15.6 (62.5) 15.6 (62.5) 
2 (1R,3S)-5 5.0 ± 1.0 15.6 (31.2) 15.6 (31.2) 15.6 (62.5) 
3 (1S,3R)-5 > 200 15.6 (31.2) 31.2 (31.2) 31.2 (62.5) 
4 (1R,3R)-5 > 200 15.6 (15.6) 15.6 (15.6) 15.6 (31.2) 
5 (1S,3S)-5 > 200 15.6 (15.6) 15.6 (15.6) 31.2 (31.2) 
6 AMSf n.dg 3.9 (3.9) 1.9 (1.9) 0.16 (0.32) 
a E. coli MenE. b MIC values in parentheses determined with addition of exogenous 
menaquinone-4 (10 mg/mL). c MRSA = methicillin-resistant S. aureus. d Equimolar mixture of 
four diastereomers, prepared by the original synthetic route.3  e This IC50  is higher than the 1.5 
mM that we reported previously,3 due to batch-to-batch variability of the enzyme; IC50 values 
reported herein were all determined with the same batch of enzyme. f 5´-O-sulfamoyl-
adenosine. g n.d. = not determined. 
We then began exploring the structure–activity relationships (SAR) of 
the acyl-sulfamate region of OSB-AMS.  We anticipated that efforts in this area 
would increase favorable physicochemical properties while simultaneously 
decrease the inherent toxicological liability of the acyl-AMS motif and move our 
MenE inhibitor platform into more favorable drug-like space.  
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We reasoned that conducting a virtual screen of rationally designed 
OSB-AMS linker analogues using our previously reported docking construct of 
MenE could narrow a large swath of chemical space within this region.  We 
proposed this would also potentially increase the relative rate of new 
biochemically active lead compounds.  Guided by the results from the docking 
study, we synthesized a series of OSB-AMS linker analogues before testing 
	
Figure 5.2.  Biochemical activity of OSB-AMS linker analogues. 
 201 
them in biochemical activity assays against MenE (Figure 5.2).  Interestingly, 
more than half of the analogues exhibited activity against MenE.  The most 
promising hit from our first-generation library was the m-phenolic linker 
analogue 8, which although it substituted nearly the entire acyl-sulfamate for a 
simple aromatic ring, only exhibited a ~2-log loss of activity versus that of 
OSB-AMS.   While the biochemical activity of early iterations of the aromatic 
linker analogues is  ~2-log worse than that of OSB-AMS, the aromatic linker 
region presents an excellent platform for extensive diversification and 
functionalization which will allow for a great breadth of SAR to be performed, 
giving ample opportunity for increasing potency.  Importantly, the aromatic 
linker analogues are significantly less polar and more stable than OSB-AMS, 
which offers a possible solution to the ADME and stability problems inherent 
with OSB-AMS and similar acyl-AMS scaffolds.   
 
5.2. Future Directions   
The research reported thus far has highlighted a number of different 
discovery avenues toward new analogues with improved antimicrobial activity.    
The difluoroindanediol analogue exhibits improved activity against bacteria 
versus OSB-AMS, but (as was discussed in Chapter 3) the lack of specificity 
between the diastereomers in antimicrobial assays suggests a potentially 
complex or non-specific mechanism of action.  When combined with what is 
only modest activity against bacteria compared to other acyl-AMS based 
analogues explored by our laboratory, and the relative instability of the 
difluoroindanediol analogue, which raises significant toxicological concerns, 
this avenue of further exploration is less attractive than other approaches.  
 202 
However, these highlighted examples address several areas in which 
significant improvements can be made to our current line of MenE inhibitors. 
 
5.2.1 Future Directions: SAR of the OSB binding pocket   
Although we have explored the SAR of the OSB carboxylate and found 
it to be relatively intolerant to modification, there is potentially significant work 
that can be done in this area of the molecule.  We have determined that the 
keto-acid form of OSB-AMS is the active pharmacophore of MenE, but that 
does not preclude our use of the lactol form to decrease overall polarity of the 
molecule with the goal of increasing cellular accumulation and antimicrobial 
activity.   A number of different modifications can be considered to the OSB 
scaffold that would reversibly favor the lactol form in solution (Figure 5.3).   
	
Figure 5.3.  Proposed OSB functionalized analogues of OSB-AMS.  
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scaffold and MenE.  Alternatively, the electrophilicity of the o-ketone could be 
increased through a number of different means such as addition of fluorine to 
the α-keto position of the succinyl chain, which could increase the relative 
fraction of OSB-AMS existing as the lactol form at physiological pH.    
 Alternatively, a pro-drug approach where the carboxylate is temporarily 
masked could be explored.  Although we have seen in previous studies that 
the OSB-carboxylate itself is too hindered to allow for enzymatic cleavage of a 
simple ester derrivative,4 other pro-drug strategies could reasonably be 
employed to temporarily mask the carboxylate, allowing for increased cellular 
permeability and cleavage after entering the bacterial cytosol.5-8  When 
combined with linker analogues discussed in Chapter 4, this could allow for 
significantly decreased polarity and greatly improved ADME of our MenE 
inhibitor platform.  
 
5.2.2 Future Directions: SAR of the acyl-phosphate binding pocket   
Another area of further exploration is the linker region of the OSB-AMS 
scaffold.  While we discussed a number of analogues in Chapter 4, there is 
extensive remaining SAR to be performed in this area of the scaffold (Figure 
5.4).  Although the aromatic and heteroaromatic linker analogues provide the 
greatest opportunity for diversification and improvement for ADME of the 
inhibitor scaffold, there are also a number of different analogues from the first-
generation docking study that are yet to be explored.  
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Figure 5.4. Proposed aromatic and heteroaromatic OSB-AMS linker analogues. 
Additionally, once a new lead inhibitor is found, the designed docking 
model will allow for rapid screening of second and third-generation virtual 
libraries to assist in the exploration of each new scaffold.  Critically, this work 
has broad implications across all acyl-AMS inhibitors and could potentially be 
widely applicable to the field of adenylate-forming enzyme inhibitors.  
 
5.2.3 Future Directions: SAR of the adenosine binding pocket   
The last major area of exploration and possible optimization in the 
OSB-AMS scaffold is the adenosine portion of the molecule.  As has been 
demonstrated with the exponential growth of kinase inhibitors, the adenosine 
binding pocket of many enzymes is open to a large variety of different 
scaffolds if properly designed and explored (Figure 5.5A).9-10   
Returning to the computational docking model of MenE may greatly 
assist in the probing of the adenosine-binding pocket.   Although the 
adenosine-binding pocket has been examined by other groups exploring other 
members of the ANL family, in MenE this area is largely unexplored despite it 
accounting for over half of the mass of the scaffold.  Therefore, the first-
generation virtual library of analogues to probe this binding pocket would need 
to be much larger than the one used to originally explore the linker region.  
The library could focus on any number of substitutions for the adenine ring 
(Figure 5.5B), or could fully substitute the entire adenosine structure for a 
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larger variety of aliphatic, aromatic, heteroaromatic, and heterocyclic 
substituents (Figure 5.5C).  Alternatively, the use of automated ligand design 
as proposed by Professor John Chodera at Memorial Sloan Kettering Cancer 
Center could generate proposed analogues that might have been overlooked 
by the in silico rational design approach.11  Once work has been completed in 
the linker region of the scaffold (Section 5.2.2), the adenosine analogues could 
easily incorporate bioisosteres from that work into the scaffold to take the 
place of the current acyl-sulfamate.   
Examination of the docking structure of OSB-AMS to MenE (Figure 
	
Figure 5.5. Modification of the OSB-AMS adenosine region A) Examples of approved 
kinase inhibitors B) Examples of substitutions for the adenine region of OSB-AMS. C) 
Examples of substitutions for the adenosine region of OSB-AMS. 
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5.6A) suggests that, as has been seen with kinase inhibitors, future inhibitors 
could also omit or circumvent the relatively polar ribose binding pocket all 
together and instead focus on transitioning from the linker region directly into  
	
Figure 5.6.  Proposed elimination of ribose in MenE inhibitor platform A) OSB-AMS 
liganded E. coli MenE crystal structure with distances between key points. B) Examples of 
proposed “ribose free” MenE inhibitors.  
the adenine binding pocket (Figure 5.6B).12   There are three key points in the 
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OSB-AMS scaffold that both present themselves directionally towards the 
adenine ring and are in close proximity.  While these analogues would lose 
favorable hydrogen bonding interactions present in the ribose binding pocket, 
the entropic gain through decreased desolvation penalties associated with the 
polar ribose region may more than compensate for the loss of enthalpic 
binding in that region.  These analogues could also greatly benefit from the 
work performed in the linker region (Section 5.2.2) to access the optimal 
bioisostere of the acyl-phosphate, and could then incorporate that structure in 
the phosphate binding pocket region of the scaffold. 
 
5.2.4 Future Directions: Final words   
The work described herein has focused on efforts to optimize the 
parameters of our current lead MenE inhibitor, OSB-AMS.  During our efforts 
we aimed to increase antimicrobial activity and favorable ADME properties 
while reducing the toxicological liability inherent in the scaffold.  We have 
garnered important SAR about our scaffold through exemplary studies, which 
include: the keto-acid/lactol equilibrium of the OSB scaffold, the elucidation of 
the difluoroindanediol and its antimicrobial activity, and exploration of the linker 
region of OSB-AMS.  Future work will focus on exploration of the SAR around 
the three key areas of the OSB-AMS scaffold, while attempting to optimize a 
variety of physiochemical and physiological properties.  Ultimately, this 
research will address and optimized inhibitor of MenE with high selectivity that 
can someday be used to treat patients suffering from antibiotic-resistant 
bacterial infections.  
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